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Summary  
Molluscum contagiosum (MC) is a common skin condition in children presenting to primary 
care in the United Kingdom (UK) and is typically diagnosed based on its distinct appearance. 
There are limited data on the epidemiology of MC in UK children. Little is known about its 
presenting symptoms, time to resolution, likelihood of transmission and impact on quality of 
life (QoL), highlighted within a systematic review of the epidemiology of childhood MC 
presented early in this thesis. This thesis aimed to address this gap in evidence. 
A retrospective longitudinal cohort of 9,245,847 children registered at primary care centres in 
the UK extracted routinely collected data from the Clinical Practice Research Datalink (CPRD). 
The study highlighted decreasing trends in consultation rates for MC by 50% during the 10 year 
study period 2004-13. Children who were previously diagnosed with atopic eczema were more 
likely to have a future MC consultation than controls. 
The ‘Molluscum Contagiosum Diagnostic Tool for Parents’ (MCDTP) was developed to aid 
parents in diagnosing spots, lumps or bumps on a child’s skin as being MC or not. The MCDTP 
was assessed in primary care centres to measure its diagnostic accuracy (n=203, 
sensitivity=92%, specificity=88%), and used to recruit a prospective community cohort of 306 
UK children with MC. Results showed that MC lesions were most common on legs and arms, 
and nearly 70% of children had lesions in more than one site. The average time to resolution 
was 12 months, however over a quarter still had lesions after 18 months and 12% after 24 
months. Nearly half of households reported transmission to one or more children from an 
index case. Overall MC had a small effect on QoL however, 1 in 10 children experienced a very 
severe effect on QoL. 
The findings presented in this thesis can facilitate self-care of MC in the community where 
parents can self-diagnose their child’s spot, lumps or bumps on the skin as MC or not using the 
MCDTP. These data can provide parents, and other interested stakeholders, with accurate 
information of the epidemiology of the condition to aid the management in both clinical and 
community settings. 
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Chapter one: Introduction 
1. Overview 
This thesis aims to describe the basic epidemiology, including presenting symptoms, and time 
to resolution, of the skin condition molluscum contagiosum (MC) in children. Within this initial 
chapter I will provide a background description of MC in terms of clinical description, virology, 
histology, treatment, the main risk groups, and research gaps. I will conclude by highlighting 
why the research conducted within this thesis is important. I will also discuss the importance 
of describing the epidemiology of common skin conditions.  
The specific aims and objectives will be presented at the end of this chapter as well as ethical 
and research governance approvals. 
 Molluscum contagiosum (MC) 1.1
1.1.1 Clinical Features  
MC is a common skin condition that can present in persons of all ages and is an infection of the 
skin and mucous membranes (1-3). MC is characterised by discrete, single or multiple flesh 
coloured papules. MC typically presents as one or more umbilicated, smooth, flesh-coloured, 
pearlescent, domed shaped lesions (4). Lesions can appear anywhere on the body (5), forming 
from slightly raised lesions of rubbery consistency up to 5mm in diameter (1). Although lesions 
are generally self-limiting, for some they can be extensive, cause itching, discomfort, anxiety 
and social stigma, can result in scaring, and on some occasions bacterial superinfections with 
inflammation and pain (4, 6).  
1.1.2 Virology 
MC is caused by a viral infection of the skin and is a member of the poxvirus family which, 
since the eradication of smallpox, is the most prominent poxvirus presenting in a human host 
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(7). The MC virus (MCV) is a large double stranded DNA virus (8) which has four major viral 
types based upon DNA analysis: MCV-I, MCV-IA, MCV-2 and MCV-3. The strand with the highest 
prevalence is MCV-I, which is more common in children, whereas MCV-2 affects older people as 
it is more commonly seen through sexual transmission (9) and is not usually found in patients 
aged under 15 years (10). MC is a cytoplasmically replacing virus, and the maturation of the 
virus takes five days (7). Lesions resolve spontaneously, possibly when the virus-infected 
tissues are exposed to the immune system (4), and the time to resolution of symptoms has not 
been well described in the literature.  
1.1.3 Histology 
The lesions are histologically characterised by inverted lobules of hyperplastic, acanthotic, 
squamous epithelium, which form a central crater that is filled with semiliquid debris (4, 7). 
The lesions are limited to the epidermal layer of the skin, and have a resemblance to hair 
follicles (4). 
1.1.4 Transmission 
Transmission of MC is described as occurring by two routes; direct skin to skin contact (9) or by 
indirect contact of the mollusca through sharing of towels, bath sponges, clothing or bedding 
(2, 11). Early studies published in the 1950’s described poor hygiene with increasing the 
likelihood of transmission of MC (12), however this research did not provide statistical 
associations and since this studies have shown a high proportion of cases of MC in families 
with average to excellent hygienic standards (13). 
1.1.5 Diagnosis 
MC is typically diagnosed through clinical examination of the distinct lesions, and are 
commonly diagnosed and managed in primary care. Unusual and more severe cases may be 
referred to a dermatologist (2). The condition can be diagnosed by the histopathology found in 
biopsies of lesions (3), however this is generally uncommon practice in the UK. 
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1.1.6 Treatment 
There are four main treatment options; application of topical agents that cause skin disruption, 
physical procedures to debride the lesion, systemic treatments such as immunomodulatory 
agents, or awaiting natural resolution (2, 4, 14, 15). Physical treatment options can be painful 
and leave the risk of scarring (1). However, it can be difficult to ascertain whether scars result 
from the treatment or the lesions (4, 16).  
Some researchers have recommended that MC should be treated, arguing that in light of the 
availability of safe, efficacious and convenient treatment options, physicians have the 
appropriate tools to improve patient quality of life (QoL) while providing a convenient, well-
tolerated easily administered treatment regime (6). However, a recent systematic review of 
cutaneous MC (‘a review of interventions for cutaneous MC in non-immunocompromised 
children and adults’) conducted by the Cochrane Collaboration in 2009 found insufficient 
evidence to recommend any treatment. The review suggested that until there is better 
evidence for superiority of other treatments then MC should be left to heal naturally (17). 11 
studies were included within this review, nine were of topical ointments, one of a systemic 
treatment (cimetidine therapy) and one of a homeopathic intervention (calcarea carbonica). 
The review found no evidence either for or against the most commonly used treatment 
options for MC, and concluded the review by recommending well-designed, prospective, 
blinded randomised controlled trials on common treatment options for MC against a credible 
placebo or no intervention. These recommendations were based mainly upon the small size of 
studies that were included in the review that offered limited power within treatments arms 
and also the methodological shortcomings of those studies. Highlighting clearly that ‘no 
treatment’ is not recommended based upon ineffectiveness in treating MC but that previous 
research studies have been insufficient in providing a well conducted study providing results of 
an effective treatment.  
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1.1.7 At risk populations 
MC mainly affects three distinct populations; children (8), sexually active adults (18) and those 
who are immunocompromised. The latter group consists primarily of those with Human 
Immunodeficiency Virus (HIV) infection (19). Overall MC is most prevalent in children, who are 
generally healthy and school aged (9). Strikingly this is also the group where there has been 
relatively little epidemiological data published. This is in contrast to sexually active and 
immunocompromised adults, where there is more published data. This may be due in part to 
adults having their MC diagnosed in GUM and specialist clinics (20), where there is a large 
amount of routinely collected data available for analysis. 
1.1.8 Risk Factors 
Some studies have suggested an association between an increased risk of a child developing 
MC and swimming, atopic eczema (AE), geography and climate (7, 21, 22), but provide only 
anecdotal evidence. Often data are presented from small studies as proportions without 
robust statistical analysis being performed. None of these risk factors have been explored in 
children recruited from the UK.  
 Is there a gap in the knowledge in the description of the epidemiology of MC?  1.2
In this section I highlight the need for an updated review on the incidence, prevalence and risk 
factors associated with MC. Previous reviews have been published, but as I will highlight 
below, these have significant limitations and have produced inconsistent results.  
Two recent reviews which described the epidemiology of MC found between 11 and 13 
publications within their literature searches (7, 23). Nevertheless, these studies described MC 
in populations of children in diverse settings, such as New Guinea (1970’s (21)), Japan (1980’s 
(24)) and Mali (1990’s (25)) that are unlikely to be generalisable to children living in Western 
Europe and North America. There is very little evidence available from the UK. Of the three 
published UK studies identified in these two recent reviews, one was published in the 1960’s 
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describing children in Aberdeen (22), and two more recent studies extracted routinely 
collected data to describe primary care consultation rates of MC, both published in the 2000’s 
(5, 26). Although routinely collected data can be a rich data source containing a large amount 
of information, it is limited with regard to the information that is captured within the data 
collection systems. In most cases these systems do not allow flexibility in capturing data from 
the perspective of the child or parents that also describe the presentation, time to resolution, 
behaviours, and QoL impact.  
Many studies describing the epidemiology collect data from only children who consult to 
primary care or speciality dermatology centres and these can be subject to healthcare access 
biases where findings may not be representative of all cases that may exist in the community 
(27). Children who consult with MC may represent more severe cases of the condition 
compared to those children who are successfully managing the condition at home without 
visiting a physician.  
Both of these reviews highlighted that there is little adequately designed epidemiological 
research that has been published for MC (7). The two reviews described above differ by the 
studies included within the searches, the analysis of data extracted from studies, and provide 
no suggestions of whether the findings are acceptable to Western European and North 
American populations. From this it seems there have been no recent reviews of the 
epidemiology of childhood MC that have systemically synthesised data from the original 
research articles to provide a concise and accurate description of the current epidemiology 
that can be applied to children residing in the UK.  
Clearly there is little evidence describing the epidemiology of MC in UK children, meaning that 
current health information available to clinicians and parents describing presenting symptoms, 
the natural history and impact on QoL from the condition may not be adequate. It is also clear 
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from the most recent reviews conducted that there are disparities in what has been reported 
from previous studies. 
 Why is describing the epidemiology of MC important? 1.3
Parents who visit their GP have a thirst for information (28), and questions such as, “how 
common is it”, “why have I got it”, and “will it go away” (29), are likely to be common. 
Currently for MC there is little evidence available to both parents and clinicians to answer 
these questions. 
The findings from epidemiological data can support clinicians in being able to provide parents 
with accurate information regarding the potential risk factors which would increase the risk of 
disease for an individual, and the time to resolution of the disease (30). Interestingly, the 
paucity of this epidemiological evidence in the UK is not limited only to specific conditions such 
as MC but there is a well described imbalance within the field of dermatology between basic 
science and describing the distribution of a disease and factors that may influence this (31).  
 Summary 1.4
MC is a common skin condition that is typically diagnosed in primary care following a clinical 
examination of the lesions, and presents most frequently in children. Risk factors which have 
been associated with a higher prevalence of MC in children are AE, age and swimming. In the 
UK there have been no studies in the scientific literature that have described the presentation, 
time to resolution and QoL of children with MC since a small study providing little data 
published during the 1960’s. Recent reviews of world-wide publications of childhood MC differ 
in both the number of studies included and analysis of extracted data; this highlights a clear 
starting point of this thesis to conduct a systematic review of the epidemiology of childhood 
MC within the subsequent chapter.  
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The research within this thesis will be limited to only UK children, and will be conducted in the 
primary care and community setting. The evidence base for many skin conditions that are 
managed primarily in primary care comes from secondary care settings (32), and therefore is 
likely to be biased. MC is managed primarily in primary care, and therefore it is important to 
generate an evidence base from this setting.  
 Thesis Aims and Objectives 1.5
1.5.1 Aim 
The overall aim of this thesis is to describe the epidemiology of MC in children. The main 
research question of this thesis is ‘what is the presentation, time to resolution and prognosis 
of MC in children?’  
1.5.2 Objectives 
To address this aim, the objectives of the thesis have been identified: 
a) Provide, within the subsequent chapter, a systematic review of the current literature 
describing the epidemiology of MC to highlight research gaps in current evidence. 
b) Describe the basic epidemiology of MC in a community cohort of children recruited in 
the UK. The cohort established will describe: 
- The presentation and time to resolution of symptoms of MC in UK children. 
- The impact of MC and impairment on quality of life. 
- Cases of transmission of MC between other children living in the same household. 
- Treatment and management of MC by doctors, and parents self-medicating. 
c) To develop a diagnostic tool which enables parents to identify whether their child has 
a current diagnosis of MC and which can be used for recruitment in a large 
epidemiological study. 
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d) To evaluate the effectiveness of parents using the MC diagnostic tool to identify a 
correct diagnosis of MC when compared to an expert’s diagnosis. 
e) To describe the current number of children who present to primary care in the UK and 
are diagnosed with MC in a longitudinal cohort. The cohort established will describe: 
- The age and sex variation of MC consulting to primary care in the UK. 
- Currently treatments prescribed when a child is diagnosed with MC. 
- The variation in the incidence of MC presenting to primary care in the UK by year and 
season. 
- Associations between MC and a history of atopic eczema. 
f) To understand the interpretation of QoL scores through a systematic review of 
common skin conditions, including MC, that have used the CDLQI. 
  Patient representation 1.6
Involving lay representatives in research is important as it has been shown to improve the 
quality of the research. There are many benefits that a lay perspective can bring to research 
through their insights which may otherwise have been overlooked, and they can act to 
counterbalance ideas that may dominate from academic researchers (33). Input of lay 
representatives is varied and can be through several areas of the research process, such as 
helping to adapt academic language, and improving the wording of patient information and 
invitation letters (34). A lay representative, Ms. Samantha Woods (SW), was appointed to 
participate in bi-monthly supervisor project meetings which took place at Heath Park, Cardiff. 
If SW was unable to attend meetings feedback on patient documentation or specific areas of 
the project would be discussed by email or telephone. SW was recruited through ‘Involving 
People’ (NISCHR), where an advert was place for parents who have children who have a 
current diagnosis of MC to be involved in this research. An advert was placed in early 2012, 
and SW was added to the research team by mid-2012. The organisation ‘Involving People’ 
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provided expenses towards the costs of attending the meetings such as travel costs and also a 
small token payment per hour for involvement in meetings. 
 The MOSAIC study 1.1
The MOSAIC study [MOlluScum contAgiosum In the Community] was developed for this thesis. 
The MOSAIC study consisted of three study phases that are described in chapters five, six and 
seven. The study title and logo were used on study materials, the study website, 
communication with NHS ethics, local health boards and participants (Figure 1). All references 
to ‘the MOSAIC study’ within this thesis refer to the title of this clinical research study. 
Figure 1. Example of MOSAIC study documents using the study logo 
 
 Approvals, governance, funding and study reporting 1.2
Copies of formal communication and approvals can be found within Appendix 5. 
1.2.1 Ethical approval 
The research was granted a favourable ethical opinion by the ‘NRES Committee South Central 
– Berkshire B’ research ethics committee (Ref: 12/SC/0455). 
1.2.2 NHS research governance approval 
Cardiff & Vale University Health Board granted research governance approval for practices 
within the health board. I was also issued with a letter of access for research practices (chapter 
six). Approval was granted by all health boards within wales for GP practices and secondary 
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care dermatology outpatient clinics to act as participant information centres (PICs) (chapter 
seven). 
1.2.3 Study sponsorship 
The study was sponsored by Cardiff University (Ref: SPON 1131-12). 
1.2.4 National registration and reporting 
The study was a UK clinical research network (UKCRN) adopted study within the skin portfolio 
(UKCRN Ref: 13430). Monthly recruitment data was submitted to the UKCRN database whilst 
the study was actively recruiting participants. 
1.2.5 Funding 
The research within this thesis was funded as part of a postgraduate research studentship by 
the Cochrane Institute of Primary Care and Public Health and School of Medicine, Cardiff 
University (Ref: BX1150NF01).  
1.2.6 Study support costs 
Service support costs were sought and obtained from the Wales School of Primary Care 
Research (WSPCR – NISCHR CRC); the total grant awarded was £15,890. The allocation towards 
the validation of the parental diagnostic tool (chapter six) was £10,500; practices were paid 
£35 per GP assessment at each site. This cost was to compensate the practice for clinical time 
spent with the participant, for local management of the study by identifying potential 
participants, collecting data forms, and returning completed study forms. £3,000 was allocated 
to compensate participants who were recruited to the prospective cohort study of children 
(chapter seven); each participant who completed the study questionnaires received a £10 high 
street gift voucher. An additional £2,000 was allocated to the study website that hosted the 
parental diagnostic tool and collected data from questionnaires which was secure and 
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conformed to data protection laws. A further £390 was allocated for additional study 
equipment. 
 Thesis synopsis 1.3
This chapter has outlined the background of the thesis.  
Chapter two describes the methods and results of a systematic review of the published 
scientific literature describing the epidemiology of MC in children. 
Chapter three describes a review of common skin conditions that have used the children’s 
dermatology life quality index (CDLQI); a validated questionnaire measuring QoL in children 
presenting with dermatological conditions. The CDLQI will be used later in the thesis (chapter 
seven) to measure QoL in children with MC and this review will allow the results from this 
thesis to be presented and compared in relation to the QoL impact from other common skin 
conditions. 
Chapter four presents the methods and results from a longitudinal study of primary care 
consultations for MC. Routinely collected data are extracted to describe recent trends of 
consultations and associations with other skin conditions. 
Chapter five and six will describe the development and assess the extent to which a parental 
diagnostic tool for MC is a valid instrument to be used for recruitment in a large community 
based epidemiological study (chapter seven). 
Chapter seven recruits a prospective cohort of children with MC to describe the presentation, 
management and advice, and QoL. Participants are followed up for the duration of their 
conditions to describe transmission and the time to resolution of symptoms. 
Chapter eight is the final chapter of this thesis and provides a summary of the main research 
findings, a summary of the main limitations and potential biases of the methods used within 
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this thesis, and places the results in context to those from other relevant published literature. 
The chapter concludes by highlighting clinical management implications and future research 
recommendations. 
A GANTT chart is presented in Figure 2 showing how the individual studies within this thesis 
were completed during the three year time period that this thesis was conducted. 
Figure 2. GANTT chart of individual studies within this thesis completed during study period. 
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Chapter two: Systematic review of epidemiological studies of childhood molluscum 
contagiosum. 
The results from this chapter were published as a systematic review in Family Practice. A copy 
of this paper can be found in Appendix 1.1.  
2. Overview 
MC is a common skin condition which regularly presents and is managed within both primary 
and secondary care, however the reported incidence and prevalence of MC varies widely in the 
most recent published reviews of the condition, therefore it is difficult to estimate the true 
number affected by MC. Evidence of factors increasing the risk of transmission is mixed. In this 
chapter I aim to synthesise the current epidemiology of childhood MC.  
The chapter will firstly describe how prevalent MC is; whether there have been recent studies 
conducted within the UK, and, if not, whether the results from studies outside of the UK are 
generalisable to the UK population. Secondly the incidence of children presenting to primary 
or secondary care providers will be described, and associations with age and gender. Finally 
the chapter will describe the presentation of symptoms and risk factors associated with 
children presenting with MC in both primary and secondary care, and in the community.  
Studies describing the QoL effect from MC using the CDLQI are included within a systematic 
review in the subsequent chapter (chapter three). 
 Design 2.1
This is a systematic literature review of bibliographical databases on the prevalence, incidence, 
risk factors, age distribution and association with other conditions for MC in children. 
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 Search Strategy 2.2
I conducted a systematic search of bibliographical databases using a pre-defined search 
strategy in October 2012. Papers were also identified from reviews of citations within papers, a 
preliminary scoping exercise using ‘Google Scholar’, and identification of papers by experts in 
the field. 
Medical subject headings (MeSH) were used in OvidSP 1 to search the Medline (1946-October 
2012), Embase (1947 – October 2012) and Cochrane databases (for MeSH terms please see 
Appendix 2.1). Duplicates were removed and the search was restricted to English language and 
studies involving humans. The search was performed again in October 2014 to identify 
whether there had been any further publications since this initial search. 
2.2.1 Data extraction and analysis 
All publications identified in the search were screened by title and abstract using the inclusion 
criteria below. The full texts of all articles which may have potentially been relevant were 
requested for full review using a template covering key study characteristics, incidence and 
prevalence of MC, age distribution, risk factors and other conditions associated with MC.  
2.2.2 Inclusion and Exclusion Criteria 
Papers were included if they were original research articles on the incidence, prevalence, risk 
factors, age distribution or other conditions associated with MC in children. I excluded studies 
if they were non-original research, review papers, singular case reports, treatment trials, or 
related exclusively to adults, immunocompromised individuals, those attending sexual health 
clinics, or dental MC.  I included studies if they related to both children and adults, and where 
possible extracted only the data that pertained to children. 
                                                          
1
 OVID
SP
 provides access to online bibliographic databases and journals in the field of health sciences. 
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2.2.3 Search results 
The search identified 441 papers. After reviewing the abstracts of all 441, 25 publications met 
the inclusion criteria (Figure 3). Data, where available, was extracted for analysis. 
Figure 3. Flow chart of study selection process 
 
The search was duplicated in October 2014 to identify whether there were additional 
publications since the initial search of bibliographical databases (October 2012). This search 
identified one additional publication that met the inclusion criteria, this was a longitudinal 
study and the data from within this publication are included within this chapter. Therefore, in 
total 26 publications are included in the review. 
 How prevalent is MC? 2.3
2.3.1 Definition of Prevalence 
Prevalence measures a slice through the population at a certain point in time to determine 
who has and who doesn’t have the disease/condition in question. The calculation of 
prevalence is performed by dividing the number of people affected by the condition, by the 
number of persons in the population at that time (30). This calculation measures the point 
prevalence of a disease, there is also a second measure called period prevalence. Period 
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prevalence accumulates all cases during a period of time, including those who developed, and 
may be symptom free, by the total population. The important aspect in this calculation is that 
it includes all individuals who have had or currently have the disease during the time period. It 
must be noted however that prevalence does not determine when a disease developed but 
that the disease was present during the time frame being measured. 
Prevalence is often presented as a rate, but by strict definition it is a proportion of individuals 
who are affected by the disease in the population (35). 
2.3.2 Summary of worldwide prevalence studies of MC 
The prevalence of MC was described in eight papers (Table 1) however no papers reported the 
prevalence of MC in Western Europe or North America. Studies reporting the prevalence in 
children in a variety of settings in Israel, Romania, New Guinea, Mali, Japan and Turkey 
described a prevalence of MC ranging from 0.27% in six to 12 year olds in Romania (36)  to 34% 
in two to nine year olds in Israel (37).  
Table 1. Prevalence studies of MC (worldwide) 
Ref Location 
Age 
Group 
(years) 
Population Cases Prevalence 
95% 
Confidence 
Interval (CI) 
Sturt (1971) 
(21) 
New 
Guinea 
0 to 10 78 17 21.8 12.6 to 31.0 
Niizeka (1984) 
(24) 
Japan 4 to 11 7472 517 6.9 6.3 to 7.5 
Oren (1991) 
(37) 
Israel 2 to 9 81 28 34.6 24.2 to 44.9 
Mahe (1995) 
(25) 
Mali 0 to 12 1817 65 3.6 2.7 to 4.4 
Popescu (1999) 
(36) 
Romania 6 to 12 1114 3 0.3 0 to 0.6 
Tuncel (2005) 
(38) 
Turkey 14 to 16 166 2 1.2 -0.5 to 2.9 
Tabari (2007) 
(39) 
Iran 1 to 5 986 21 2.1 1.2 to 3.0 
Hayashida 
(2010) (40) 
Japan 0 to 6 913 180 19.7 17.1 to 22.3 
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The study population which is most similar to Western Europe and North America, in terms of 
economic development, is Japan, where two studies reported prevalence of 6.9% (1984) (24) 
and 19.7% (2010) (40). The largest prevalence of MC (19.7%) was reported in a cross-sectional 
study of children where parents were asked to recall a current or previous diagnosis of MC for 
their child. This may overestimate the point prevalence of MC as it includes any previous 
diagnoses’, and relies upon accurate recall by parents (40). Similarly, the second study 
(prevalence 6.9%) also questioned parents about a diagnosis of MC, the authors did not report 
how a diagnosis of MC was obtained or if it was a current diagnosis (24). 
Two studies showed an exceptionally high prevalence of 34% and 22%. The first of these was 
conducted in a small rural community in the warm and dry climatic area of the Jezreel Valley, 
Israel following reports of a small epidemic in 1991 (37). The other was a study of 16 villages in 
the West Sepik District of New Guinea (21). Both of these studies concluded that the warm and 
dry climates of the areas under study were likely to have resulted in the unusually high 
prevalence rates found. However, the first study was described as taking place during an 
epidemic and the second had large variation in prevalence between individual villages, and 
therefore it can be questioned whether the results of either are representative of warm, dry 
areas. Indeed, studies from other warm and dry climates such as Mali (3.6%) (25), Turkey 
(1.2%) (38) and Iran (2.1%) (39) have reported considerably lower prevalence.  
The lowest prevalence reported was 0.27% in Romanian school children, where each child had 
two independent paediatric assessments by dermatologists (36). Although the study did have 
robust methods in the diagnosis of MC it only included children aged between six to 12 years, 
and therefore did not include those at greatest risk (under fours (as shown later in incidence 
section)).  
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The remaining prevalence studies were conducted in Mali (3.6%) and Iran (2.12%) where these 
populations do not allow for a direct comparison with that of Western Europe and North 
America due to significant cultural and climatic differences.  
Meta-analysis of prevalence data gives an overall estimated weighted prevalence in children of 
8.28% (95% CI 5.1 to 11.5) (Figure 4), this figure may be skewed by the three studies reporting 
a considerably higher prevalence of MC due to potential outbreaks and a lifetime prevalence 
recorded. Where these studies are excluded the estimated prevalence is lower 2.83% (95% CI 
0.0 to 5.9) (Figure 4). 
Figure 4. Comparison of prevalence of childhood MC reported in cross-sectional surveys by 
study subset 
 
2.3.3 Summary of Prevalence Studies 
The reported prevalence of MC varies widely between 0.27% to 34.6%. Two studies reported a 
high prevalence of 22% and 34% in children. Due to the occurrence of a small epidemic, with a 
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relatively low sample size, in one study and the unexplained variation in prevalence rates 
between villages of similar climates and demographics of the second, these figures are not 
generalisable to other populations. The authors of both studies concluded that the high 
prevalence of MC was associated or caused by the warmer climate of that area but provided 
no further evidence of this. The prevalence of MC in other warm and dry climates such as Mali 
(3.6%) (25), Turkey (1.2%) (38) and Iran (2.1%) (39) have reported considerably lower 
prevalence and from this we can summarise that there is insufficient evidence to conclude that 
a warm and dry climate is a risk factor for a higher prevalence of MC. 
Each of the prevalence studies have limitations which do not allow the prevalence rates to be 
generalised to a population within the UK, and where estimates are limited to only those 
conducted in the general population, the actual rate may lie between 0.27% to 5.88%. Until a 
comprehensive prevalence study is conducted within the UK, the most accurate data available 
to measure the number of children who have a MC diagnosis could be provided by longitudinal 
studies. Longitudinal studies extract routinely collected data to describe consultation or 
incidence rates of children presenting with MC to physicians; in the UK this is primary care 
centres. These study designs are particularly informative due to generally having a large and 
inclusive population. 
 What is the Incidence of MC? 2.4
2.4.1 Definition of incidence 
Incidence is a measure of the proportion of a group of at risk individuals, within a population 
who are initially free of the disease or new outcome, who then go on to develop a certain 
condition being measured during a specified time period (41). The critical element of the 
definition is that it identifies new cases in those who were initially symptom free at the start of 
the study period (30). Incidence is usually presented as a rate of development of a disease by 
the total population subset over a set period of time (42) and the denominator used for 
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calculating an incidence rate will be identified at baseline, where it is from this group that any 
new cases of disease will be measured (30). 
2.4.2 Summary of worldwide incidence studies of MC 
There are five longitudinal studies which describe the incidence of MC consultations using 
routinely collected data. Two of the studies were conducted within the UK, two in North 
America, and one in Holland (Table 2).  
Table 2. Incidence of MC 
Ref Data 
Age Group 
(years) 
Population Sex 
Annual 
Incidence 
(per 1,000) 
95% CI 
Konning 
(1994) 
(43) 
1987-88, 
Holland 
10 - M&F 25.0 - 
Pannell 
(2005) (5) 
1994-03, 
United 
Kingdom 
1 to 4 
119,920 Male 15.0 14.4 to 15.8 
113,682 Female 15.2 14.5 to 16.0 
5 to 14 
321,624 Male 10.7 10.4 to 11.1 
306,015 Female 10.5 10.1 to 10.8 
Reynolds 
(2009) 
(44) 
2001-05, 
North 
America 
<1 - M&F 1.9 - 
1 to 4 - M&F 7.7 - 
5 to 14 - M&F 3.1 - 
Schofield 
(2011) 
(26) 
2006, 
United 
Kingdom 
1 to 4 
- Male 17.2 - 
- Female 15.5 - 
5 to 14 
- Male 9.5 - 
- Female 10.7 - 
McCollum 
(2014) 
(45) 
2001-09, 
North 
America 
<1 - M&F 1.9 - 
1 to 4 - M&F 7.8 - 
Notes: - data not reported. 
2.4.3 Incidence of MC reported in the UK 
Two incidence studies of MC have been conducted in England and Wales, both extracting data 
from the weekly returns of the Royal College of General Practitioners of primary care 
consultations. The first study by Pannell (2005) used data from 1994 to 2003 to calculate 
incidence rates for a MC diagnosis recorded by a GP (5). The largest incidence was in those 
Page | 21 
 
aged one to four years, and females had a slightly higher incidence compared to males (15.2 
and 15.0 per 1,000 respectively), however this was not significant. The five to 14 year age 
group had slightly lower incidence rates (males 10.7 and females 10.5 per 1,000), and again 
there were no significant differences between gender.  
Schofield (2011), analysing data from the same source as Pannell, described the incidence of 
MC during 2006 (26). The incidence in males aged one to four were higher than those reported 
by Pannell (2005) (17.2 per 1,000), although females did rise to 15.5 per 1,000, but not 
significantly. Using the same age groups as Pannell (2005), the five to 14 age group males has 
slightly lower incidence rate than those previously reported (9.5 per 1,000), and in females 
they had risen slightly to 10.7 per 1,000. 
Pannell described trends in the incidence of MC, reporting a 50% increase from 1994 to 1999 
of 8.0 to 12.0 per 1,000 in those aged one to 14 years. The results seem to decline or steady 
from 1999 to 2002, although the poor presentation of figures by the authors does not allow for 
detailed analysis. Incidence rates in those aged 15 and over remained constant during the 
study period, and when monthly incidence rates were explored they show variation but no link 
to temperature or seasonality were reported.  
2.4.4 Incidence of MC reported world-wide 
The largest incidence of MC was reported in Holland as 25 per 1,000, where data was 
extracted from 10 Dutch general practices with a total study population of 332,300 (43), 
although this figure is calculated only for those aged 10 years. Regional differences were found 
in the incidence rates in regions of Holland, ranging from 1.0 to 3.2 per 1,000 between three 
regions. The author noted no differences in the climate, temperatures or urbanisation 
between the areas, with very similar rates reported in each population size examined. Regional 
differences were also found in two studies in North America (44), where differences were 
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consistent in the five and nine years of study data examined and, again, there was no 
explanation that could attribute a higher incidence to a region.  
In North America, two studies examined the annual incidence rate in outpatient visits for MC. 
Both studies extracted data from the Indian Health Service, which is representative of 57% of 
the American Indians/Alaskan Natives (AI/AN) population in North America. Reynolds (44) 
examined data for the period 2001 to 2005 where the greatest incidence was in children aged 
one to four years (7.7 per 1,000). Similarly, McCollum (45), who included a further four years 
of data in their analysis (2001 to 2009), provided only a marginally higher rate for the same age 
group (7.8 per 1,000). The latter study included only children aged less than five years. Both 
studies found no differences in the incidence of MC between genders. 
2.4.5 Summary of the incidence of MC 
In all ages the greatest incidence of MC was in children aged zero to 14 years. Where age 
ranges were analysed further within this zero to 14 year age group, the highest incidence was 
found in those aged one to four years. It can be concluded that there is no difference between 
incidence rates for gender. 
Each study produced incidence rates by different age categories, some narrower than others 
which does not allow direct comparison between the groups. The two studies within the UK 
analysed rates by zero to four and five to 14 aged children, and this may have been due to the 
limitations of the database for extraction as both used the same source (5, 26), but it did not 
provide further expansion of incidence rates within the five to 14 year age group. As MC is 
most common within these age groups, the use of narrower age groups would be beneficial for 
a more detailed description of what aged children are most at risk of MC.  
There were regional differences found by Koning  (43), Reynolds (44) and McCollum (45), and 
no results by region were produced in the two UK studies. Koning, Reynolds and McCollum 
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showed there were geographical regions that had a higher incidence rate of MC than others, 
but none could determine a cause. Urbanisation was modelled in Koning’s analysis and 
showed no differences between the population densities of the area. All three authors 
described there were no significant climatic differences between the regions to account for a 
difference in incidence; however this was not factored this into their analysis.  
The difference between the incidence of MC reported in Western Europe and North America 
may be due to the different healthcare systems in the two continents, the Western European 
studies recorded data where patients had visited a GP, which is first point of contact for all 
non-emergency patients. Data extracted in North America included only outpatient visits to a 
specialist physician, which was exclusive to the AI/AN population, and is not representative of 
the North America population. 
In conclusion, the largest incidence of MC is in children, aged between zero to 14 years. Where 
results are combined the incidence expected is shown to be 12 to 14 per 1,000. Incidence rates 
in the UK were beginning to steady from 1999 to 2002, and a more recent single-year study in 
2003 showed the rates had slight decline. Current rates have not been explored to determine 
if rates have declined further or to provide a detailed analysis of age groups within those aged 
zero to 14 years. Studies outside the UK have shown regional variation in incidence rates, and 
although they have provided no conclusive reasoning for this, there would be merit in 
modelling this into a future incidence study. 
 Presentation and prognosis of symptoms 2.5
2.5.1 Age 
In a large cohort of Greek children (n=4071) of children consulting to a dermatology outpatient 
clinic, the peak age of children with MC was four to six years (46). This study did not include 
children over the age of 12 years; nevertheless the results were comparable to those of a 
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similar study of 650 French children aged zero to 15 years, where the peak age of individuals 
was six years.  
Age was further described in seven studies of children consulting with MC (3, 11, 22-24, 47, 
48), and the peak or mean age lay between five to 12 years (Table 3). There was large variation 
in the age range of the sample recruited in each. 
2.5.2 Gender 
There was no evidence of a difference in prevalence by gender for children who consult to a 
dermatologist with MC, with the proportion of males ranging from 41.2% to 62.0% and 
confidence intervals including 50% in most studies (Table 3). 
2.5.1 Time to resolution 
The typical time to resolution of symptoms described in literature ranges considerably from 
several months to five years (2, 9, 49, 50). However, from this search there were only two 
studies, of small sample size, to have followed up cases of MC to describe the time to 
resolution during the 1960’s in children who consulted with MC. Alaska (n=13) and Fiji (n=14) 
reported the time to resolution that ranged from 2 weeks to 24 months (13). The mean time to 
resolution was calculated only in Fiji as 8 months (47). 
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Table 3. Characteristics of children and natural history of MC 
a) Age 
 
Ref Sample 
Age 
Range 
(years) 
Peak Age 
(year) 
Measurement 
used 
 Sturt (1971) (21) 401 0 to 57 2 Peak 
 Niizeka (1984) (24) 405 4 to 11 8 Peak 
 Oren (1991) (37) 34 2 to 31 5 Median 
 Castilla (1995) (51) 24 4 to 13 9 Median 
 Choong (1999) (11) 198 0 to 47 8 Average 
 Osio (2011) (52) 650 0 to 15 6 Mean  
b) Gender 
Ref Sample Male Female 
Proportion 
males 
95% CI 
Sturt (1971) (21) 401 217 184 54.1% 49.2 to 58.9 
Oren (1991) (37) 34 14 20 41.2% 26.4 to 57.8 
Castilla (1995) (51) 24 16 8 66.7% 46.7 to 82.0 
Choong (1999) (11) 198 86 112 43.4% 36.7 to 50.4 
Kakourou (2005) (48) 110 60 50 54.5% 45.2 to 63.5 
Braue (2005) (23) 30 17 13 56.7% 39.2 to 72.6 
Dohil (2006) (3) 302 145 155 48.0% 42.4 to 53.6 
Tabari (2007) (39) 21 13 8 61.9% 40.9 to 79.2 
Kuchabal (2010) (53) 100 62 38 62.0% 52.2 to 70.9 
Osio (2011) (52) 648 330 318 50.9% 47.1 to 54.8 
c) Time to resolution of lesions 
 
Ref Sample 
Age 
Range 
(years) 
Median 
(months) 
Range 
(months) 
 Overfield (1966) (13) 13 0 to 14 - 0 to 18 
 Hawley (1970) (47) 14 3 to 11 8 0 to 24 
 Notes: - missing data. 
2.5.2 Quality of life 
QoL can be impacted on greatly by dermatological conditions (54), although there are few 
studies specifically describing the impact upon QoL from MC. Where children and parents 
(n=30) completed QoL questionnaires when attending primary or secondary care consultation 
for MC, parents were significantly more concerned about MC than their child, 82% of parents 
(n=23) stated ‘it concerned them moderately or greatly’, compared to 43% of children (23). No 
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information was given of the validity of the QoL questionnaire which was used in the study, 
and there was no comparison of these results to other dermatological conditions. 
Studies reporting QoL using the CDLQI are reported in the next chapter in the systematic 
review of common skin conditions that used the CDLQI. 
 What are the reported risk factors of MC? 2.6
2.6.1 Swimming 
Table 4. Association between swimming and MC 
Ref 
Controls (num) MC positive (num) 
Relative 
Risk 
CI (95%) 
Sample 
History of 
swimming 
Sample 
History of 
swimming 
Postlethwaite 
(1967) (22) 
1848 915 13 13 - - 
Niizeki (1984) 
(24) 
24 4 24 12* 2.0 1.25 to 3.20 
Castilla (1995) 
(51) 
6995 5925 517 481 2.3 1.65 to 3.21 
Notes: - missing data. *High frequency swimming pool use 
Swimming was firstly discussed by Wilson (1910) as an activity causing an increased 
opportunity for transmission of MC (55), and from the published data it is clear there is an 
association between a recent history of swimming and development of MC in children (Table 
4).  
Comparing swimmers against non-swimmers, showed a strong association (RR 2.3 (95% CI 1.65 
to 3.21)) (51), and the relative risk was similar to that which compared high to low frequency 
swimming pool use (RR 2.0 (95% CI 1.25 to 3.20)) (24). It was not possible to calculate relative 
risk using data from a third study, however all children with a positive diagnosis of MC (n=13) 
did swim (22). 
An association was shown between swimming pool based activities, bathing and a more severe 
case of MC (> 26 lesions), specific activities being; using a school swimming pool (RR 1.86 (95% 
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CI 1.79 to 3.37)), sharing a bath sponge (RR 2.79 (95% CI 1.69 to 5.43)), and sharing a bath 
towel (RR 1.57 (95% CI 1.33 to 3.67)) with someone infected with MC (11). The cohort 
recruited in this study (n=210) consisted of persons aged zero to 47 years, this may skew the 
results as the risk factors described would be typically associated with school aged children 
who are more at risk of developing MC. The study does not show an increase risk of 
developing MC, but that children may have a more aggressive infection due to these specific 
activities. 
2.6.2 Transmission between family members 
Only one study described the incidence of MC in children in a household of an index case. A 
small number of children (n=8) were followed-up for the duration of their lesions during the 
1960’s, and reported two cases (n=2/8) where there was development of lesions in other 
family members (13). Although this does provide a description of development of lesions 
between family members, this is a relatively small sample and it was unknown if all eight cases 
did indeed have siblings.  
2.6.3 Associations with atopic eczema (AE) 
A group of children in Greece (n=110) with MC were compared to a previous national study to 
examine prevalence of AE between the two groups. 18.2% (n=20) of the MC cohort had AE 
compared to the results of the national survey of 5% (48). Although the data from this study 
illustrates the prevalence of AE in children with MC as high, the national survey examined 
children aged one to six years whereas the cohort of children attending the dermatology clinics 
were aged between eight months and 11 years, therefore not allowing a direct comparison. In 
North America the case notes of children attending paediatric outpatient clinics were 
prospectively reviewed (n=302) and showed a slightly higher proportion of children with MC 
(24%) also having AE (3). In France, a larger proportion of children with MC were shown to 
have a history of AE 43% (n=279) (52). North American children, aged less than five years with 
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a current MC diagnosis (n=84) were more likely to have had an AE diagnosis (n=109) (odds 
ratio (OR) 2.51 (95% CI 1.1 to 6.0) p=0.029) and more likely to have had or have a current AE 
diagnosis (OR 3.58 (95% CI 1.77 to 7.52) p< 0.05) than controls. 
A prospective observational study in a paediatric outpatient clinic in Brazil (n=284) suggested 
no relationship between MC and the development of AE (56) in children presenting with MC 
and/or AE; where the prevalence of MC in those with AE was 18.2% (n=38/209), and AE in 
those with MC 33.6% (n=38/113). However, an association was described between having a 
higher number of lesions and developing AE (p=0.045).  
2.6.4 Summary of presentation, QoL and risk factors 
All studies in this review showed the peak age would lie between 4 to 12 years, and the studies 
consisting of the largest number of children (46, 52) showed the mean age of children with MC 
to be in those aged 4 to 6 years. There were no differences in those presenting with MC 
between genders. 
There were two studies which described the time to resolution of lesions in children during the 
1960’s, both of these were of small sample sizes (Alaska:n=13 (13), Fiji:n=14 (47)). Highlighting 
that there is little evidence to describe the time to resolution of MC or estimate the prognosis 
in children who develop symptoms, and a clear gap in the scientific literature. 
Where a small number of parents and children were asked to complete a QoL questionnaire 
(23), the findings showed that MC was a concern for both. A universally validated instrument 
was not used, therefore not allowing for QoL comparisons between other dermatological 
conditions. 
The associations between swimming and a higher risk of MC development have been 
described often within the literature. Postlethwaite (22), Niizeki (24), Castilla (51), and Choong 
(11), all showed that swimming was common in those with MC. Where relative risk has been 
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calculated it indicates that swimming is a causal factor for development of MC in children. The 
sharing of towels and bath sponges with someone infected with MC was shown to increase the 
risk of having a more aggressive infection of MC (11).  
There is little evidence suggesting that children who have AE will develop MC during their 
childhood. Although the development of AE in children with MC is high and may lie between 
18% to 43%, the likelihood of a current or previous AE diagnosis in children with MC compared 
to controls is high (45). The search found no studies that have examined the relationship 
between children with a previous episode of AE and if they are more likely to develop MC. 
 Discussion 2.7
The three sections within this literature review chapter provide a detailed review of published 
epidemiological data of childhood MC. In summary, the largest incidence of MC in all ages is 
for children. Combining data from different studies it showed there was an overall incidence 
rate in children of 12 to 14 episodes per 1,000 person-years. Incidence rates in the UK were 
greatest in those aged one to four years, and there was little variation between genders (5, 
26).  Current rates have not been explored to describe recent trends or to provide a detailed 
analysis of age groups within those aged zero to 14 years. These age groups may show 
different rates of MC due to the changing behaviours for younger primary school aged children 
compared to older children who are attending secondary school. 
The analysis found an overall reported prevalence of MC in children of between 5.1% and 
11.5%. Where gender of those attending specialist dermatologists were examined, there was 
little variation in numbers between males and females. There is evidence for an association 
between swimming and having MC and MC is more common in those with AE, however there 
is little evidence for other risk factors. 
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 Limitations of systematic review 2.8
2.8.1 Potential limitations in the data collection methods 
The data collection methods used to capture a diagnosis of MC varied considerably, in two 
studies in Japan there may be over estimate of the point prevalence due to the self-reporting 
of a diagnosis. One study includes any previous diagnoses, and relies upon accurate recall by 
parents (40) and another did not report how a diagnosis of MC was obtained (24). Where a 
robust diagnostic method consisting of two independent dermatologist examinations was 
used, it only included children aged between six to 12 years, and therefore did not include 
those at greatest risk (aged under four years - as shown in incidence section). The results of 
the meta-analysis may also be skewed by the three studies reporting a much higher prevalence 
of MC.  
All studies on the incidence of MC used routinely collected data and this is subject to coding 
problems and under-ascertainment (2, 6, 57-64). Therefore, the true incidence of MC is likely 
to be considerably higher than reported in these studies. This is supported by the reported 
prevalence, especially in studies that involved examinations, compared to the reported 
incidence. 
2.8.2 Potential limitations of the study populations 
The association between MC and AE is not well described, and comparisons between the two 
are limited. Where the number of children with AE in a cohort of MC cases were compared to 
that of a national survey (48), they did not allow a direct comparison due to the different age 
groups; the national survey examined children aged one to six years whereas the cohort of 
children attending the dermatology clinics were aged between eight months to 11.5 years.  
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In the two studies in North America where data was extracted for the AI/AN population (44, 
45) the results may not be generalisable to wider population due to the selectiveness of study 
population being limited to only AI/AN’s. 
Where swimming pool and bathing activities such as using a school swimming pool, the sharing 
of towels and bath sponges with someone infected with MC were shown to increase the risk of 
having a more aggressive infection of MC (11). The analysis in this study included both adults 
and children and as the risk factors described would typically only be associated with school 
aged children who are more at risk of developing MC, this may have skewed the results. 
2.8.3 Potential biases of this review 
2.8.3.1 Limiting search results to the English language 
This systematic search of the literature was limited to only those published in the English 
language and therefore excluded non-English studies reporting the epidemiology of MC. 
Excluding studies based upon language could miss potentially important findings being 
reported within the results and this is a limitation of the results presented here. The limitation 
may be reduced as there is evidence that excluding research published in the non-English 
language are found to have generally little effect on summary effect estimates (27). 
2.8.3.2 The effects of citation bias 
The search results could have been affected by citation bias, whereby highly cited journals 
which are easy to find and often present at the top of search results are included within 
literature reviews and those which may prove difficult to find are potentially unjustifiably 
excluded. To avoid citation bias a systematic search of the most appropriate bibliographical 
databases was conducted that selected published research articles from all journals within the 
database that matched the search terms regardless of number of citations and place of 
publication. 
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2.8.3.3 Bias of the reviewer 
A final potential limitation of the systematic review is that the search could have been 
influenced by the reviewer (myself) as only I reviewed the papers that were included within 
the search. It is common for search results to be reviewed independently by at least two 
reviewers, however due to the feasibility and availability of a second reviewer only I reviewed 
the papers and extracted data of those identified from the search. This may have reduced the 
validity of the results and the Cochrane Collaboration guidance for systematic searches 
recommends more than one reviewer to minimise errors and reduce potential bias introduced 
by reviewers (65). To provide transparency in the search methods, and conforming to the 
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement 
(66), the method of study selection including search strategy, process for selecting studies, and 
method of data extraction were provided explicitly in the methods and consistently adhered 
to. Papers were also discussed with JG2 who advised on data extraction, any further analysis 
and the presentation of results. 
          Conclusions 2.9
 This systematic review highlights that data on the epidemiology of MC is of poor 
quality and this may be due, in part, to MC often being considered to be a trivial 
condition by some clinicians (2) and therefore there has been little research in the 
area. 
 In the UK there have been no studies that have described the presentation, current 
management, transmission, impact on quality of life and time to resolution of MC. 
 Summarising the available published data suggest the prevalence of MC in children 
aged zero to 16 years may lie between 5.1% to 11.5%. 
 The greatest incidence of MC is for children aged one to four years; however the 
incidence in the five to nine age group has not been clearly described. 
                                                          
2
 John Gallacher (JG), Professor of Epidemiology and academic supervisor for this thesis. 
Page | 33 
 
 There are few data on the time to resolution but the best available data suggests that 
lesions last anywhere from 2 months to 2 years.  
 MC appears to be more common in children who swim. 
 Children with MC seem to have a higher prevalence of AE, the relationship between a 
previous diagnosis of AE and future risk of MC has so far not been reported.  
The following chapter will conduct and report the findings of a systematic review of studies 
that have used the CDLQI to describe the impact of common skin conditions on QoL. 
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Chapter three: Systematic review of common skin conditions using the children’s 
dermatology life quality index (CDLQI). 
3. Overview 
This chapter describes a second systematic review exploring studies that have used the CDLQI 
to describe QoL for childhood MC and other common skin conditions presenting in children. 
The overall findings of CDLQI scores by study and condition will be described, including a meta-
analysis of these conditions which will summarise the weighted average CDLQI score for a 
condition and for all common skin conditions. A detailed description of QoL in children with 
MC that have used the CDLQI scores will be provided. Finally, the results will be summarised 
and I will discuss how these impacted the interpretation of results later in this thesis. 
 Children’s Dermatology Life Quality Index (CDLQI) 3.1
The CDLQI was developed by academics within the Department of Dermatology at Cardiff 
University to measure the QoL in children with skin disease (67). The validity of the CDLQI in 
measuring QoL in children aged four to 16 years has been measured and found to be 
acceptable, and the instrument is available as a text or a cartoon version (68). Since its 
creation in 1995 recent publications have described the CDLQI being used in over 102 research 
studies (69) and it is the most widely used dermatological specific instrument for measuring 
QoL in children with skin conditions worldwide. 
The CDLQI has been used in this thesis therefore it is important that the meaning and an 
understanding of a CDLQI score is provided prior to the interpretation of the results. Although 
a thorough review of the CDLQI use from its development was recently published in 2013 (69) 
this paper did not provide a pooled summary or meta-analysis of each condition’s CDLQI score 
and compare this to other common skin conditions. By providing a meta-analysis of the mean 
CDLQI score of a range of common skin conditions it can aid interpretation between these 
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conditions and also provides a weighted average CDLQI score for individual and grouped 
conditions; therefore providing a more accurate representation of QoL effect. 
3.1.1 Interpretation of CDLQI scores 
The CDLQI is predominately used to mark changes in QoL between two time points during 
treatment trials or to describe the natural history of a condition where the main outcome of 
the research may be to provide the percentage change of a QoL score at different times for the 
same patient (67). For epidemiological studies where the aim is to measure QoL impact of the 
same condition within a large sample of children, the meaning of an overall mean CDLQI score 
is required to aid interpretation. Waters (2010) developed a severity stratification of CDLQI 
scores that can be used to interpret a CDLQI score (Table 5). This stratification was published 
as a conference abstract and therefore the full methodologies and validity of those scores are 
not provided in detail. However, this severity banding is widely used to interpret a mean CDLQI 
score within the scientific literature (69). The CDLQI severity bands developed by Waters will 
be used within this chapter and later in this thesis (chapter seven) to interpret CDLQI scores. 
Table 5. Interpretation of CDLQI score by severity banding (70) 
Score QOL Effect 
0 to 1 No effect 
2 to 6 Small effect 
7 to 12 Moderate effect 
13 to 18 Very large effect 
19 to 30 Extremely large effect 
 Literature search methods 3.2
3.2.1 Aim 
The aim of this review is to compare the mean CDLQI scores from published data of childhood 
MC and other common childhood skin diseases. 
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3.2.2 Search strategy 
A systematic search of bibliographical databases was carried out using a predefined search 
strategy in January 2014. Articles were also identified from citations within articles, from 
identification by experts, and from searching the online CDLQI bibliography (71). 
The search term “CDLQI” was used in OVIDsp to search the Medline (1995 to January Week 2 
2014) and Embase databases (1995 to January 2014) (1995 chosen as date CDLQI was first 
published). Duplicates were removed and the search was restricted to articles in English. 
3.2.3 Data extraction and analysis 
All publications identified were screened by title and abstract using the inclusion criteria stated 
in the following sub section. All potentially relevant articles were fully reviewed by myself 
using a template to record condition, study location, setting, study design, sample, and CDLQI 
score (mean, standard deviation (S.D.)). 
3.2.4 Inclusion and exclusion criteria 
Articles were included if they were original research articles of skin conditions that reported 
QoL using the CDLQI. I excluded studies if data was not presented at baseline in intervention 
studies, if data had been split by treatment arm, or overall CDLQI data was not presented. 
Studies were excluded where CDLQI and DLQI scores were combined as this has been shown 
to potentially invalidate results (72). 
A list of articles that had been screened and met the inclusion criteria was produced. The list 
was discussed with a panel of two experts; NF3 and AYF4 who identified which conditions were 
‘common’ or ‘uncommon’ and therefore should be included within the final analysis.  
                                                          
3
 Nick Francis (NF), Clinical Reader and GP with expertise in skin conditions.  
4
 Andrew Finlay (AYF), Professor of Dermatology. 
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 Results 3.3
3.3.1 Search results 
The search identified 187 articles. After reviewing the abstracts of all 187 articles, 26 met the 
inclusion criteria (Figure 5). Within the 26 articles, CDLQI scores were given for 22 skin 
conditions. The following ten common conditions were included within the meta-analysis: 
acne (number of articles=4), AE (n=19), MC (n=2), naevi (n=1), psoriasis (n=7), pityriasis rosea 
(n=1), scabies (n=1), urticarial (n=1), vitiligo (n=4), and warts (n=2) (Table 6). The following 
uncommon conditions were excluded: alopecia, congenital ichthyosis, ectodermal dysplasia, 
epidermolysis bullosa, erythropoietic protoporphyria, hydroa vacciniforme, neurofibromatosis, 
photosensitivity disorders, pigmentary abnormality, scleroderma, vascular abnormality, and 
xeroderma pigmentosum. 
Figure 5. Flow chart of study selection process 
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Table 6. CDLQI scores of common skin conditions by study, setting and design 
  
Ref Ref Year Location Setting Study Design Sample Size 
CDLQI Score 
(mean) 
SD (±) 
Acne 
  
Beattie (73) 2006 UK Secondary Care Case series 50 5.4 4.69 
Jankovic (74) 2012 Serbia Community Cross-sectional 353 4.35 9.5* 
Lewis-Jones (67) 1995 UK Secondary Care Case series 40 5.7 4.4 
Walker (75) 2006 UK Community Cross-sectional 147 1.7 5.9* 
Atopic Eczema 
  
Hon  (76) 2008 China Secondary Care Case-control 44 7.4 4.8 
Chinn (77) 2002 UK Secondary Care Case-control 120 7.9 6.1 
Chuh (78) 2003 China Secondary Care Case series 10 7.7 2.95 
Dertlioglu (79) 2013 Turkey Secondary Care Case-control 50 7.74 4.59 
Ganemo (80) 2007 Sweden Secondary Care Case series 50 7.1 4.4 
Holm (81) 2006 Denmark Secondary Care Case series 35 8 (median) - 
Hon (82) 2007 China Secondary Care Treatment trial 28 8.7 5.4 
Hon (83) 2010 China Secondary Care Case-control 110 8.6 5.3 
Jirakova (84) 2012 Czech Republic Secondary Care Case series 48 8 4.98 
Kim (85) 2012 Korea Secondary Care Case series 415 6.6 6.3 
Maksimovic (86) 2011 Serbia Secondary Care Case series 64 12.74 6.29 
Amaral (87) 2012 Brazil Secondary Care Case series 52 9.5 7.8* 
Manzoni (88) 2012 Brazil Secondary Care Case series 50 9 (median) - 
Noor Aziah (89) 2002 Kuala Lumpur Secondary Care Case series 33 10 6.6 
Shum (90) 2001 UK Secondary Care Case series 237 10.5 7.3* 
Sunderkötter (91) 2006 Germany Secondary Care Case series 1438 12.2 6 
Lewis-Jones (67) 1995 UK Secondary Care Case series 47 7.7 5.6 
Beattie (73) 2006 UK Secondary Care Case series 106 9.14 6.69 
Beattie (73) 2006 UK Secondary Care Case series 38 4.9 5.25 
Molluscum Contagiosum 
  Beattie (73) 2006 UK Secondary Care Case series 14 3.07 3.58 
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Ref Ref Year Location Setting Study Design Sample Size 
CDLQI Score 
(mean) 
SD (±) 
Lewis-Jones (67) 1995 UK Secondary Care Case series 7 4.9 3 
Naevi 
  Beattie (73) 2006 UK Secondary Care Case series 56 1.46 3.04 
Pityriasis Rosea 
 Chuh (78) 2003 China Secondary Care Case series 10 3.5 1.18 
Psoriasis 
  
Beattie (73) 2006 UK Secondary Care Case series 29 9.17 7.83 
de Jager (92) 2010 Netherlands Secondary Care Case series 39 6 (median) - 
Lewis-Jones (67) 1995 UK Secondary Care Case series 25 5.4 5 
Manzoni (88) 2012 Brazil Secondary Care Case series 25 7 (median) - 
Oostveen (93) 2012 Netherlands Secondary Care Case series 125 7.5 5 
Oostveen (94) 2014 Netherlands Secondary Care Case series 34 9.6 5.4 
Paller (95) 2010 North America Secondary Care Case series 182 2.6 3.3 
Scabies 
  Lewis-Jones (67) 1995 UK Secondary Care Case series 6 9.5 10.5 
Urticria 
 Beattie (73) 2006 UK Secondary Care Case series 17 6.12 6.39 
Vitiligo 
  
Dertlioglu (79) 2013 Turkey Secondary Care Case-control 50 11.68 6.54 
Njoo (96) 2000 Netherlands Secondary Care Treatment trial 51 5.6 3.8 
Manzoni (88) 2012 Brazil Secondary Care Case series 43 2 (median) - 
Kruger (97) 2012 Germany Secondary Care Case series 51 2.8 3.8 
Warts 
  
Beattie (73) 2006 UK Secondary Care Case series 24 2.87 3.38 
Lewis-Jones (67) 1995 UK Secondary Care Case series 34 3.3 2.9 
Notes: * Standard deviation not provided in published data, calculated using methods by Hozo (2005)(98) - Standard deviation not provided in published data and 
insufficient information to calculate.  
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3.3.2 Study design and geography 
Of the 42 conditions that were extracted from the 26 published articles, the majority of data 
for these conditions were from case series studies of children attending a specialist 
dermatology centre (n=33 (78.6%)), five were case-control studies and the remaining four 
treatment trials (n=2) or cross-sectional studies (n=2). Over half of the conditions (n=27 
(64.3%)) were described in children of Western Europe or North American countries.  
Most studies contained data of just one condition, however two studies, both of UK children, 
used the CDLQI in children attending dermatology outpatient clinics to describe QoL from 
multiple conditions (67, 73).  
3.3.3 CDLQI score of children with MC 
Two similar studies in the UK provided CDLQI scores for children with MC (Table 6). Firstly 
children, aged four to 16 years, attending a paediatric dermatology clinic in Wales, UK were 
asked to complete the CDLQI during 1992 to 1993 (67) (younger children may be assisted by 
their parents when completing the CDLQI). 223 children provided complete CDLQI’s, and seven 
of those had presented to the clinic with MC (four males, three females). The mean age of 
children with MC was 7.6 years and the mean CDLQI score was 4.9 (range 2 to 11) indicating a 
small QoL effect. A second study of children attending paediatric dermatology clinics in 
Scotland, UK recruited 379 children aged five to 16 to complete the CDLQI where they had 
experienced symptoms of their condition for over 6 months (73).  Fourteen children with MC 
completed the CDLQI and had a mean age of 8 years. The mean CDLQI score was 3.07 and 
ranged between 0 to 11, indicating again a small QoL effect for children with MC. 
3.3.4 CDLQI scores for other conditions 
The mean CDLQI scores of common skin diseases ranged between 3.9 to 6.5 (Figure 6), 
indicating that overall they have a small to moderate effect on QoL. The CDLQI has been 
mostly used for children with AE and the mean CDLQI scores were provided in 19 studies and 
Page | 41 
 
provided a weighted average of 5.7 to 10.7; suggesting that overall AE has a moderate effect 
on QoL in children.  
Data of five conditions (contained within three publications (81, 88, 92)) were not included 
within the meta-analysis as means and standard deviations were not given. However for these 
five conditions the median data fell between the ranges of estimates calculated within the 
meta-analysis. 
Figure 6. Comparison of mean CDLQI scores by skin condition 
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The weighted-estimated mean CDLQI scores for acne (0 to 9.9), naevi (0 to 7.4), psoriasis (1.4 
to 9.7), scabies (0.0 to 30), urticaria (0 to 18.6), vitiligo (0.4 to 10.5), and warts (0 to 7.4) were 
based on small numbers with wide confidence intervals and therefore the QoL effect cannot 
yet be fully determined.  
 Discussion 3.4
Two studies used the CDLQI to describe QoL in children with MC, both highlighting an overall 
small QoL effect from the condition when the mean CDLQI scores are provided. Both of these 
studies represent small numbers of children (n=7,14) and therefore it is difficult to provide a 
more detailed description of QoL effect from MC with strong statistical power; when the 
results are included within a meta-analysis it provides wide confidence intervals. 
Overall the common skin conditions included within this review are shown to have had a small 
effect on a child’s QoL. Of all of the conditions the CDLQI has been used most frequently to 
measure QoL for children with AE; where overall there is a moderate effect on QoL in children 
(CDLQI score range 5.7 to 10.7). Data included within the meta-analysis are from various study 
designs; in most studies (92.7%), children were recruited from dermatology outpatient clinics 
with only two cross-sectional studies recruiting from the community. Typically dermatologists 
are referred the more severe and complicated cases from primary care and so the CDLQI 
scores reported from secondary care may be higher than typical cases existing in the 
community. Studies of AE that recruited from the community reported lower CDLQI scores  
than studies from secondary care (males 4.7 Females 4.3 (99)), although there was a relatively 
low response rate (urban 35%, rural 78%) which may have been a contributing factor. This may 
highlight an area for future research in assessing whether the CDLQI is valid in measuring QoL 
in both primary, secondary, and community care scenarios. Where the dermatology life quality 
index (DLQI) (a QoL tool developed for use in adults aged 16 years and over) was used in adults 
in primary care there were comparable results to that of patients seen in secondary care (100).  
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Studies were excluded from the meta-analysis if data was not given of all participants at 
baseline before treatment or stratification into study arms.  The meta-analysis therefore does 
not include some studies which did use the CDLQI to measure QoL and this is a limitation of 
the findings. 
 Conclusions 3.5
The CDLQI is a useful instrument to measure QoL as it allows the score to be given a severity 
rating and this provides a meaningful interpretation of scores. There were two published 
studies that provided data for children with MC, both of relatively small numbers of UK 
children. Where the mean CDLQI scores are produced in both studies they showed an overall 
small effect on QoL from the condition; meta-analysis combining the data from these two 
studies estimates MC has between no effect to a small effect on a child’s QoL. Although the 
mean scores for both of these studies showed a small effect on QoL, the range of scores 
highlight that some children are experiencing a moderate effect on QoL (CDLQI score greater 
than seven) and neither study indicated what proportion of children presenting with MC are 
experiencing this higher disease severity. To explore symptoms of MC and QoL later in chapter 
seven, data of the presentation of MC symptoms are analysed by a child’s CDLQI score to 
describe whether different presentations in symptoms are associated with a higher or lower 
effect on QoL, and provide a detailed description of the distribution of CDLQI scores within the 
cohort of children with MC. 
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Chapter four: Descriptive epidemiology of molluscum contagiosum: longitudinal 
retrospective cohort of children presenting to primary care in the UK. 
4. Overview 
This chapter will describe the incidence of primary care consultations for MC in children in the 
UK. The aims, objectives, data source, extraction and approval processes, and the analysis and 
statistical plans will be described. This will be followed by a summary of the results and a 
discussion of the key strengths and weaknesses. A comparison of these results to the 
published literature will be discussed in the final thesis discussion chapter (chapter eight). 
 Background  4.1
The two most recently published studies describing childhood MC in the UK described primary 
care consultations using data from 1994 to 2003 (5) and 2006 (26) respectively, and extracted 
from the same sentinel practice network (Weekly Returns of the Royal College of General 
Practitioners). The results of these studies were described in chapter two. I have not been able 
to identify any more recent studies of the incidence of primary care consultations for MC in 
the UK.  
4.1.1 MC and atopic eczema (AE) 
Chapter two described that AE is common in children with MC (40, 52, 56, 101, 102) and the 
prevalence of AE was higher in children with MC than in the general population (48). Children 
diagnosed with MC are more likely to have or to have had an AE diagnosis (45). Most studies 
that include data on both MC and AE have described cases in speciality dermatology care (56), 
and while these studies clearly highlighted an association in this population, there is no 
published data on whether children with a diagnosis of AE in primary care have a greater risk 
of developing MC. It is therefore important to understand whether AE presents more 
commonly in those with a current MC diagnosis and/or, alternatively, children who are 
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diagnosed with AE, a condition shown to be associated with abnormalities in immune 
regulation, are also more likely in the future to develop other skin conditions such as MC. 
Although this analysis can’t describe the causes of diseases, it may highlight an association 
between the two conditions which may lead to further exploration of the basic science for 
both conditions. 
 Clinical Practice Research Datalink (CPRD)  4.2
Data was extracted from the UK CPRD which is a primary care database of anonymised patient 
records representing almost 6% of the UK population. CPRD collects routinely collected data 
prospectively from participating general practices in the UK and currently contains data from 
over four million active patients and 500 primary care practices across the UK (103). The 
database is maintained and managed by the NHS National Institute for Health Research (NIHR) 
and access to the data are available to researchers to support innovative and informative 
research. Data can be linked to secondary care data, diseases registries and key socio-
demographic datasets. The data held within CPRD are validated and been found to be 
generalisable to the UK population (104).  
4.2.1 CPRD Datasets 
CPRD is a relational database and uses data from registered UK primary care practices. CPRD 
includes data relating to the individual consultation such as the date, time of the consultation, 
and diagnosis. Consultation data can then be linked to further tables held within the database 
that make up the CPRD dataset containing information about the individual patient, staff 
information, practice demographics, referral/s to secondary care, immunisation/s, tests and 
prescribed therapies. The tables can be linked by the unique patient identifier which is 
provided by CPRD. The patient identifier is included within each row of all data held in CPRD 
and the data held within CPRD is anonymised meaning individual patients cannot be identified 
from the data source. 
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Any diagnosis given during a consultation is recorded as a Read-code. CPRD data are coded 
using schemes and dictionaries used in the NHS such as Read and the International 
Classification of Diseases (ICD-10), and therapies are coded using the British National 
Formulary (BNF) (105). 
4.2.2 Data quality 
CPRD defines the quality of the data recorded by the primary care practice and also the quality 
of the data relating to the patient. Practices are marked as being “up-to standard” 
(acceptable=1 or unacceptable=0) following a quality assessment, this quality marker 
measures that the practice meet specified data entry quality criteria (106). 
Individual patients are quality measured as being “research acceptable” (acceptable=1 or 
unacceptable=0), those marked as being “research acceptable” are assessed to ensure they 
hold a complete and valid dataset (complete data for age, gender, date of registration, and 
hold no data outside of normal ranges (i.e. a consultation prior to birth)). 
 Aims and objectives 4.3
This study aims to describe the consultation rate of children presenting to primary care with 
MC in the UK, the management of MC in primary care, and test the hypothesis that a history of 
AE increases the likelihood of a future MC consultation during childhood. 
4.3.1 Primary objective 
The primary objective was to describe the consultation rate for MC per 1,000 total CPRD 
practice population, age and sex distribution, and trend analysis of overall rates of disease 
presenting to general practice. 
4.3.2 Secondary objectives 
The secondary study objective was to examine management of MC in terms of treatments 
prescribed and referral to other services, and relationship to AE. 
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 Study Design 4.4
Two studies are reported in this chapter: a retrospective longitudinal study of MC cases and an 
age-sex matched case-cohort study of AE cases.  
4.4.1 Primary Aim (Study one - descriptive) 
(A) Describe the trends in consultation rates for MC in individuals presenting to general 
practice. 
Research objectives/questions 
1. Stratified age/sex trends in consultation rates of MC by year of age. 
(B) Describe the management of MC in primary care as recorded in primary care records. 
Research objectives/questions 
1. Describe medications prescribed or procedures administered for MC. 
2. Describe referrals to secondary care following a diagnosis of MC. 
4.4.2 Secondary Aim (Study two - hypothesis testing) 
(C) Hypothesis: Children, aged zero to 14 years, are more likely to consult for MC during 
childhood if they have a previous diagnosis of AE. 
Null Hypothesis: There is no association between a diagnosis of AE and a subsequent diagnosis 
of MC. 
Research objectives/questions 
1. Determine the likelihood of an MC consultation in children with a prior diagnosis of AE 
compared to those without a previous diagnosis of AE. 
2. Determine whether prescribed treatments during an AE consultation, severity of 
eczema (based upon coded diagnosis marked as secondary aim), or age from AE 
impacts on likelihood of a future MC consultation. 
3. Describe average time between onset of AE and first MC diagnosis. 
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4.4.3 Study Population 
CPRD “research-acceptable” patients were extracted from all practices that were “up-to-
standard” at the time of a diagnosis of MC and/or AE within a specific population subset. 
 Statistical Analysis 4.5
4.5.1 Retrospective longitudinal study of MC cases (study one) 
4.5.1.1 Sample size calculation 
From previous research (described in chapter two) the suggested incidence of primary care 
consultations for MC in the UK ranged from 15.0 to 17.2 per 1,000 for those aged zero to 14 
years (5, 26), estimating an average practice will see 10 paediatric cases of MC per year. Within 
CPRD, and with an estimated number of primary care practices of 650, there may be 6,500 MC 
consultations per year in the zero to 14 population. If this figure over estimates the actual 
number and the true population is as much as 20% lower, the CPRD database will provide a 
large sample for the analysis being conducted. This would also provide a larger population 
than previous studies in the UK.  
4.5.1.2 Analysis 
The consultation rate was calculated using age-specific rates of numbers diagnosed against 
total population in the specified age group of CPRD. Consultation rates were produced by age 
and year to produce annual trends of MC. To test for seasonality of consultations, rates were 
produced quarterly with an ARIMA test of seasonality performed, and data presented in a 
correlogram to highlight seasonal variation. 
4.5.1.3 Denominator 
The denominator data used was the overall population of CPRD. Patients were included within 
the denominator dataset from practices marked “up-to standard” and if the patient was 
“research acceptable”. 
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4.5.2 Age-sex matched case-cohort study (study two) 
4.5.2.1 Sample size calculation 
Previous studies have been insufficient in calculating the likelihood of a child having a future 
MC consultation following an AE diagnosis by a GP, and this is mainly due to having no control 
group within their study population. Given an estimated consultation rate for MC and AE of 
172 and 603 per 10,000 respectively, in order to detect a minimal OR of 2.0 with 90% power 
and 95% confidence it would require a minimum of 2,259 cases with AE and age-sex matched 
controls within each age subset. Controls for the case-cohort analysis were selected at random 
within age-sex strata at a ratio of 1:1. This estimate was calculated within STATA 12 using the 
sampsi_mcc command (107), the values used within this calculation and output are shown 
below (Figure 7). 
Figure 7. Case-cohort study sample size calculation  
 
The CPRD dataset holds over the required number of annual paediatric cases of AE, indicating 
that the proposed secondary analyses will be adequately powered. 
4.5.2.2 Analysis 
Logistic regression analysis was used to determine odds ratios for the association between 
‘exposure’ to AE and the risk of an MC outcome. Multivariate analyses were also performed. In 
the multivariate models the data were adjusted for age, treatment and eczema diagnosis 
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(primary and secondary diagnosis, as marked on Read-codes (Table 8)). Significance was 
assumed at the 5% level, and 95% confidence intervals are reported. 
For the purposes of reporting results of the multivariate analysis no data were reported where 
numbers are less than five to ensure no unintentional (deductive) disclosure arose.  
4.5.2.3 Exposure 
Baseline exposure to AE was defined as a 30 day AE free ‘wash-in’ period where there are no 
consultations for AE prior to first recorded diagnosis of MC. An AE diagnosis during the 
‘primary outcome’ consultation for MC will not be classed as prior exposure. 
4.5.2.4 Treatments  
Treatments or no treatment for AE were categorised for covariate analysis. The severity of AE 
was also measured by the potency of corticosteroids prescribed as shown in Table 7 below. 
Consultations that involved a code for mild to moderate AE treatment and a dermatology 
referral were classed as having severe AE. The dermatology referral for AE needed to be 30 
days prior to the MC diagnosis to ensure the referral was not for MC. 
Table 7. Treatments for AE and severity 
Severity Potency of corticosteroids 
Severe 
Very potent or super potent (up to 600 times as potent as hydrocortisone) 
Potent (100-150 times as potent as hydrocortisone) 
Moderate Moderate (2-25 times as potent as hydrocortisone) 
Mild Mild (Hydrocortisone) 
4.5.3 Analytical Software 
Analysis was performed using statistical software STATA 12. 
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4.5.4 Missing Data 
As only data from patients flagged as being of ‘research-acceptable’ quality were used there 
was no missing data for age, gender or practice. No participants were recorded as gender 
indeterminate. 
4.5.5 Read-Codes 
For MC there were two Read-codes that clinicians were able to use when diagnosing MC 
within CPRD, both of these were selected for extracting data. NF produced a list of AE 
diagnosis for extraction; less common eczema’s were marked for secondary analysis. The 
Read-codes used for extraction of data from CPRD are shown in Table 8. 
Table 8. MC and AE CPRD Read-codes 
  Read-code Description Secondary analysis 
Molluscum Contagiosum 
  A780000 Molluscum contagiosum with eyelid involvement - 
  A780.00 Molluscum contagiosum - 
Atopic Eczema 
  8HTu.00 Referral to eczema clinic 
   A540.00 Eczema herpeticum - Kaposi's varicelliform eruption 
   F4D3000 Eczematous eyelid dermatitis 
   M07y.11 Pustular eczema Secondary 
  M102.11 Pustular eczema Secondary 
  M111.00 Atopic dermatitis/eczema 
   M112.00 Infantile eczema 
   M113.00 Flexural eczema 
   M114.00 Allergic (intrinsic) eczema 
   M119.00 Discoid eczema 
   M11A.00 Asteatotic eczema Secondary 
  M12z100 Eczema NOS 
   M12z111 Discoid eczema 
   M12z200 Infected eczema Secondary 
  M12z300 Hand eczema Secondary 
  M12z400 Erythrodermic eczema Secondary 
  Myu2.00 Dermatitis and eczema Secondary 
  Myu2200 Exacerbation of eczema 
   M11..00 Atopic dermatitis and related conditions Secondary 
  M11z.00 Atopic dermatitis NOS 
   M252100 Pompholyx unspecified Secondary 
  M12z000 Dermatitis NOS Secondary 
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 Approvals 4.6
The study protocol was reviewed by the Independent Scientific Research Committee (ISAC) for 
the UK Medicines and Healthcare Products Regulatory Agency (MHRA) database research. 
Approval was granted on 17th March 2014 for CPRD data to be extracted and used for the 
purposes defined within this chapter and within the study protocol [ISAC Ref: 14_058R]. A 
copy of the ISAC approval letter relating to this research can be found in appendix 5.4. 
 Data extraction and cleaning 4.7
4.7.1 Data extraction 
Data were extracted from the CPRD database through the Cardiff University licence providing 
access directly to the data source. The data was requested from the ‘Pharmatelligence’ team5 
within the Institute of Primary Care and Public Health by NF and provided to myself on 19th 
May 2014 in a series of linked data tables in text format. Data was only provided from “up to 
standard practices” and therefore each data field held complete data and was ranked by CPRD 
as having a high standard of accuracy.  
4.7.2 Data cleaning 
Data were provided in nine text files which each held the unique identifiers for a consultation 
of patient ID and event date. All MC and AE consultations for the period 2004-13 were 
provided in a master file that contained information relating to the consultation, patient, and 
practice.  
4.7.3 MC dataset (study one) 
Data relating to MC consultations identified by the appropriate Read-code were extracted 
from the master file to prepare the dataset for analysis. Where a patient had multiple 
consultations for MC during the time period, the data for each consultation was grouped 
within a single row of data (Figure 8). Data relating to referrals to dermatology and therapies 
                                                          
5
 Pharmatelligence is a private enterprise located and aligned with Cardiff University. 
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prescribed were merged into the dataset using the identifiers of patient ID and event-date. 
Within the dataset new fields were created to describe the time between consultations, 
number of consultations, age at event, and the month, quarter, and year of event. 
Figure 8. Data cleaning and preparation for analysis (MC consultations 2003-14) 
 
4.7.4 MC and AE dataset (study two) 
Data for all AE consultations during 2004-13 were extracted from the master dataset. 
Consultations per patient were joined to produce a wide database where each row was a 
uniquely identifiable patient (Figure 9). The total number of consultations per patient for an AE 
Read-code was calculated and included on the row, as was the date of the first AE consultation 
for that patient. Data relating to referrals and therapies were joined based upon patient ID and 
event-date of the consultation; only referrals coded for ‘dermatology speciality’ were included 
in the final dataset. Therapies for corticosteroids were marked by severity based upon their 
BNF chapter classification of potency (as per Table 7). The data were merged with the ‘MC 
Master’ file (all consultations 2004-13) by patient ID. The dates between the first AE and initial 
MC consultations were calculated and coded for the purposes of analysis. 
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An age (year of birth) and sex matched control group was extracted from the CPRD registered 
population. Patients who ‘transferred out of practice’ or died during the study period were 
removed. Children who had an AE diagnosis or also featured within the cases group were 
extracted from the population pool before the controls were selected randomly.  
The control group was merged with the ‘MC master’ database to identify if any patients 
consulted for MC during 2003-14. 
Figure 9. Data cleaning and preparation for analysis (MC and AE consultations 2003-14) 
 
 Results 4.8
4.8.1 Retrospective longitudinal study of MC cases (study one) 
During the period 2004-13 there were 116,234 consultations for MC within the CPRD database 
that met the inclusion criteria for 89,015 unique individuals. The initial consultation that a 
patient had for MC is used within the analysis of the data in this chapter. 
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Two Read-codes for MC are available: one for, ‘Molluscum contagiosum’ and one for, 
‘Molluscum contagiosum with eyelid involvement’. Almost all cases identified in CPRD had 
been coded with the first Read code, 38 cases (0.04%) used the ‘eyelid involvement’ code 
(Table 9). 
Table 9. Count and percentage of MC consultations aged 0 to 14 years, 2004-13 by Read-
code. 
Read-code Description Events % 
A780.00 Molluscum contagiosum 88,977 99.96 
A780000 Molluscum contagiosum with eyelid involvement 38 0.04 
Total 89,015 100 
4.8.1.1 Patient demographics 
Of the 89,015 unique patient consultations, 44,995 were for males, representing 50.6% of the 
total study population (Table 10).  
Table 10. Count and percentage of patient gender aged 0 to 14 years, 2004-13 
Gender Events % 
Male 44,995 50.55 
Female 44,020 49.45 
Total 89,015 100 
 
4.8.1.2 Consultation rates for MC 
Gender 
There was little difference in mean consultation rates between males and females in children 
aged zero to 14 years over the 10 year period (Table 11). 
Table 11. Consultation rate per 1,000 registered population 2004-13 aged 0 to 14 years by 
gender 
Gender Events Pop 
Rate per 
1,000 
LCI UCI 
Male 44,995 4,739,203 9.5 9.4 9.6 
Female 44,020 4,506,644 9.8 9.7 9.9 
Total 89,015 9,245,847 9.6 9.6 9.7 
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Age 
The highest consultation rates were in children aged four and five years for both males and 
females (Table 12). Figure 10 shows that MC consultations rates are more common in younger 
children aged less than 10 years. The main peak in consultation rates is seen in children aged 
three to seven years. 
Table 12. Consultation rate per 1,000 registered population,2004-13,by age(year) and gender 
Age 
Events Population Consultation rate per 1,000 
M F M F M LCI UCI F LCI UCI 
0 547 411 282,744 268,564 1.9 1.8 2.1 1.5 1.4 1.7 
1 3,090 2,603 337,101 320,516 9.2 8.8 9.5 8.1 7.8 8.4 
2 4,236 3,906 332,492 316,642 12.7 12.4 13.1 12.3 12.0 12.7 
3 4,768 4,457 326,299 310,812 14.6 14.2 15.0 14.3 13.9 14.8 
4 5,202 5,271 320,142 304,949 16.2 15.8 16.7 17.3 16.8 17.8 
5 5,235 5,336 314,413 299,534 16.7 16.2 17.1 17.8 17.3 18.3 
6 4,392 4,544 310,215 295,805 14.2 13.7 14.6 15.4 14.9 15.8 
7 3,950 4,092 308,714 294,364 12.8 12.4 13.2 13.9 13.5 14.3 
8 3,497 3,520 309,071 294,392 11.3 10.9 11.7 12.0 11.6 12.4 
9 3,077 3,108 310,205 295,437 9.9 9.6 10.3 10.5 10.2 10.9 
10 2,398 2,452 311,589 296,797 7.7 7.4 8.0 8.3 7.9 8.6 
11 1,807 1,817 314,791 299,657 5.7 5.5 6.0 6.1 5.8 6.3 
12 1,363 1,258 318,224 301,966 4.3 4.1 4.5 4.2 3.9 4.4 
13 870 777 321,068 303,422 2.7 2.5 2.9 2.6 2.4 2.7 
14 563 468 322,135 303,787 1.7 1.6 1.9 1.5 1.4 1.7 
Total 44,995 44,020 4,739,203 4,506,644 9.5 9.4 9.6 9.8 9.7 9.9 
Figure 10. Consultation rate per 1,000 registered population, 2004-13, by age (year) and 
gender 
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Year 
Consultations for MC have been steadily declining from 2004 to 2013 (Figure 11). Rates for 
males have declined by 48.1% over the 10 year period, and for females the decline is similar 
(51.1%) (Table 13). During the period 2004-2011 females had a higher consultation rate for MC 
than males, in 2012 the rates between genders were equal, and is 2013 males had a marginally 
higher rate than females (Figure 11). 
Table 13. Consultation rate per 1,000 registered population aged 0 to 14 years, by year and 
gender 
Year 
Events Population Consultation rate per 1,000 
M F M F M LCI UCI F LCI UCI 
2004 6,415 6,302 489,203 459,188 13.1 12.8 13.4 13.7 13.4 14.1 
2005 5,504 5,395 487,412 459,831 11.3 11.0 11.6 11.7 11.4 12.0 
2006 5,256 5,280 491,478 465,970 10.7 10.4 11.0 11.3 11.0 11.6 
2007 4,981 4,788 488,420 464,567 10.2 9.9 10.5 10.3 10.0 10.6 
2008 4,407 4,493 481,759 459,298 9.1 8.9 9.4 9.8 9.5 10.1 
2009 4,328 4,069 477,245 455,940 9.1 8.8 9.3 8.9 8.7 9.2 
2010 4,037 3,867 474,016 452,026 8.5 8.3 8.8 8.6 8.3 8.8 
2011 3,758 3,820 462,035 441,239 8.1 7.9 8.4 8.7 8.4 8.9 
2012 3,368 3,231 451,934 432,115 7.5 7.2 7.7 7.5 7.2 7.7 
2013 2,941 2,775 435,701 416,470 6.8 6.5 7.0 6.7 6.4 6.9 
Total 44,995 44,020 4,739,203 4,506,644 9.5 9.4 9.6 9.8 9.7 9.9 
 
Figure 11. Consultation rate per 1,000 registered population aged 0 to 14 years, by year and 
gender. 
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4.8.1.3 Trends 
Overall for males and females consultations for MC decreased by 50.5%, decreases were 
highest for children within the one to four and five to nine age groups between 2004-13 
(Figure 12). Rates for children aged 10 to 14 years declined between 2004 to 2008 and 
remained constant from 2008 to 2013. There was little variation in the rate of consultations for 
children aged less than one year for the 10 year period. 
Figure 12. Consultation rate per 1,000 registered population, males and females, by year and 
age group 
 
4.8.1.4 Consultations per patient 
Most patients consulting for MC did so once (77.3%), 17.6% had two consultations for MC, and 
a small proportion (~5%) presented on three or more occasions (Table 14).  
Table 14. Number of consultations per patient during period 2004-13. 
Number of consultations Frequency % Cumulative % 
1 68,820 77.3 77.3 
2 15,662 17.6 94.9 
3 3,544 4.0 98.9 
4 685 0.8 99.7 
5 or more 304 0.3 100.0 
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The time between MC consultations varied, 89.5% of patients who did consult more than once 
for MC (n = 20,195) did so within one year of their initial consultation for MC (Table 15). 
Table 15. Time between initial MC consultation and final consultation between 2004-13 
Time between consultations Frequency % 
Less than 1 year 18,082 89.54 
Over 1 year 2,113 10.46 
Total 20,195 100 
4.8.1.5 Patient episodes of MC 
Where data are presented as patient episodes, assuming a singular episode of MC as one or 
more MC consultations within 180 days, 90.4% of children had one episode, 9.3% two, and 
0.3% three or more. 
4.8.1.6 Referral to secondary care 
There were 733 (0.8% of total children) referrals to a secondary care dermatology department 
in children during an MC consultation (Table 16). The greatest referral rate was in those aged 
10 to 14 years (9.9 per 1,000 MC consultations). The rate in referrals from 2004 to 2013 
reduced significantly by 74.4% during the 10 year period (Table 17). In 2004 there were 174 
referrals to a dermatologist; this had reduced to 20 referrals in 2013. 
Table 16. Referral’s to secondary care dermatologist per 1,000 MC consultations, males and 
females, 2004-13, by age group 
Age Group Referrals Population 
Referral rate per 1,000 MC 
consultations 
Under 1 6 958 6.3 
1 to 4 280 33,533 8.3 
5 to 9 310 40,751 7.6 
10 to 14 137 13,773 9.9 
Total 733 89,015 8.2 
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Table 17. Referral’s to secondary care dermatologist per 1,000 MC consultations aged 0 to 14 
years, males and females, by year 
Year Referrals Population 
Referral rate per 1,000 MC 
consultations 
2004 174 12,717 13.7 
2005 114 10,899 10.5 
2006 75 10,536 7.1 
2007 78 9,769 8.0 
2008 51 8,900 5.7 
2009 55 8,397 6.5 
2010 70 7,904 8.9 
2011 44 7,578 5.8 
2012 52 6,599 7.9 
2013 20 5,716 3.5 
Total 733 89,015 8.2 
Of the patients who were referred to a secondary care dermatologist, 73.4% had consulted 
two or more times to their GP with MC (Table 18). 
Table 18. Referrals to dermatology and single or multiple consultations for MC 
Consult 2 or more times for MC Frequency % 
Y 538 73.4 
N 195 26.6 
Total 733 100 
4.8.1.7 Prescribed medications 
46.6% of patients received a treatment during a consultation for MC during either their first or 
subsequent consultation (if there were multiple consultations) (Table 19). 
Table 19. Treatment prescribed during a patient’s consultation for MC 
Did patient receive a treatment coded for 
MC during a consultation? 
Event Percent 
Yes 41,489 46.6 
No 47,526 53.4 
Total 89,015 100 
Of the 41,489 patients who were prescribed a treatment coded for an MC diagnosis, a total of 
71,404 treatments were prescribed. The average number of items per patient was 1.7. 
Treatments prescribed in over 1% of these cases are listed in Table 20 by BNF sub-section 
headings. 
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Table 20. Treatments coded for diagnosis of MC (where prescribed in over 1% of cases) 
BNF sub-section heading Freq. % 
Emollient & Barrier Preparations 14,645 20.5 
Topical Corticosteroids 14,496 20.3 
Anti-Infective Skin Preparations 13,075 18.3 
Antibacterial Drugs 10,647 14.9 
Antihistamines, Hyposensitisation & Allergic Emergencies 3,097 4.3 
Preparations For Warts And Calluses 1,727 2.4 
Bronchodilators 1,635 2.3 
Skin Cleansers, Antiseptics & Wound prep 1,412 2.0 
Analgesics 1,129 1.6 
Anti-Infective Eye Preparations 938 1.3 
Corticosteroids 829 1.2 
Top Local Anaesthetics & Antipruritic 750 1.1 
4.8.1.8 Time series of consultations 
Consultation rates for MC by quarter are shown in Figure 13, and although there are 
decreasing consultation rates overall for the period 2004 to 2013, seasonal peaks can be seen 
during the second quarters of each year from 2004 to 2011. During 2012 there was little 
variation in consultation rates between each quarter. Consultation rates were lowest during 
the fourth quarter of each year.  
Where the data are plotted in a correlogram (Figure 14) a pattern emerges whereby each forth 
data point peaks, showing a stronger correlation than the previous three, thus implying that 
there is a seasonal relationship in the rates of consultations for MC within the dataset. Overall 
there is negative correlation shown in the correlogram representing the declining consultation 
rates. 
To explore the strength in relationship between the rate of consultations of MC and 
seasonality, an ARMIA test of regression was performed. The test results show a strong 
relationship between each data point and the average of those previous data points combined 
(AR[1]) (α1=0.95 p=<0.05). The moving average between each forth point (to highlight 
quarterly data) (MA[4]) also shows  a very strong relationship (α1=0.61 p=<0.05) highlighting a 
seasonal pattern in MC consultations. 
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Figure 13. Consultation rate per 1,000 registered population, males and females, by quarter 
2004-13 
 
Figure 14. Correlogram of consultation rates for MC in relationship to point zero by quarter 
2004-13 
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4.8.2 Estimation of actual patients presenting to primary care 
The most recent practice populations published for England and Wales by ONS in 2011 (108) 
can be used to model the number of MC consultations a hypothetical practice of 6,000 
patients may have during a year. This hypothetical practice accepts the overall population 
structure of practices in England and Wales, providing a population structure of: children aged 
one year and under (1.3% (of total population), n=77.9), one to four years (5%, n=298.8) five to 
nine years (5.6%, n=334.7) and 10 to 14 years (5.7%, n=343.8).  Where the consultation rates, 
by age band, calculated in this chapter are applied to this model, it provides an estimate that 
an average practice would experience 11 recorded consultations for MC per year in children 
aged one to 14 years. This calculation can be compared to estimates produced in other 
publications. 
4.8.3 Age-sex matched case-cohort study (study two) 
During the period 2004-13 there were 792,282 consultations identified with an AE Read-code, 
where data are reformatted from long to wide format, and consultations were merged into 
unique patient identifiable rows there were a total 377,885 patients consulting for AE during 
the 10 year period. 
In summary, 58.9% of children consulted once for AE (Table 21), 19.4% did so twice, and one 
patient consulted 105 times during the 10 year period. The median (Q1,Q3) consultations per 
patients with AE was 1 (1,3). 
Table 21. Number of consultations for AE per patient during period 2004-13 
Number of consultations Frequency Percent 
1 222,710 58.9 
3 73,270 19.4 
4 32,523 8.6 
5 or more 49,382 13.1 
 
Range 1 to 105 
Median 1 Q1 to Q3 1 to 3 
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In children who consulted for both AE and MC around three quarters (65.2%) of initial AE 
consultations were over 30 days prior to their first consultation for MC (Table 22). 1.0% of 
cases consulted within 30 days of their first MC diagnosis, and 33.8% of children consulted for 
AE on the same date or after an MC consultation. 
Table 22. Time between AE and MC consultation in cases of AE who also consulted for MC. 
Time from AE>MC consultations Frequency Percent 
Initial AE >=30 days prior to MC consultation  15,016 65.2 
Initial AE consultation during or after an MC 
consultation  
7,793 33.8 
Initial AE consultation < 30 to 1 day prior to MC 
consultation  
240 1.0 
Total children who consulted for AE and MC 23,049 100 
Children diagnosed with AE were more likely to have a future MC consultation during 
childhood than controls (OR 1.13 (95% CI 1.10 to 1.16) P<0.005) (Table 23). 
Table 23. Odds ratio (OR) of MC consultation in patients with previous AE diagnosis 
Cases Controls 
OR 95% CI P 
No MC MC No MC MC 
362,869 15,016 364,599 13,289 1.13 1.11 to 1.16 <0.005 
In the multivariate model, odds ratios were adjusted for the following confounders; 
corticosteroid potency prior to MC diagnosis, age at initial AE consultation and primary or 
secondary AE diagnosis (Table 24). Corticosteroid potency and type of AE diagnosis did not 
influence the likelihood of an MC diagnosis. However, younger children were more likely to 
have an MC consultation than older children aged 10 to 14 years (OR 1.37 (95% CI 1.32 to 1.42) 
P<0.005).  
Corticosteroid therapy during an AE diagnosis was prescribed in 102,838 children before an 
MC diagnosis (>30 days) or where there was no future MC consultation documented. In 97.3% 
of cases the potency was mild, 0.1% moderate, and 2.6% potent or very potent. There was no 
significant difference in the risk of developing MC between children prescribed various 
potencies of corticosteroids. 
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Table 24. Unadjusted odds ratios (OR) for future MC consultation in children with AE 
a) Corticosteroids potency 
  Corticosteroid strength OR 95% CI P 
  
Mild Ref 
Moderate 0.37 0.10 to 1.50 0.16 
Potent or very potent 0.88 0.73 to 1.06 0.17 
b) Age at initial AE diagnosis 
  Age group (years) OR 95% CI P 
  
Under 1 Ref 
1 to 4 1.37 1.32 to 1.42 <0.005 
5 to 9 1.04 0.99 to 1.10 0.07 
10 to 14 0.25 0.23 to 0.27 <0.005 
c) AE diagnosis (as per Table 8) 
  Analysis OR 95% CI P 
  
Primary AE diagnosis Ref 
Secondary AE diagnosis 0.89 0.83 to 0.94 <0.005 
 Discussion 4.9
Data were extracted from CPRD, a large primary care database containing over four million 
active patients in the UK for the period 2004 to 2013. In total 89,015 children aged zero to 14 
years presented to their GP and were diagnosed with MC on one or more occasions. The 
consultations rate for MC in children for males was 9.5 per 1,000 (95% CI 9.4 to 9.6) and 
females 9.8 per 10,000 (95% CI 9.7 to 9.9). The greatest rate for both genders is for children 
aged two to seven years (12.3 to 17.8 per 1,000). Children aged zero years, and aged 13 years 
and over had the lowest rate of consultations (less than 3 per 1,000). There are no significant 
differences in consulting between genders. 
The rate of consultations in primary care for children diagnosed with MC by their primary care 
doctor declined by 50.0% during the 10 year period (48.1% in males, 51.1% females). The 
greatest reduction in the rate of consultations was in those aged one to four and five to nine 
years. The consultation rate in children aged under one year remained consistently low for the 
10 year period.  
The data highlights seasonal trends of consultations for MC, showing a peak during the second 
quarter of each year (April to June). Most children with MC presented to their GP once 
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(77.3%), and 17.6% had two visits relating to MC; of those who consulted more than once 90% 
were within one year of the initial MC consultation. Very few children were referred to 
secondary care (0.8% of all patients), and this reduced by 74.4% from 2004 to 2013 
representing 20 referrals in total during 2013. Although a sharp reduction in consultations is 
shown, this data represents the current clinical management of MC in the UK that the 
condition should be managed by primary care doctors. 
Under half of children were prescribed a medication when presenting with MC (46.6%), and 
the two most common prescriptions were for emollient and barrier preparations (20.5%), and 
topical corticosteroids (20.3%). 14.9% of children were prescribed antibacterial drugs 
(antibiotics) and this may suggest cases where the lesions or surrounding areas had become 
infected. 
The study explored the associations between MC and AE, hypothesising that an AE 
consultation increases the likelihood of a future MC diagnosis. The results of an age-sex 
matched case-cohort study showed there was an increased likelihood of a child being 
diagnosed with MC following a previous AE diagnosis (where consultation was 30 days or more 
prior to initial MC consultation) (OR 1.37 (95% CI 1.32 to 1.42) P<0.005). Therefore the 
hypothesis proposed earlier in this chapter was accepted. Younger children, aged one to four 
years, were more likely to have a future MC consultation if they had previously been 
diagnosed with AE compared to the older aged children. 
The results of this chapter will be discussed in relation to those in the other studies of this 
thesis and other published research within the final discussion chapter of this thesis (chapter 
eight). 
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 Limitations 4.10
Routinely collected datasets in primary care were designed for clinical practice and not for 
research. However, these datasets have become a valuable data source for research and are 
subject to limitations, these limitations are described within this section. 
4.10.1 Potential limitations of data 
As with all studies reporting the incidence of a condition using routinely collected data, this is 
subject to coding problems and under-ascertainment (57-59, 61-64). The most fundamental 
element of using data collected from primary care databases retrospectively is the reliance and 
assumption that the diagnoses and other data held are accurate and that the most appropriate 
Read-codes are used (109). For MC there are only two Read-codes available for the diagnosis 
and this limits errors of an incorrect diagnosis being entered for MC. Both of these Read-codes 
were used for data extraction in this thesis. The data extracted from CPRD for the purposes of 
analysis was limited to include only that marked as “up to standard”; therefore ensuring that 
the data extracted from CPRD is from gold standard practices by CPRD definition.  
A significant limitation of the numerator data are that clinicians can also provide data about 
the consultation as ‘free text’. ‘Free text’ data are not coded or freely available for analysis. 
The ‘free text’ data are extracted and held within CPRD but accessing this data incurs 
substantial additional charges due to the additional steps required to ensure no potentially 
patient identifiable information is disclosed. The potential charges that this data extraction 
would have incurred meant it was not feasible for my research/this thesis. A diagnosis such as 
MC that will often accompany another diagnosis during a consultation, and may be considered 
a trivial condition by some clinicians, could be entered within the ‘free text’ area and therefore 
will not be included within the dataset. A ‘free text’ entry for MC may be more apparent in 
cases where there are no prescribed medications. 
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Previous studies have described regional variation in the incidence of MC (43-45), however 
due to the limitations of the CPRD database we were unable to explore if there were any 
regional variation in the incidence of primary care consultations for MC in the UK. 
4.10.2 Assumptions of the dataset 
The analysis performed within this chapter is limited by the assumption that the data 
extracted was correct and that the numerator and denominator used for the analysis will not 
under or over report incidence of MC. The numerator and denominator data were extracted 
by an experienced research analyst, and this should limit errors in the data extraction process.  
The data held within CPRD represents five million patients and data within CPRD are validated 
and found to be generalisable to the UK population (104, 110, 111). Our sample of primary 
care centres does not provide us with the true number of consultations for MC in the UK, 
however, by applying statistical techniques to the dataset it provides the range in which we 
believe the true estimates of the incidence of MC consultations lie (within 95% confidence). 
The data analysis described consultations for MC and is unable to establish the true prevalence 
of MC cases in the community. It can be assumed that the true prevalence of MC in the UK 
may be higher than the incidence rates presented when those who may be successfully 
managing the condition at home (and do not consult to a GP) are included.  
It is also important to note that as an observational study the analysis represented in this 
chapter does not determine causal relationships but describes statistical associations within 
the data. Although observational studies do not categorically identify ‘cause and effect’ they 
are important, by identifying associations between patients characteristics, behaviours and 
outcomes they provide evidence of the etiology of disease and can lead to further research to 
explore this further. 
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 Conclusions 4.11
Routinely collected data from UK primary care centres was extracted to describe the rate of 
MC consultations in children. The incidence of consultations were greatest for children aged 
three to seven years and have reduced by 50% since 2004 to 2013. The presence of MC is 
often accompanied by AE and children who have a history of AE are more likely to have a 
future MC consultation.  
The result presented in this chapter are discussed in the context of other published literature 
in the final discussion chapter of this thesis (chapter eight). 
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Chapter five: Development of a parental molluscum contagiosum diagnostic tool 
(MCDTP) 
The design outline of the MCDTP was presented at the International Investigative Dermatology 
conference 2013 and the abstract was published within the supplementary publication in the 
Journal of Investigative Dermatology. The published abstract can be found in Appendix 1.4. 
5. Overview 
This chapter will describe the process of developing the MC self-diagnostic tool for parents. 
Outlining the processes used for the development, the characteristics of a good disease 
definition for epidemiological research and initial planning phase will be explained. 
The assessment of the extent to which the instrument is valid, and processes used for this 
assessment in GP practices are described in chapter six.  
 Theoretical Perspective 5.1
Some epidemiologists have argued that the standardisation of a disease definition as being of 
paramount importance for studies if epidemiological comparisons are to be made, and that it 
may even be better to have a slightly deficient definition of known validity than a definition 
proposed by experts of unknown validity (112).  
Epidemiologists have tried to identify the elements of a good disease definition. These have 
been summarised nicely by Williams (1997) (112) who suggests a good epidemiological disease 
definition should be formed with careful consideration and that it will conform to the following 
areas: 
1) Valid (sensitivity and specificity) 
2) Repeatable (between and within observer) 
3) Acceptable to the population 
4) Rapid and easy to perform by field workers 
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5) Coherent with prevailing clinical concepts 
6) A reflection of some degree of morbidity 
7) Comprehensive in its applications 
8) Comparable with other studies 
Where conditions are characterised by their distinct features, parents when supported with a 
diagnostic aid, can complete self-administered questionnaires to mark the presence of the 
condition (113). Parental diagnosis of conditions have provided reasonably adequate answers 
regarding the current occurrence of clear-cut symptoms (114). Self-diagnosis, or parental 
diagnosis for minors, of conditions for the purposes of epidemiological research can be 
beneficial as an alternative to a physicians’ diagnosis, and for the purposes of assessment for 
an epidemiological study, an examination by a medical practitioner can be expensive and 
impractical (115). Patient administered questionnaires also have many benefits; being easy to 
administer, convenient for the patient, and require less funding and personal resources than 
many alternative methods (116). It is essential, however, that assumptions and recruitment 
into epidemiological studies are only given where the validity and limitations of the tool 
measuring responses are known (117). 
Recent epidemiological cross-sectional studies examining children for a diagnosis of MC have 
used various methods; six studies confirmed a diagnosis following a clinical examination (21, 
25, 36-39), one relied upon parents to recall a diagnosis (40), and one did not state how a 
diagnosis was confirmed (24). Currently no tool with known validity exists to allow parents to 
self-diagnose MC in their children. The aim of this chapter is to develop a tool for this purpose. 
In dermatology, tools using medical illustrations and text to help patients self-diagnose other 
skin conditions have been evaluated. The Psoriasis Screening Tool (PST) was designed with the 
purpose of being used in epidemiological studies and was found to have a high sensitivity and 
specificity of 96.4% (95% CI 93.2 to 98.0) and 97.3% (95% CI 94.1 to 98.9) respectively when 
compared to a dermatologist diagnosis (115). 222 adults (aged 18+) completed the PST and 
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they were equally distributed between a psoriasis and non-psoriasis group. Participants were 
recruited from a North American dermatology clinic and therefore may be familiar with 
examining their skin condition prior to attending the centre to distinguish the key diagnostic 
elements, this may limit the future application of the PST to dermatology centres or require 
further testing if it were to be used in the community. A study exploring the accuracy of self-
diagnosis of a variety of skin lesions through the use of 12 lesion images and matching them to 
a correct diagnosis using diagnostic support software found that non-clinicians (n=23) correctly 
diagnosed 96% of lesions (n=231/240). The software image library contained 80 images from 
five diagnostic classifications that are typical referred to dermatologists in the UK and 
participants were guided through levels in the software before confirming a final diagnosis. All 
images were taken by a medical photographer and the participants were not diagnosing their 
own skin conditions. When this is compared to medical students (n=27) who had recently 
completed a two week dermatology attachment and did not use diagnostic support software, 
their diagnostic accuracy is considerably lower 51% (n=160/312) (118).  
Using a standardised questionnaire to measure the presence of skin disease in both a health 
seeking (n=99) and non-health seeking population (n=98) of Norwegian adults (aged 30+ 
years), it provided a best sensitivity and specificity of 61% specificity 69% compared to a 
dermatologist (119). This instrument guided participants through 10 questions that were 
developed to measure presence of common skin diseases in the population and did not 
identify specific conditions. Although it has a relatively low accuracy in measuring the presence 
of a skin condition, the authors noted further development was required before use in a large 
epidemiological study. This tool could be used to measure the burden of skin conditions, but 
without an accompanying clinical diagnosis this tool cannot diagnose a specific condition. 
By using medical illustrations to aid parents in making a diagnosis of a dermatological 
condition this can increase the sensitivity of a diagnosis (115), therefore medical images 
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combined with a textual description will form the basis of the MC parental diagnostic tool that 
will be used later in this thesis as a recruitment tool. 
Through this chapter, I will use the eight components described by Williams to develop a good 
epidemiological disease definition of MC in children using images and text, summarising in the 
discussion how each of the components have been fulfilled. 
 Development of a draft diagnostic tool 5.2
5.2.1 Initial Planning and Development 
The initial planning and development of the MCDTP was discussed during project planning 
meetings attended by NF, JG, VP6, SW (patient representative) and I. These initial meetings 
resulted in the development of an outline of what was considered to be the key components 
of a self-diagnostic tool. These components were; a clinical description of MC, good clear 
images of lesions, and images and/or text describing other common conditions which parents 
might confuse for MC to help distinguish these from MC. 
The instrument and format initially chosen to be used for the parental diagnostic tool was a 
simple single sided sheet of A4 paper with printed images and text.  
For the purposes of discussions and in line with other diagnostic tools, the final tool designed 
was given a title of the ‘Molluscum Contagiosum Diagnostic Tool for Parents (MCDTP)’. The 
final name was created following discussions with the project team and involved feedback 
from a dermatologist specialist nurse as to whether this would be acceptable in clinical 
practice. For the remainder of the thesis and in all study materials the tool that was designed 
in this chapter is referred to as the MCDTP. 
                                                          
6
 Vincent Piguet (VP), Professor of Dermatology. NF, JG and VP were academic supervisors for this 
thesis. 
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5.2.2 Development process summary 
A thorough development process was formed which included the following steps: outlining a 
clinical diagnosis of MC with experts, ensuring clear understandable terms were used, and a 
pilot with parents to test its usability. These three phases of the MCDTP development are 
shown in Figure 15 and the procedures summarised below;  
Figure 15. MCDTP development process 
 
Phase one: Nine dermatologists participated in semi-structured interviews to establish the key 
components of diagnosing MC and identify images which were most typical of MC. 
Photographic images of MC lesions came from a selection extracted from the Cardiff and Vale 
University Health Board medical image library. 
Phase two: The findings from the dermatologist interviews were tabulated and summarised, 
then discussed in interviews with a patient representative, a school nurse, and a dermatology 
specialist nurse. The data from these interviews were discussed in project management 
meetings and used to produce a first draft of the MCDTP.  
Phase three: The initial design of the MCDTP was piloted at a local parent network meeting 
with 12 members in Cardiff, Wales. The aim of this pilot was to ensure the instructions and 
wording of the tool were clear, and that parents would be willing to use the MCDTP to 
diagnose their child’s skin lesion. Following the pilot the findings were discussed at a project 
management meeting to assess if further changes were required to the MCDTP. 
 Approvals and Consent 5.3
Consent was gained prior to conducting interviews or inviting participants to complete the 
study questionnaires. Each participant was given verbal information about the study, handed a 
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participant information sheet, and given the opportunity to ask questions about their 
participation. Interviews were only conducted once this consent had been granted. 
Each study phase received a favourable ethical opinion prior to commencement by the NHS 
NRES South Central-Berkshire B board (12/SC/0455). For phase one and two where the 
research was conducted with NHS staff and potentially on NHS premises, R&D approval was 
granted by Cardiff and Vale University Health Board (12/CMC/5055) (Appendix 5.2). I was 
issued with a letter of access to conduct the study with NHS staff and on NHS premises within 
Cardiff and Vale UHB jurisdiction (Appendix 5.7). 
 Phase one: Establishing key features of MC 5.4
5.4.1 Initial literature review of clinical diagnosis of MC 
The first step of the development process was to establish the clinical diagnosis of MC through 
the process of a brief review of the published literature. For the brief review I, supported by VP 
(Professor of dermatology), conducted a search of dermatology textbooks, and recently 
published clinical reviews for the description of the key diagnosis features.  
5.4.1.1 Results of brief review 
MC is most commonly diagnosed following a clinical examination of lesion appearance by 
general practitioners or dermatologists, and can also be confirmed by the histopathology 
found in biopsies of lesions (3, 4); although biopsies are rare and they generally only occur in 
unusual cases. The clinical summary of MC is of single or multiple clusters of wart-like 
pearlescent lesions which can appear anywhere on the body (5), formed of slightly raised 
lesions of rubbery consistency up to 5mm in diameter (1). They are characterised by small, 
discreet, waxy, skin-coloured, dome-shaped papules presenting as generally less than 20 in 
immunocompetent hosts (7). The Rook Textbook of Clinical Dermatology (120) describe MC as 
spots on the skin, which are flesh-coloured, domed shaped papules with a central depression. 
This umbilication or central depression is the most important diagnostic sign, however may not 
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be present in all lesions. A description in the textbook Dermatology by Rapini R et al (121) 
describe MC lesions as firm, umbilicated, pearly papules with a waxy surface.  
This description from the published literature formed the basis of the MC diagnosis; this was 
combined with current clinical practices for diagnosing MC that was established during the 
following interviews with dermatologists. 
5.4.2 Study design for Dermatologist interviews 
I conducted a series of semi-structured interviews with experts (dermatologists) to establish 
the key visual diagnostic characteristics of MC. Structured interviews were conducted using a 
structured topic guide/interview questionnaire (Appendix 3.1) and both open and closed 
questions were used. This approach was selected because the aim was to generate ‘hard’ data 
based on unequivocal measures (122) to describe the facts of what is the clinical diagnosis of 
MC, and how is this diagnosis made (123). Other approaches that were considered include 
non-structured interviews and focus groups. These were deemed less suitable because 
although both methods would have generated rich data from the discussions about personal 
‘experiences’, ‘behaviours’, and ‘attitudes’ towards diagnosing MC, they may not have 
answered the specific aim. The aim was relatively simple, and for a senior clinician diagnosing a 
common self-limiting condition such as MC, it would not require great perspectival thinking or 
discussion. Both focus groups and non-structured interviews can be time consuming and costly 
due to training involved, the need of facilitation, and extended time of interviews for the 
participants taking part (123).  
Where possible, interviews were conducted face to face but if where this was not possible a 
telephone interview was conducted. As this was a brief interview of a non-sensitive topic, 
telephone interviews are found to be as effective in terms of providing equal accuracy rates as 
when conducting them face to face (124).  
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5.4.2.1 Selection of images 
The MCDTP relies greatly on the images of MC used and therefore those images used required 
careful consideration. To select these images, dermatologists were shown 10 images of MC 
and asked to select those that they felt were most representative of MC lesions seen in clinic, 
noting what attributes of the images should be emphasised to aid a diagnosis. The initial 10 
images were selected by AA7 from the Cardiff University medical image library.  
5.4.2.2 Participants 
Dermatologists were recruited from University Hospital of Wales (UHW) following 
identification by the Head of Department of Dermatology and Academic Wound Healing (VP). 
Participants were eligible to take part if they were either consultant or registrar level 
dermatologists currently working within the department to ensure expert opinion in the 
design of the MCDTP. They were also selected by their availability for interview. Each 
participant was sent an email inviting them to participate. Of 11 invited, nine agreed to 
participate, one was currently on maternity leave, and one did not respond. Dermatologists 
were selected to act as key informants and provide specific information of the key diagnostic 
criteria of MC to aid the development of the self-diagnostic tool. Selecting Dermatologists as 
key informants allowed experts to be purposefully identified for the gathering of specific 
information which may not be otherwise available (125). For the purposes of this study, they 
were recruited to gain a particular understanding of diagnosing MC by experts in the field.  
5.4.2.3 Procedure 
Interviews were conducted at the preferred location of the participants. In the majority of 
cases (n=5) they were in the individual participant’s office in Glamorgan House (UHW), or in a 
clinical consultation room prior to a clinical session (n=3). One interview was conducted over 
the telephone where materials were sent prior to the interview and the participant was asked 
to have these available on their computer screen during the phone interview. The interviews 
                                                          
7
 Alex Anstey (AA), Professor of Dermatology. 
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were conducted following a structured interview plan; responses were written down during 
the interview by the interviewer (myself). 
5.4.2.4  Analysis 
A thematic analysis was used to group together the results of the interviews with 
Dermatologists. Although this study conducted a short structured interview with a relatively 
small number of participants, the thematic approach was beneficial due to the exact uses and 
measurements not being defined (126). 
For the purposes of selecting images of MC for the MCDTP, each image marked as appropriate 
during the interview phase were counted. The four with the highest count were used. 
5.4.3 Results: Text selected for MCDTP 
The responses from the nine dermatologist interviews were tabulated by question; these were 
then grouped into key emerging themes which were constant throughout all of the responses 
to signify that they were important features for a diagnosis of MC. 
The responses were grouped into the following categories; History & population, appearance, 
site, and symptoms. Figure 16 shows terms which were grouped into these categories 
following analysis. 
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Figure 16. Key categories and text for diagnosing MC by Themes 
 
 Phase two: Improving usability of MCDTP 5.5
5.5.1 Medical terminology 
It is important to be aware when producing documents for public use that the same words can 
mean different things to different people or may not be understood at all (127). To avoid any 
potential misunderstanding by parents of the commonly used medical terms which were used 
by clinicians in describing MC there must be careful consideration of the final wording used in 
the MCDTP. The interpretation of medical terms by doctors and patients can be significantly 
different (128), and even the most commonly used medical terminology should be carefully 
explained to parents to avoid confusion (129). The differences between doctors and patients 
choices of definitions can be clearly different; however other health professionals can bridge 
the gap between the two groups (130). Ensuring that what is meant in the terms is clearly 
relayed, the choice of wording can ensure that there is effective communication between 
clinicians and patients (130), and for the purposes of designing the MCDTP, wording is an 
essential element to its usability.  
5.5.2 Study Design 
This phase conducted an informal conversation/interview aiming to gain rich detailed answers 
to a brief specific guide to generate the most suitable lay terminology for use in the MCDTP. 
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Following phase one a brief guide of medical terminology was established; this then formed a 
checklist/prompt which was used for the interview (Appendix 3.2). The interview style used for 
this phase is referred to as ‘unstructured’ (131) or an interview with a ‘general interview guide’ 
(132). This method is beneficial for allowing the probing or expansion of a set group of points 
in a conversational style; the wording of the questions is not set but is spontaneous depending 
on the flow of the interview. It is important that the integrity of the terms highlighted from the 
earlier dermatologist interviews were translated into a lay language, understandable to 
parents but also maintaining the same meaning and therefore this style of probing and 
questioning participant responses is useful. 
5.5.2.1 Participants 
As described previously, in bridging the gap between terms used by doctors and the meaning 
being understood by patients, other health professionals can be key. Therefore in this study 
phase practicing healthcare professionals who have regular contact with parents were selected 
to take part. A school nurse from the local health authority was emailed and agreed to 
participate, as was a dermatology speciality nurse from UHW. Recruiting both a school nurse 
and dermatology specialist nurse, utilised the experience of health professionals who regularly 
relay medical information directly to parents and their children. The dermatology specialist 
nurse also added value due to a specialist background in skin conditions. SW, patient 
representative, also participated in a separate interview using a similar format. Including 
patients or members of the public within planning and implementation of the MCDTP helps to 
ensures that it will be more reliable and relevant to the end users’ needs and concerns (133). 
Using a patient representative in the initial design of the MCDTP  helped by making the 
information more relevant to people affected by MC, ensuring it contains all the information 
parents would want to know and making the tool more accessible by eliminating jargon (134). 
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5.5.2.2 Procedure 
I conducted two informal meetings firstly with health professionals, and secondly with a 
patient representative to discuss the wording of the clinical diagnosis of MC which would be 
used in the final MCDTP. Participants were asked to respond to questions about medical terms 
with suggestions of what language they would use during their day to day clinical practice.  
The first meeting included the school nurse, dermatology specialist nurse and I at the Public 
Health Wales office, Cardiff using the structure developed from phase one. Following this 
meeting a first draft of the MCDTP was developed. The second meeting between SW, patient 
representative, and I at NM, Cardiff University used a first draft of the MCDTP as a guide to 
discuss the potential wording used.  
5.5.3 Data Collection 
Notes were made during the two informal meetings. Wording and phrases were tabulated and 
matched against that in the schedule. Any expansions or advice on how to describe 
dermatological conditions based upon the participants experience were also noted. 
5.5.4 Analysis 
5.5.4.1 Wording 
The analysis conducted was to match the wording from the results of phase one to terms 
which were considered to be clear and concise for lay readers. Notes made using the interview 
schedule were tabulated to show matching words (Table 25). The analysis was split into two 
sections; original wording and recommended words to aid parental diagnosis using a paper 
tool.  
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Table 25. Recommended wording for use in MCDTP 
Category Original wording Recommended wording 
Lesion Lesion Spot 
Spot, lump or bump 
Appearance Umbilicated 
Flesh Coloured 
Smooth / Raised 
Multiple 
Little dimple in the centre 
Same colour as skin 
Smooth / raised & show in image 
Multiple & show image of multiple lesions 
Site Crops / One site 
Locations 
Multiple normally appearing in just one area 
Tummy, back, arms, legs or face 
Symptoms Asymptomatic / Painless 
Itchy 
Inflamed and scaling 
around papules, and 
excoriated 
Usually painless 
Can be itchy 
If the spots are scratched they may look red 
and sore 
5.5.4.2 Further recommendations 
During the first interview both the school and dermatology nurses stressed that a diagnosis 
would not be possible without any images of common MC lesions in the final MCDTP. There 
was also a recommendation for the lesions images to be clearly annotated to highlight any 
features which would aid a diagnosis.  
It was recommended that the MCDTP should exclude information of a history of AE and the 
duration of lesions; both of which were earlier described by dermatologists as factors which 
may help a diagnosis of MC. However, the nurses argued that as AE may not be present in all 
children with MC this may wrongly influence parent diagnosis or cause confusion, and that 
including the duration of lesions may also lead to confusion as the potential study participants 
would be visiting their doctors at various stages of the virus. 
Both dermatologists and nurse participants noted that although the features described are of 
typical MC lesions, not all lesions within a cluster may have the same distinctive characteristics 
that are seen in most MC lesions. Therefore it was recommended to use wording such as 
‘typically’, ‘usually’, ‘normally’, ‘most common’, and ‘may look’ within the descriptive text as 
this will imply that although these are important features, they may not be typical in each 
lesion. 
Page | 83 
 
Finally it was suggested that including other conditions which MC could be misdiagnosed as 
should be removed from the MCDTP. It was thought this would lead to confusion with users 
and as the MCDTP will provide a comprehensive description of MC that distinguishes it from 
other conditions, then this information would not be required to aid a diagnosis. 
5.5.5 Results: Draft MCDTP 
The first draft of the MCDTP was made following this second stage in the development process 
using the images, suggested wording and annotation recommended. The initial document was 
shared with the project team for feedback, slight edits were made and a final first draft was 
produced to pilot with parents (Figure 17). 
The initial design and layout of the MCDTP was completed using Microsoft PowerPoint to 
produce a pdf version for use in the pilot phase. The design phase aimed to produce an 
attractive and well laid out tool with clear instructions on how it should be completed, which is 
important for the design of questionnaires used in research (127). 
Figure 17. First draft MCDTP 
 
Page | 84 
 
 Phase three: pilot of MCDTP 5.6
5.6.1 Introduction 
Phase three of the development process aimed to test the MCDTP for its comprehensiveness 
and usability with a small group of the population of interest (135). For the purposes of the 
MCDTP and its future use, the most relevant group for testing were parents with no clinical 
background.  
5.6.2 Study Design 
The study design was an observational pilot study of a group of parents attending a local 
parent network meeting. The pilot aimed to understand whether there were any concerns 
with the flow and use of the ‘MCDTP’, if any questions were being missed by respondents, or if 
the ‘MCDTP’ highlighted any issues in the process of diagnosing MC by parents. 
5.6.2.1 Participants 
Parents attending a local parent network in Cardiff were invited to take part in the research. 
The group was identified following an online search of local parent groups in Cardiff. The 
search found the ‘Cardiff Parent Network’, whose website outlined that this group has a 
specific purpose of bringing local parents together to meet other parents, discuss their views, 
and influence services for children and families. I initially contacted the network co-
ordinator/chair via email, outlining the study and asking for permission to attend a future 
meeting to conduct a small pilot of the MCDTP. It is important to note this group had no 
specific interest in research or a purpose to review research projects. 
5.6.2.2 Procedure 
The study procedure followed a structure outlined in Figure 18. Data was collected using a 
semi-structured questionnaire consisting of two questions and a ‘free text’ area. This method 
was chosen as the preferred data collection method due to its ability to ask directly about the 
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points concerned with the research, and its benefits of being a relatively cheap and easy data 
collection method (136). 
The procedure for the pilot was as follows; the outline of the study was explained to the 
parents attending the group, and what their participation entailed. Once the parents 
consented they were given the study materials to discuss and complete. The study materials 
consisted of a participant information sheet, first draft version of the MCDTP, and a short 
semi-structured questionnaire.  
Figure 18. Pilot with parent network group (study steps) 
 
5.6.3 Data Collection and Analysis 
Data was collected on paper questionnaire forms (Appendix 3.3). The data was entered into 
Microsoft Excel for descriptive analysis. Parents were asked to note all of their comments on 
the data collection forms but if there was any further verbal feedback, I included this in my 
own notes and  within the results.  
5.6.4 Results 
The group meeting took place in a local community and children centre in Riverside, Cardiff in 
December 2012. A total of 12 parents attended the session as well as the chair (an employee 
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of Cardiff City Council) and a local government commissioning manager who was observing the 
session. 
Generally the feedback to understanding the questionnaire and if parents would be willing to 
complete the MCDTP if they were asked to in a GP surgery was positive, where 11 of the 12 
respondents indicted yes to both questions (Table 26).  
Table 26. Feedback questionnaire to MCDTP 
 
Yes No 
Q1) Did you understand the 
instructions? 
11 (92%) 1 (8%) 
Q2) Would you be happy to 
complete the questionnaire on 
behalf of your child? 
11 (92%) 1 (8%) 
Participants were also asked to provide additional feedback after reading the MCDTP; eight of 
the 12 participants provided additional feedback. Generally feedback was positive (n=5/8), 
three gave short positive descriptions; 
 “was useful to know.” [P01] 
“fine.” [P02] 
“Can be handy, will take the scare out of the symptoms.” [P03] 
Two participants suggested parents would like to have more information about MC, and one 
indicated that information about common conditions in children should be sent to all parents 
when their child begins school; 
 “A leaflet sent to school would be useful to raise awareness.” [P06] 
“Instructions were clear. Clear instructions and pictures, easy to follow. No info on MC. 
More info on how long it lasts would be good if poss.” [P09] 
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Some parents were confused with the purpose of the tool, not knowing why this would be 
used in GP surgeries when parents were already attending the practice to see a doctor, and 
that the exact use was unclear; 
 “Confusing as to the use, why self-diagnose if having to go to the GP?” [P07] 
 “Confusing at first.” [P08] 
 “some of the info is contradictory and confusing.” [P11] 
As the instructions and compliance to complete the MCDTP in GP surgeries was positive (11 of 
12 indicating they would), there were no further changes required to the draft MCDTP. The 
additional ‘free text’ feedback suggests that the MCDTP instructions may not be clear. 
5.6.5 Conclusions of pilot phase 
The two page MCDTP was found to be acceptable to parents where 92% (n=11/12) of parents 
indicated they understood the MCDTP and would completed it if asked in a GP surgery; 
suggesting that this version of the MCDTP can be used in the subsequent validation phase. 
However, a key finding from the pilot and an area which did confuse some parents was the 
exact purpose of the MCDTP and why they would be asked to look at the document in a GP 
surgery. This feedback suggests that before assessing the extent to which the instrument is 
valid the instructions featured on the MCDTP, in describing why parents are being asked to 
complete it in the GP surgery, need to be clearer and more concise to avoid confusion. 
During the session the parents were instantly engaged in the study, they were very curious 
about knowing exactly what the research was and the overall study aims. As I attended the 
session I explained the overall aims of the wider MOSAIC study and this became a discussion 
point. This may have caused confusion with parents as to how a self-diagnostic tool would fit 
into these wider aims and the confusion may have been caused by myself. On reflection, and if 
I were to replicated this pilot phase again, I would not explain the overall study to the 
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participants but keep my explanation only to the aims of the study phase which were being 
conducted on that day. The group who took part in the pilot was well established and had 
been meeting monthly for over 12 months, all members were confident to voice any questions 
they had about the research. These questions did snowball where the more questions that I 
provided answers to, the more questions about the whole research project and about MC in 
general were raised. To ensure the objective of the pilot was achieved within the timescale 
allocated to myself during the meeting, I made a conscious effort to gently stop any further 
questions that weren’t about the MCDTP and to ask the group to complete the questionnaires 
and ensure that they noted all of the points they had raised in voice within the paper form.  
5.6.6 Outcome: Final MCDTP 
Feedback from the pilot did not highlight that there were any changes needed to the design of 
the MCDTP as the majority of parents indicated that the language was understandable and 
they would be willing to complete the MCDTP on behalf of their child if asked in a GP surgery. 
Feedback indicated that the overall instructions were not clear as to why they were 
completing the MCDTP and what it would be used for. This is an area of the design that must 
be made clearer when assessing the validity of the MCDTP as a parental diagnostic instrument 
to ensure participants understand what they are required to do and why. 
 Discussion 5.7
The MCDTP was developed using a framework established by epidemiologists (112) to produce 
a good disease definition for the purpose of epidemiological studies. How these elements have 
been incorporated into the final MCDTP are shown in Table 27.  
The first draft of the MCDTP did change from the initial designs that were discussed in the 
early meetings of the project management group. The changes made were following feedback 
given during the development stages and these were; the section describing the key diagnosis 
differences from other conditions were excluded, and images of MC lesions were annotated 
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with the key diagnostic features. Important elements incorporated into the MCDTP were that 
it was clear, ensuring simple wording was used with no medical jargon, and that it maintained 
the key diagnostic elements provided by experts.   
Table 27. MCDTP disease definition framework 
Disease definition 
characteristic 
Incorporation in MCDTP 
Valid (sensitivity and 
specificity) 
Measured in subsequent chapter (chapter six). 
Repeatable The developed MCDTP is a tool which will can be reproduced and 
used for all participants who were asked to take part in this study 
(chapter seven) or potentially in other epidemiological studies. 
Acceptable to 
population 
This is a non-invasive test. Feedback from pilot shows the procedure 
of completing the MCDTP is acceptable to parents and that parents 
would complete the MCDTP if asked when attending a GP surgery. 
Rapid and easy to 
perform 
The MCDTP has been designed with the intention of being short and 
concise with and ability to be completed while parents wait to see 
the doctor in the GP surgery waiting area. Areas which may have 
confused have been excluded following the pilot phase. For 
clinicians, they will diagnose the lesion and note a yes/no diagnosis 
question – keeping the impact upon consultation to a minimum. 
The exact features of how the test will be performed are described 
in chapter six of this thesis. 
Coherent with 
prevailing clinical 
concepts 
A brief review of current clinical textbook and publications along 
with practicing dermatologists (n=9) were included in the 
development of the MC diagnosis to ensure key elements for the 
current disease syndrome were included. 
Reflect some degree 
of disease morbidity 
The MCDTP highlights the features of common MC seen in primary 
care; therefore it must be acknowledged that it may not be suitable 
for unusual and rare cases. 
Comprehensive in its 
application 
The principle use of the MCDTP is in the UK which has a 
predominately White English speaking population. The features of 
MC are mirrored in ethnic skin types however the images used in 
the MCDTP do not features any other skin types than white. 
Page | 90 
 
Disease definition 
characteristic 
Incorporation in MCDTP 
Inclusion of elements 
comparable with 
other studies 
The majority of studies of children with MC confirm a diagnosis of 
MC given by a medical practitioner, or in some cases self-reported 
of a previous diagnosis. This is the first parental diagnosis tool to for 
MC in children that will be tested in primary care. 
 
5.7.1 Potential limitations in the development of the MCDTP 
5.7.1.1 Potential limitations of using the MCDTP to identify MC 
A limitation of the MCDTP is that it may not be suitable for identifying unusual and rare cases 
of MC, as in these cases where a diagnosis is difficult or uncertain they are sometimes referred 
for biopsy to confirm a diagnosis. The skin colour of all the images used in the final MCDTP is of 
children with white skin, therefore its acceptability to other more diverse populations needs to 
be considered. The external validity of the MCDTP and its acceptability to the populations of 
Cardiff, Wales, and England will be discussed further in chapter six of the thesis. 
5.7.1.2 Potential limitations in the data collection methods 
During the interviews with key stakeholders and other phases of the MCDTP development field 
notes were taken to collect study data and these notes were later used for data analysis. 
Collecting data in this way is inevitably selective and subjective to observer bias (137). 
Although this method was an efficient way of collecting data that was cheap, non-intrusive and 
freely available independently of budget and time available, alternative methods were 
available for data collection. These alternative methods were tape or video recording, however 
these methods can be expensive in equipment costs, transcription and coding, and they also 
can be deemed intrusive by study participants. 
The interviews conducted in this study phase had a narrow and pre-defined scope, and this 
provided direct interviews generating responses that required little philosophical 
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interpretation therefore reducing potential errors in reporting of results through the method 
of data collection. Collecting study data and observing interviews myself was also an important 
of the research process as it allowed me to “see for myself” how responses were given and 
aided in the interpretation of findings. In terms of personal development it also allowed me to 
gain interview skills and confidence in the processes of research. 
5.7.1.3 Potential limitations of participants 
Dermatologists were selected to provide an ‘expert’ diagnosis of MC from their clinical 
training, experience and knowledge, however it can be argued that it is GPs who see the most 
cases of MC in the UK and therefore they could have been selected as ‘experts’ to provide this 
knowledge. Although GPs could have feasibly participated in the research to provide this 
diagnosis of MC, dermatologists were chosen due to their position as being the experts in 
diagnosing skin conditions in the UK, however using either medical specialty would have 
brought its own limitations.  
The parent group used for the pilot of the MCDTP may not be representative of the target 
population who will completed it in GP surgeries. The group consisted of local parents (n=12) 
that were formed as a local community group by Cardiff Council in a largely socially deprived 
area of the city, rather than a mix of parents from differing demographic backgrounds brought 
together for research purposes. No data was collected of the parents such as age, educational 
level, postcode (to derive socio-economic status) that would provide further description of the 
group or to compare if there were any differences in these characteristics between parents 
who provided positive or negative feedback. Although focus groups are found to be useful for 
testing the paraphrasing of questions, the MCDTP was tested with only this group rather than 
in multiple group sessions which are recommended in qualitative research (138). However, 
due to the training, time and cost constraints associated with conducting focus groups the 
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benefits of using a well-established freely available group to receive feedback of the MCDTP 
usability was beneficial to this research phase.  
 Conclusions 5.8
The overall feedback from the pilot study shows that the MCDTP is understandable and 
parents were positive that they would complete it if asked in a GP surgery. However some 
participants provided feedback that the general instructions of why they were completing the 
MCDTP were confusing, highlighting further development was required before assessing the 
validity of the instrument to ensure that the wording of the instructions are clear and concise 
when handed to parents.  
The subsequent chapter will assess the extent to which the MCDTP is valid by describing its 
effectiveness in supporting parents to diagnose MC when their diagnosis is compared to a GP. 
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Chapter six: Assessing the extent to which the MCDTP is valid as a parental 
molluscum contagiosum diagnostic tool 
The development and validation of the MCDTP was published as an original research article in 
the British Journal of General Practice. A copy of the published paper can be found in Appendix 
1.2. 
6. Overview 
This chapter will describe the extent to which the MCDTP that was developed in the previous 
chapter is valid as a parental diagnostic tool for MC. The diagnosis of a parent (index test) was 
compared to that of a GP (gold standard) to measure the accuracy of the MCDTP as a 
diagnostic tool for MC. This chapter will define the study design, setting, procedure, and 
results of this assessment. The chapter will conclude by discussing the potential limitations of 
this study. 
 Objectives 6.1
6.1.1 Primary Objective 
The primary object of this study phase was to measure the accuracy of parental diagnosis of 
their child’s skin lesion as MC or not, when supported by use of the MCDTP, compared to a 
gold standard of GP diagnosis of the skin lesion. 
6.1.2 Secondary objectives 
The secondary objectives were to; 
 Explore the relationship between parental confidence in their diagnosis and 
agreement with the gold standard. 
 Describe the inter-rater agreement between the gold standard test (GP diagnosis) and 
diagnosis made by a panel of expert clinicians. 
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 Study design 6.2
Following development of the MCDTP (which involved three phases with dermatologists, 
nurses, GPs and parents, described in chapter five) the diagnostic accuracy was assessed. The 
diagnostic accuracy was measured using data from two tests; an index test performed by the 
child’s parent, and reference standard (gold standard) performed by a clinician. Inter-rater 
agreement was measured between the reference standard test (GP diagnosis) and diagnosis 
made by a panel of expert clinicians where photographs of a sample of participants were 
obtained, allowing a diagnosis of MC to be made independently by three further clinicians. 
6.2.1 Index test 
Parents of children, aged one to 14 years, completed the index test. The index test consisted of 
parents of children with a skin lesion viewing and reading the images and text within the 
MCDTP. They would then use this to make an educated decision on whether their child’s skin 
lesions were MC or not. The test was performed prior to a child’s consultation with their GP. 
Parents were asked to mark how confident they were in making that decision on a scale of 
‘Very Confident’, ‘Confident’, ‘A bit confident’ or ‘Not confident’.  
6.2.2 Reference test 
The reference test was completed by the child’s GP. This was conducted during the 
subsequent consultation where a clinical examination of the child’s skin lesion was performed 
and the GP noted a yes/no diagnosis of MC.  
6.2.2.1 Rational for reference test 
GP clinical diagnosis was selected as the reference test. The gold standard diagnosis for MC 
would be performed following biopsy (4); however parents may be uncomfortable with this 
test being performed on their child for research purposes. Adding intrusive or burdensome 
methods to the study may reduce participation rates not only by parents (139), but also the 
research sites. Conducting a more comprehensive procedure would require practitioner 
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training and impact on clinical time which may not have been appealing to all sites. GP 
diagnosis was deemed the most rational selection for our reference test as (within the UK) 
most cases of MC will be seen in primary care and diagnosed by a GP. Only the most rare and 
unusual cases will be referred to a dermatologist. GP’s will be accustomed to diagnosing MC as 
part of their usual practice. Furthermore, a two-page information sheet about MC was 
provided to each GP who participated in the study (appendix 3.4) as a guide to the most 
common features of the condition.  
Dermatologists could have been used as the reference standard test, and a similar study 
design as outlined for GPs surgeries could have been used in a dermatology outpatient clinic 
setting. Dermatologists specialise in diagnosing skin conditions, and may be viewed by some as 
the next best gold standard to a biopsy for a confirmed MC diagnosis. There is no evidence 
supporting whether a GP or dermatologist provide better diagnostic accuracy for MC when 
compared to a biopsy. However MC is typically rarely seen in dermatology clinics and within 
the UK patients with MC will normally present and be diagnosed in primary care. Indeed, 
children attending dermatology clinics would have provided a higher proportion of children 
with a skin lesion, and this subsequently may have shortened the recruitment timetable, or 
provided an increased sample size. However in dermatology clinics there may have been a 
much lower proportion of skin lesions being MC due to the condition being seen in this setting 
infrequently. Parents of children visiting a dermatologist may be accustomed to examining 
their child’s skin and in addition may have already received diagnostic information from the GP 
during the original consultation, impacting on their own diagnosis of MC. Performing the test 
in a dermatology clinic scenario may have introduced selection bias meaning the results were 
not generalisable to the wider population. Inviting parents and their children, who completed 
the index test in GP surgeries, to have the reference test conducted whilst attending their local 
GP practices provides a readily available population which is representative of the wider 
population in the UK. 
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6.2.3 Inclusion and exclusion criteria 
The inclusion criteria were children aged one to 14 years attending a consultation with a 
primary care general practitioner (GP) and having a skin lesion.  
Children were excluded if they currently or had previously been diagnosed with MC by their 
GP. 
6.2.4 Setting 
The setting for completion of the MCDTP was in primary care surgeries within the geographic 
area of Cardiff and the Vale of Glamorgan, and governance of Cardiff and Vale University 
Health Board (UHB). This setting was selected as it ensured that both the index and reference 
test could be carried out on the same day with minimum impact upon both the parent and GP. 
Conducting the research within Cardiff and the Vale of Glamorgan meant all sites were within 
a daily commutable distance from Cardiff University, and allowed the researcher (myself) to be 
able to travel to research sites for recruitment. Only parents with children attending the 
surgery for a GP consultation on that day were asked to participate.  
6.2.5 Research sites 
All GP practices within Cardiff and Vale UHB (n=92) were invited to participate in the research 
study. Each practice manager received a letter (appendix 3.5) that explained the study 
procedure, what the study would involve for the practice and invited them to participate. 
Practices who participate in teledermatology at UHW were also emailed the same letter 
directly to the teledermatology administrator at the practice from the Head of Department of 
Dermatology, UHW. As the study was a NISCHR CRC registered project, recruitment of sites 
was supported through the South East Wales Network Team who raised awareness of the 
study through their established practice network. 
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In total 16 practices responded to the materials which were sent, indicating they had reviewed 
the study during a senior partner practice management meeting. Of those 16 who responded, 
12 indicated that they would like to participate in the study and four declined. Five of the 12 
practices agreed to participate in the additional phase of obtaining photographs of skin lesions. 
6.2.6 Screening 
To narrow the selection of ineligible children participating in the study, parents were screened 
before receiving information about the study. Firstly, the child was screened by age, as only 
children aged one to 14 years were eligible to participate in the study. Secondly, only children 
with skin lesions were required for the study. Although the term ‘lesion’ is commonly used and 
acceptable by medical practitioners, this may not be the case in the general population and 
could lead to misinterpretation and/or confusion. During the development of the MCDTP 
recommended wording for ‘lesion’ in patient facing documents was defined as ‘a spot, lump or 
bump’. 
Children were screened upon entering a practice if they were within the age range, and 
answered yes to the screening question of ‘having a spot, lump or bump on the skin’. The 
screening wordings were printed on a study pack envelope (Appendix 3.6) which was handed 
to parents by reception staff.  
6.2.7 Providing clear instructions to parents completing the MCDTP 
Within the development phase of the MCDTP a key conclusion was that the instructions for 
using the tool and why parents were being asked to participant were not clear, and this caused 
confusion for some parents who participated in the pilot. To improve the instructions and 
usability of the MCDTP a front and back page were added to the MCDTP to form an A5 
booklet. The front page provided clear instructions of the study steps for participating parents 
using cartoons and text. On the back page parents and GP’s were guided as to which sections 
they should complete and what to do next. During discussions with SW, a lay representative, 
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she suggested that simple and clear instructions about the study should also be included on 
the study envelope. A draft study envelope was produced and discussed with SW who 
provided feedback on all content within the study envelopment that was used.  
6.2.8 The ‘study pack’ 
The study pack which was given to each participant by the receptionist at the practice 
contained the following; participant information sheet, information sheet for children, consent 
form, assent form, ‘MCDTP’, and a pen. These documents were inserted into an A5 white 
envelope with the screening questions and brief information about the study printed on the 
front (Appendix 3.6).  
6.2.9 Procedure 
Parents of children, aged one to 14 with skin lesion/s, were asked to read the study materials, 
provide consent, and complete the MCDTP in the practice waiting area prior to their 
consultation with a GP (index test) noting on the form whether they would diagnose their 
child’s skin lesion as MC. Parents also marked how confident they were in making that decision 
on a scale of ‘Very Confident’, ‘Confident’, ‘A bit confident’ or ‘Not confident’. During their 
consultation a clinical examination of the lesion was performed by the GP (reference 
standard), who noted a yes/no diagnosis of MC. The index and reference tests were performed 
on the same day. The complete procedure in GP surgeries following the patient journey is 
shown in Figure 19. 
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Figure 19. MCDTP study process in GP practices 
 
 Inter-rater agreement 6.3
6.3.1 Design and outcome 
Photographs of 20 participants’ skin lesions (10% of total sample) were obtained. Two 
consultant dermatologists and a second GP independently reviewed these photographs to 
measure agreement between the MC diagnoses given by the reference standard (GP). The 
photographs were taken of the singular lesion, or group of lesions which the parents viewed 
when making a diagnosis using the MCDTP.  
The three photographs assessors, GP and two dermatologists, viewed each of the images 
independently making an MC diagnosis solely using the photographs using the following 
options; negative, suspect negative, positive, suspect positive 
6.3.2 Procedure 
Although many GPs do indeed take photographs of skin conditions for purposes such as 
teledermatology, not all practices participating in this study were part of this. Therefore not all 
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sites would have had prior training in medical photography and access to cameras or 
equipment. To reduce equipment costs, photographs were taken using a camera (Camera 
model: Olympus SP-620UZ) loaned by the South Wales Trials Unit (SEWTU) for research 
purposes, and each photograph was taken by myself. 
Photographs were taken whilst I attended GP practices for recruitment, all parents who 
participated in the study during July to September 2013, across five practice sites, were asked 
if they would like to take part in the additional stage of providing images. Five sites 
participated in this additional stage. The photographs were taken in a designated consultation 
room within the practice whilst the parents and their child waited to see the GP once they had 
completed the MCDTP. 
Parents who participated in this study phase completed additional consent for the 
photographs to be taken. 
6.3.3 Training 
I undertook a one hour training session with a medical photographer from the Media 
Resources Centre, UHW. During this training session I was guided through the correct settings 
for the camera, the optimum positioning for taking the photographs, and developed a study 
photograph protocol to be used when in practices (appendix 3.7).  
6.3.4 Outcomes 
Photographs were categorised independently by each rater as MC positive, suspect MC 
positive, suspect MC negative or MC negative. 
 Recruitment 6.4
Participants were recruited at GP practice sites to complete the index test. The reference 
standard was completed by the GP at the research site. 
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The management of the study at each site was conducted by the Practice/Assistant practice 
manager or research manager. Their main duties were to ensure reception and clinical staff 
were aware of the study and trained in the study procedures. They also managed the 
administration of the study at the site. 
 Sample size 6.5
The sample size calculation was based upon achieving 90.0% sensitivity and specificity with 
confidence intervals of 74.4% to 96.5% (sensitivity) and 85.8% to 93.0% (specificity), and 
assuming an incidence of MC of 10% amongst children with a skin lesion (warts) (36, 140). This 
resulted in a required sample of 300 participants. As the sample size was based upon 
assumptions of the desired effect size and variance within the data, I planned to recalculate 
the sample size during the study to ensure that enough patients were recruited to give 
adequate power and that time was not wasted in collecting more data than necessary (141). 
6.5.1 Sample size review (mid-study) 
The sample size was revised by the project group following initial analysis of the first 75 
participant data. The incidence of MC within this sample was 30%; higher than the 10% 
assumed in the original sample size calculation. The initial data was analysed and used to 
model the precision in the sensitivity and specificity, given a sample size of n=200, n=300 or 
n=400 and found little variation in the width of the confidence intervals. Subsequently the 
sample size was reduced to n=200 participants completing the MCDTP.  
 Data collection 6.6
Data was collected on the back page of the MCDTP, where the parent completed their 
diagnosis of MC, and how confident they were in the diagnosis. The GP then completed a small 
section on the same page, giving their name and ticking either ‘yes’ or ‘no’ for a diagnosis of 
MC. This, along with the completed consent and, where applicable, assent form were returned 
to the research team by the site administrator. Once returned, the data was entered into an 
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excel spreadsheet, the paper forms then stored within a locked cabinet in a secured office in 
Neuadd Meirionnydd (NM), Cardiff University. 
 Practice Retention 6.7
Maintaining recruitment and awareness of the study within practices was an important part of 
the study and as recruitment was over a period of nine months, it was essential to encourage 
and maintain active recruitment across all practices.  
Three methods were used to maintain engagement with practices throughout the active 
recruitment period. Firstly, monthly newsletters were emailed to each practice; the newsletter 
contained recruitment updates, news about the study and tips to aid increasing recruitment in 
practices. Secondly, regular contact was maintained with the practices via a monthly email to 
the site administrator at each practice requesting the number of participants recruited, discuss 
how recruitment was progressing, and to arrange collection/delivery of the data forms. Finally, 
engagement with practices was also maintained through attendance at sites for recruitment. 
Although primarily the aim of attending GP surgeries was to aid and improve recruitment it 
also served as an opportunity to improve the relationship between the researcher (myself) and 
site. During attendance at GP surgeries it allowed me to speak directly to the reception staff 
where I could explain the study, the study procedures and also the importance of giving out 
the study envelopes to all parents entering the practice. Overall this was a success as many 
receptionists would be pleased to inform me directly that they had recruited participants 
during visits, however in some instances, especially larger practices with a large reception 
team, this did not encourage all of the reception staff to engage with the study. 
 Data management 6.8
Completed MCDTP forms were returned to Cardiff University where they data were entered 
into an excel spreadsheet. Each participant was then assigned a unique ID, practice ID, and GP 
ID to store the data anonymously, this additional coding was also recorded on the primary 
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source (MCDTP). The spreadsheet was held on a password protected computer on the Cardiff 
University network. Paper forms were marked as entered onto the database and then stored 
within a locked cabinet, on the 5th floor NM. 
As a UK Clinical Research Network (UKCRN) registered study, monthly data uploads were 
entered onto the UKCRN portfolio database. Once uploads were completed the MOSAIC study 
profile was updated on the UKCRN website.  
Once all data was collected, the excel file was exported into ‘.dta’ format for analysis. 
 Analysis 6.9
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 
the MCDTP diagnosis against the reference test diagnosis were calculated. Inter-rater 
agreement between GP and consultant dermatologist diagnosis was also calculated. Statistical 
analysis was performed using STATA 12. 
 Results 6.10
6.10.1 Recruitment 
A total of 203 parents of children aged one to 14 years participated between January and 
October 2013 (Figure 20). The majority of study participants were recruited within the first 
three months of the study opening, recruitment by month then gradually decreased to less 
than half of that in the initial three months. This may be due to an overall drop in awareness in 
each of the practices from the initial set-up and also that typically the number of consultations 
for children is greater in the winter months than other times in the year. Another factor may 
be the Easter school holiday break and build up to the summer holidays, where parents may 
be less likely to want to complete study documentation in a busy/hot reception area.  
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Figure 20. Participant recruitment in GP practices by month 
 
60 GP’s in 12 practices took part in the study. The number of participants recruited per site 
ranged from zero to 50 (Table 28). The sites where I personally attended to recruit participants 
(002, 006, 008, 010, and 012) were those with the highest numbers recruited. These sites were 
chosen due to having particularly poor recruitment numbers in month one; in particular site 
002 was a concern as it had recruited zero participants in the first month, and had not 
previously participated in a research study. However, once I attended the practice and spoke 
directly with the reception/clinical staff where I could explain the study, this site ended the 
study period being the highest recruiters. Other factors may well have influenced the high 
recruitment such as being centrally located in a large family housing estate. However due to 
the initial poor start I conclude that the impact of engaging directly with the practice positively 
impacted on the overall recruitment. Other sites I chose to attend were selected partially due 
to good accessibility via public transport and a willingness to allow a researcher to attend the 
site for recruitment. Although site 012 had low recruitment, the site joined the study in the 
final month (August 2013) when a new practice manager was appointed with experience in 
research.  
0
5
10
15
20
25
30
35
40
45
50
Jan Feb Mar Apr May Jun Jul Aug Sep Oct
N
o
. 
re
cr
u
it
e
d
 
Month 
Study Closed 
08/10/2013 
Easter 
half- 
term 
Summer 
holidays 
Study Open 
08/01/2013 
Photo recruitment 
Page | 105 
 
Participants were evenly distributed between genders, and the majority aged one to three 
years (40%) (Table 29).  
Table 28. Participants recruited by practice site 
Practice 
Code 
Location IMD score* 
Rural/Urban 
classification** 
No. 
Recruited 
No. GP's 
completing 
MCDTP 
001 Cardiff 46.72 Urban >10k 18 9 
002 Cardiff 1.22 Urban >10k 50 5 
003 Cardiff 8.54 Urban >10k 4 2 
004 Cardiff 10.53 Urban >10k 12 4 
005 Vale of Glamorgan 8.58 Urban >10k 7 5 
006 Vale of Glamorgan 10.44 Urban >10k 28 7 
007 Vale of Glamorgan 10.44 Urban >10k 21 3 
008 Vale of Glamorgan 8.36 Urban >10k 30 9 
009 Vale of Glamorgan 26.05 Urban >10k 13 6 
010 Vale of Glamorgan 23.05 Urban >10k 17 8 
011 Cardiff 21.70 Urban >10k 0 n/a 
012 Vale of Glamorgan 3.74 Urban >10k 3 2 
Total 203 60 
*2000 IMD scores for electoral ward (The higher the score, the higher the average level of 
deprivation) **2004 Rural and Urban classification for wards (Source: ONS 2007 (142)) 
Table 29. Participant characteristics 
Age (years) 
Sex (%) 
Total 
Male Female 
1 to 3 36 (44%) 45 (56%) 81 (40%) 
4 to 6 25 (46%) 29 (54%) 54 (27%) 
7 to 9 19 (53%) 17 (47%) 36 (18%) 
10 to 14 16 (50%) 16 (50%) 32 (15%) 
Total 96 (47%) 107 (53%) 203 
6.10.2 Main outcome 
Data on confidence in their diagnosis was provided by 186 (91.6%) parents (Table 30). Of 
these, 85% indicated they were either ‘very confident’ or ‘confident’ in their diagnosis.  
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Table 30. Agreement of MC diagnosis between GP and parent listed by parental diagnostic 
confidence 
  
Diagnosis agreement 
Total 
Agree Disagree 
Very Confident 94 (95%) 5 (5%) 99 
Confident 52 (88%) 7 (12%) 59 
A bit confident 17 (71%) 7 (29%) 24 
Not confident 1 (25%) 3 (75%) 4 
Total 164 22 186 
Pearson chi2(3) = 26.5 Pr = <0.005 
Note: 17 participants did not complete this question 
Table 31 shows the incidence, sensitivity, specificity, PPV and NPV of the MCDTP by all 
completed, and also by only those where a parent was ‘very confident’ or ‘confident’ in their 
diagnosis.  
The incidence of MC in the sample was 29.1% (Table 31). The sensitivity of the MCDTP was 
91.5% indicating a high proportion of true positives were correctly identified by parents. The 
specificity was also high (88.2%) indicating that parents using the MCDTP correctly identified 
negative MC diagnoses. The MCDTP had a high NPV (96.2%) suggesting that the majority of 
parents that gave a negative diagnosis using this tool for MC were correct. However the PPV 
was only 76.1%, indicating that a quarter of parents who thought their child’s skin lesion was 
MC using this tool, may have made an incorrect diagnosis.  
For parents with greater confidence in their diagnosis the incidence of MC was 30.4% with the 
sensitivity and specificity being 95.8% and 90.9% respectively, with a PPV of 82.1% and a NPV 
of 98.0%. Greater parental confidence in their diagnosis was positively associated with 
agreement between parental and GP diagnoses (χ2= 26.6, df=3, p=<0.005).  
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Table 31. Incidence of MC, sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV) for MCDTP 
a) All participants regardless of confidence in diagnosis  (n=202)  
  
% 
95% CI 
LCI UCI 
Incidence of MC 29.1 22.9 35.8 
Sensitivity 91.5 81.3 97.2 
Specificity 88.2 81.8 93.0 
Positive Predicative Value (PPV) 76.1 64.5 85.4 
Negative Predictive Value (NPV) 96.2 91.4 98.8 
b) Participants who indicated they were 'Very Confident' or 'Confident' in their diagnosis 
(n=158) 
  
% 
95% CI 
LCI UCI 
Incidence of MC 30.4 23.3 38.2 
Sensitivity 95.8 85.7 99.5 
Specificity 90.9 83.9 95.6 
Positive Predicative Value (PPV) 81.2 69.9 91.1 
Negative Predictive Value (NPV) 98.0 93.1 99.8 
6.10.3 Inter-rater agreement 
Photographs of lesions were obtained for a sample of 20 children participating in the study; 19 
were used in the final analysis as one image was discarded due to poor quality (image out of 
focus). This was a sample of convenience where parents and their children were asked to 
participate in this additional study phase when attending the practice on the same date as 
myself. 
When combined with the original assessor, overall agreement between the four clinicians was 
47.4%, with a fair strength of agreement (Table 32). Comparing the initial GPs rating with the 
other clinicians shows varying agreement between 57.9% with Dermatologist 2, and 84.2% 
when compared to with GP2. The strength of the agreement is mainly fair, and there is a 
moderate strength between the two GP’s. Each of the kappa statistics calculated between the 
agreements have particularly wide confidence intervals, and the overall agreement between 
the GP who saw the child and those who only saw the images is fair (kappa 0.31).  
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Table 32. Inter-rater agreement between reference standard, GP and 2 dermatologists 
Diagnosis of photographs 
(n=19) 
Agreement 
(%) 
Kappa 
statistic 
95% CI Strength of 
agreement 
(143) LCI UCI 
 
A) Agreement between GP and diagnosis made by clinician using image 
GP expert 84.2 0.52 0 1 Moderate 
Dermatologist 1 68.4 0.25 0 0.97 Fair 
Dermatologist 2 57.9 0.24 0 0.79 Fair 
 
B) Agreement between clinicians viewing images 
  42.1 0.32 0.15 0.5 Fair 
 
C) Agreement between all clinicians (reference test and those viewing image) 
  47.4 0.31 0.10 0.4 Fair 
In 35% of cases, the clinicians were unable make a definitive positive or negative diagnosis for 
MC using the images alone, and chose to give either a suspect positive or negative diagnosis. 
This may be due, in some images, to the image quality; for several images the photographs 
were out of focus or blurred.  
Table 33 provides agreement data where a ‘suspected’ and ‘certain’ diagnosis by the three 
photo assessors were combined. The overall agreement in diagnosis improved and was found 
to be high at 84.2%, with a substantial strength in agreement. In particular, the agreement 
between the GP expert’s diagnosis and the reference standard GP was very high (94.7%), again 
with a substantial strength in the agreement. The agreement ranged from 84.2% to 89.5% 
where the reference standard was compared to the two dermatologists. Including only those 
assessing the images provides a high agreement, with narrow confidence intervals. This 
suggests that there was a very strong agreement between the three clinicians irrespective of 
speciality when viewing the images alone.  
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Table 33. Inter-rater agreement between reference standard, GP and 2 dermatologists where 
suspect and confirmed diagnosis is merged 
Diagnosis of photographs 
(n=19) 
Agreement 
(%) 
Kappa 
statistic 
95% CI Strength of 
agreement 
(143) LCI UCI 
 
A) Agreement between GP and diagnosis made by clinician using image 
GP expert 94.7 0.78 0.35 1 Substantial 
Dermatologist 1 89.5 0.61 0.14 1 Substantial 
Dermatologist 2 84.2 0.5 0.04 0.95 Moderate 
 
B) Agreement between clinicians viewing images 
  89.5 0.79 0.74 0.84 Substantial 
 
C) Agreement between all clinicians (reference test and those viewing image) 
  84.2 0.71 0.56 0.7 Substantial 
  Discussion 6.11
A total of 203 parents completed the MCDTP.  The MCDTP had a sensitivity of 91.5% (95% CI 
81.3 to 97.2) and a specificity of 88.2% (95% CI 81.8 to 93.0) compared to the reference 
standard of GP clinical diagnosis. The PPV was 76.1% (95% CI 64.5 to 85.4) and NPV 96.2% 
(95% CI 91.4 to 98.8) for all parents. The MCDTP was developed to act as a recruitment tool for 
our epidemiological study and data suggests the MCDTP is suitable for this purpose. 
There was a positive association between being ‘confident’ in a diagnosis, and agreement in 
diagnosis with a clinician. This provided a sensitivity and specificity of 95.8% (95% CI 85.7 to 
99.5) and 90.9% (95% CI 83.9 to 95.6) respectively in parents who were confident or very 
confident in their diagnosis. Excluding participants where they were ‘a bit confident’ or ‘not 
confident’ provided improved sensitivity, specificity, PPV and NPV. 
Describing the inter-rater agreement between the reference standard test (GP diagnosis) and 
diagnosis made by a panel of expert clinicians was relatively fair (47.4%). This may be 
attributed to numerous factors such as image quality, limited patient history, and using images 
rather than a full consultation. Overall, 35% of the images photo assessors were unable to 
provide a definitive diagnosis towards either MC positive or negative, therefore giving a 
‘suspect’ diagnosis towards positive or negative. Where the suspect diagnosis is merged, a 
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much higher agreement is reached (84.2%). It can be assumed that during a physical 
examination a diagnosis confirming a ‘positive’ or ‘negative’ MC diagnosis would have been 
reached. Based on this data analysis the agreement of diagnosis between ‘experts’ and the 
gold standard was substantial.  
6.11.1 Comparison with other literature 
Overall the agreement between clinician’s diagnosis and the reference standard was 
substantial to moderate. Previous studies show agreement between a primary care physician’s 
diagnosis of MC and a dermatologist as correct in up to 100% of cases (144, 145), however 
these were in small studies (n=8, 3) where each rater saw the patient face-to-face.  
The results show that although photographs alone can be effective in providing a diagnosis, in 
35% of cases this was not sufficient to make a definitive diagnosis. Although this may have 
been due to the quality of the image (as described above several images were blurred or out of 
focus), we do not know how much of the observed disagreement is related to the 
photographs, as there may well be disagreement even when both clinicians exam the child. 
This is similar to other studies of much larger numbers where 20% of dermatologists did not 
provide a single diagnosis using only photographs, although dermatologists were able to 
provide a definitive diagnosis in significantly more cases during face-to-face consultations 
(146). I found high levels of diagnostic agreement which are comparable to other studies 
where agreement ranged between 81% to 89% (146). Warshaw (2011) conducted a systematic 
review of teledermatology diagnosis agreement between a dermatologist following a face-to-
face consultation, and a second using only photographs; providing a weighted average 
agreement of 65.3% (147). In a study where a similar numbers of patients were assessed 
(n=16) the k coefficient of dermatologist agreement was similar to our data when combining 
all four clinicians diagnoses(k=0.67) (119), Warshaw showed the overall k coefficient in a 
number of studies ranging from 0.65 to 0.87 (147).  
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6.11.2 Limitations  
6.11.2.1 Potential limitations of participants 
The population used to test the MCDTP were children attending primary care centres in South 
Wales and, as will be described in the subsequent subsection, the majority of this population is 
White British. We did not collected data of ethnicity and therefore it should be assumed the 
sample used to test the MCDTP may not have included children with different skin colours. 
This selection bias could have been reduced by testing the MCDTP in a sample of children with 
a range of skin colours. The features of MC are the same in children regardless of their skin 
colour but the usefulness of the images that were used in the MCDTP should be tested before 
any assumptions are made of its suitability within a more diverse population. The 
generalisability of the MCDTP to its target population will be described further in the next sub-
section. 
Clinicians were provided with an information sheet describing MC that used the same key 
points and images as that given to parents. By providing both the parents and clinicians similar 
guidance for an MC diagnosis it may have meant that both were influenced in their diagnosis 
the same way. No information was collected from the GP as to whether they had read the 
information provided and, if they had, whether this guidance had influenced their diagnosis of 
MC, however, we found a high level of agreement between clinicians suggesting that the GPs 
had not been influenced when providing a diagnosis. 
Only parents who responded to the study question of ‘does your child have a spot, lump or 
bump on the skin?’ were invited to participate in the study and therefore this population had a 
range of skin conditions that does provide the true sensitivity and specificity for conditions 
similar to MC. 
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6.11.2.2 Potential limitations in the recording of data 
During the recording of data GPs could view the diagnosis given by the parents prior to 
providing their own diagnosis, as both the parent and GP diagnosis were recorded on the same 
page. Reading the parents diagnosis could have influence the GPs decision making. This bias 
could have been reduced if clinicians were blinded when giving their diagnosis, therefore 
ensuring they were unaware of the response given by parents. This blinding did not occur and 
is a limitation of the MCDTP study design. A simple improvement in the process could have 
been implemented by parents and clinicians recording the MC diagnosis on a different page of 
the MCDTP booklet, however this would not have been true blinding as clinicians could still 
easily access the parent diagnosis by turning the page. However, this is likely to have had little 
effect as GPs are familiar with making a diagnosis in the setting of an alternative diagnosis 
being suggested by a patient / parent.  
6.11.3 Generalisability and acceptability of the MCDTP 
6.11.3.1 External validity 
External validity relates to generalisability of the study findings to other populations (35). To 
measure the generalisability of the MCDTP it is important to seek whether there are other 
populations that have similar population structures for which it can be assumed the MCDTP 
will provide similar diagnostic accuracy statistics (35). The characteristics of general practices 
who participated in the research were provided earlier in Table 28. The data showed that 
there was a wide range of practice deprivation scores (IMD) between 1.22 to 46.72, indicating 
that the practices were located in areas of both high and low relative deprivation, and suggests 
that study participants provide a range in their socio-demographics characteristics. All of the 
practices were classed as being located in ‘urban’ areas and therefore rural areas were not 
represented within the population which is a limitation of this study.  
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There is a risk of selection bias which would mean that the sample population are not similar 
to the general population, however we do not feel this was a problem because the 
characteristics of our study population appear to be similar to the general population. For 
example when further comparisons of the data are made to the populations of Cardiff, Wales 
and England (Figure 21) the percentage of the participating practice populations being 
recorded as White British ranged between 59.5% to 95.4%, and provided an overall mean 
value of 86.5%, this figure is comparable to England (86.9%), however lower than the Welsh 
average (93.2%) (142). Further comparisons are presented in Figure 21 which indicates that 
the practices who participated in the study were comparable to that of England and Wales 
using these three general measures (Figure 21 highlights the percentage of the working age 
population with qualifications, percentage of the population receiving Job seekers allowance 
(JSA) and ethnicity; these measures were chosen as qualification status can be an indicator of 
health literacy (148), the percentage receiving JSA can be an indicator of levels of deprivation 
within a population (149), and the percentage of the population classed as White British is an 
indicator of ethnic diversity).  
It is important to highlight that the demographic data of the sample is based upon the local 
data relating to the practice postcode (Lower Super Output Area (LSOA)) and not individual 
participant characterises, however as individual practice characteristics are not available this is 
the best data available for this comparison.  
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Figure 21. Characteristics of sample, English, Welsh and Cardiff populations 
 
6.11.3.2 Features to improve the external validity 
Elements of a study design can reduce the external validity of findings such as limiting the 
eligibility of those who can participant in the research (150). To avoid this, an inclusive 
recruitment plan was implanted in this study. All practices within Cardiff and Vale were invited 
to participate in the study (n=93), of those practices within Cardiff 12 responded and this 
group of practices participated in the research. Within the practices recruitment was active for 
over eight months where all potentially eligible parents visiting the practice were invited to 
participate in the study. Study materials were limited to only being available in English, and 
therefore this language barrier may have unavoidable excluded some potential participants 
from taking part in the study. 
 Conclusions 6.12
The data suggest the MCDTP is suitable for use in an epidemiological study and the population 
used to test the MCDTP are shown to be generalisable to other populations in the UK. 
Therefore, the MCDTP is suitable for use as a recruitment tool in the following chapter (seven). 
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Chapter seven: Prospective cohort study of children with molluscum contagiosum 
An original research article was published in The Lancet Infectious Diseases describing time to 
resolution, transmission and impact on QoL of MC in children. A copy of the published 
manuscript can be found in Appendix 1.3. 
7. Overview 
This chapter will describe the design, setting, procedure, and results of a prospective cohort 
study of children with MC. The chapter will conclude with a summary of the findings and 
discuss potential limitations of the study.  
 Background 7.1
Data on the epidemiology of MC is generally of poor quality. There is little data on the time to 
resolution of the condition, and there have been no studies which have described the 
presentation, management, transmission between siblings and impact on QoL in a large 
community cohort of children living in the UK. 
Measuring QoL for dermatological conditions is particularly important, and although skin 
conditions are not generally life-threatening they can have a major impact on patients’ 
psychosocial state, social relationships and everyday activities (151). By measuring QoL the 
effects of disease from the perspective of the patient or child can be ascertained (73).  
 Study Design 7.2
This is a prospective cohort study of children recruited from the community with MC. 
 Rational for study design 7.3
The prospective cohort design is useful for estimating causal relationships between exposures 
(e.g. age, sex, treatment) and subsequent outcomes (e.g. time to resolution) (30). The design 
does have limitations. Recruiting a cohort and following-up participants for the duration of 
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symptoms can be expensive, and cohort studies are subject to loss of study participants (152). 
However, this can be factored into the sample size to ensure enough study participants are 
recruited to provide significant power for potential participant drop-out (153). The 
management of the study can be amended to use techniques that are quick and simple to 
allow participants to provide follow-up data, and maintain engagement with the study. For a 
condition, such as MC, where cases infrequently report to primary care, there can be 
difficulties in recruiting a sufficient number of cases from only this setting (152). Where 
participants are recruited from the community and recruitment is not limited to only primary 
or secondary care centres, it is possible for a larger number of cases to be recruited without 
needing a substantial amount of primary care sites to recruit, which can be logistically difficult 
and expensive. Additionally, recruiting only from primary or secondary care centres can 
introduce bias to the study results whereby it can limit the generalisability of the findings as it 
includes only the health care seeking population, and possibly more severe cases (27). By 
recruiting from a larger footprint and reaching out to recruit from both health care centres and 
the community, through a range of novel techniques, the findings from this study will be more 
representative of children living in the UK than if only children attending health centres were 
recruited. 
Other study designs could have been used such as a retrospective cohort or case series study. 
The retrospective study is recommended when the objectives are to determine the incidence 
and time to resolution of a condition (154), as are the objectives for this study. The benefit of a 
retrospective cohort design are that generally the data are already collected from other 
sources and all that remains are gaining access to data and analysis. However, as the data are 
already collected it does not allow for addition information to be captured or for patients to be 
followed to describe outcomes, also, often this data are collected from the health care setting 
meaning the data may not be representative of cases in the community. A second alternative 
design was a case series; this is a descriptive study design that can provide the clinical 
Page | 117 
 
description of a disease and recruits a large number of patients with the disease for this 
purpose (155). Data from patients are captured at one point in time which distinguishes this 
design from a cohort study where data are collected for patients at different time points (41). 
If data from patients is captured to describe previous symptoms it relies upon accurate 
parental recall and this may cause a reduced reliability of results (156). 
To allow for the prospective follow-up of participants, unique data to be collected and to 
ensure the sample was representative of children in the both the community and health 
setting, both the retrospective cohort and case series study designs were dismissed in favour 
of the prospective cohort design for this study. 
 Objectives 7.4
The primary and secondary objectives of this study were; 
7.4.1 Primary objectives 
 Determine the time to resolution of MC lesions. 
 Describe the reported transmission of MC in the children living in the same household 
as a primary case.  
 Describe the impact of MC on quality of life. 
7.4.2 Secondary objectives 
 Describe the symptoms of MC in children aged four to 14. 
 Describe the management of the condition by both clinicians and parents, including 
prescribed and non-prescribed therapies. 
 Describe prevalence of other skin conditions presenting in children prior to their 
current MC diagnosis. 
 Describe prevalence of risk factors, such as contact sports. 
 Describe the impact of MC on day to day activities, mood and relationships. 
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 Population 7.5
The target population were children, aged four to 14, with a current diagnosis of MC. The 
diagnosis was confirmed by either a clinician (during a consultation) or following completion of 
an online version of the ‘MCDTP’. 
7.5.1 Setting 
Patients were recruited using three main sources a) General practices, b) Dermatology 
outpatient clinics, and c) Media advertising and social media.  
 Recruitment processes 7.6
7.6.1 General Practices and Dermatology outpatient clinics 
Children with MC were recruited from general practices and dermatology outpatient clinics 
which acted as participant information centres (PICs). Parents of children who were diagnosed 
with MC, either during a clinical assessment or when completing the ‘MCDTP’ during the 
validation study (chapter six), were invited to participate in the study. If a parent or guardian 
wished to participate they were asked to complete a study information card whilst in the clinic. 
The information card recorded the parent’s name, telephone number and email address 
(Appendix 4.3). Once completed, parents were asked to leave it with the practice receptionist 
who returned it to myself. Once I received the study card I contacted the parents and directed 
them to the study website to complete the questionnaires or sent a paper questionnaire by 
post if this was their preferred option. 
7.6.2  Media Advertisement 
Participants were recruited through a media awareness campaign which published information 
about the MOSAIC study. Published articles provided brief information about the study and 
directed potentially eligible participants to the MOSAIC study website. Once at the website, 
parents were asked to read the study materials, provide consent, and complete the online 
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version of the ‘MCDTP’. Only parents who diagnosed that their child currently had MC using 
the MCDTP were invited to join the study. 
To construct an effective process for the distribution of information for the mosaic study, a 
meeting was arranged with the Cardiff University press relations (PR) team. PR officer, Tom 
Barrett, provided advice describing the best methods to raise awareness of the study from his 
experience; advising that to gain good coverage of the study in local news outlets it would be 
beneficial to provide a press release. The recruitment methods will be described in detail 
below and examples of these methods are shown in Figure 22. 
Figure 22. Examples of recruitment and study awareness methods 
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7.6.2.1  Local media 
A ‘press release’ was distributed to local news outlets by the Cardiff University PR team that 
provided text for a print or online article. This article provided information about MC in 
children, briefly summarised the ‘MOSAIC study’, and directed parents to the MOSAIC website 
if they wished to participate in the study, or if they wished to receive more information about 
the study.  
A short article was published in the ‘Western Mail’ on Monday 15th April 2013 entitled 
‘Diagnosing a child's skin problems can be tricky: Spots, lumps or bumps on your child's skin - 
could it be molluscum contagiosum?’ (Figure 22b) (157). The Western Mail is a daily Welsh 
national newspaper with a distribution of 32,926. A copy of the article text and a scanned 
version of the print version are in Appendix 4.4. 
7.6.2.2 Health forums 
Information about the study was posted on two health forum websites ‘mumsnet’ and 
‘netmums’ (Health forums are independent websites that provide an online network for 
parents where they can post and share parenting information (158)). The same text was 
posted on each site and uploaded to the section for non-member requests. Posting a ‘non-
members request’ on mumsnet incurred a charge of £30 and posting on netmums incurred no 
charges. 
Both websites contained a mini encyclopaedia of common diseases in children and neither 
contained a page providing parents with information about MC. I contacted both website 
editors to discuss providing additional content about MC which could be posted in their 
disease encyclopaedia section. Both of the website editorial teams responded, Netmums 
noted my email, stating that for the moment they would not be providing an information page 
about MC. Mumsnet responded positively to adding an information page for MC, and in the 
following months posted an information page based on information I supplied 
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(http://www.mumsnet.com/health/children/molluscum-contagiosum) (Figure 22a). The MC 
information page on ‘mumsnet’ included a direct link to the MOSAIC study website for parents 
whose child had MC or they wished to use the MCDTP to diagnose a skin lesion. The link to the 
MC information page on mumsnet was also included within their weekly email newsletter sent 
to members on 25/04/2013.    
7.6.2.3 Social media 
Two specific social media accounts were created for advertising of the MOSAIC study on 
Facebook and Twitter; Table 34 highlights the relevance of these social media tools for health 
professionals and researchers. 
Table 34. Social media tools and relevance to health professionals or researchers 
Social media tool Relevance to health professionals or researchers 
Facebook Global social networking site contains over half a billion members and 
increasing numbers of health professionals, medical organisations, 
illness-based support groups, and medical journals using this to share 
health information. 
Twitter Free microblogging platform in which over 100 million users 
worldwide—including health professionals, patients, and members of 
the lay public—publish brief text-based posts of up to 140 characters on 
their proﬁle pages to alert others to what they are doing, thinking, 
reading, or writing in the moment. Can be used to track real-time 
information ﬂow about topical health issues. 
Table adapted from George (2011) (159) 
Facebook 
Using Facebook, a ‘page’ was created to provide information about the research study; an 
advert was developed to direct users to this page. 
Posting adverts on Facebook incurred a charge; this charge was based on the number of 
people who ‘clicked’ the advert, and whether this ‘click’ occurred at peak or off-peak times. 
The advert presented on the right hand side of the web browser while Facebook users were 
logged into the website. Facebook hold information of their users such as age, location, 
computer being used, and age of children (if user has a child). Within the Facebook advert 
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application a defined criteria was created to limit the scope of the advert to show only to 
selected users and ensure only those who may be eligible to take part in the study could view 
the advert therefore limiting the number or irrelevant ‘clicks’ and cost to the study. The 
criteria for the advert were: 
- Male or Female 
- Aged 18 to 55 
- Resident of the UK 
- Using a desktop computer 
- Has a child aged four to 14 years. 
Once parents ‘clicked’ on the advert they were directed to the study website. A total of 60,403 
impressions (advert appearances) were made when a Facebook user was online and met the 
advert criteria. From these impressions on internet browsers, 25 parents clicked on the advert 
directing them to the MOSAIC study website. The total cost of advertising using Facebook was 
£43.28 ($71.39 converted on 24/03/2014 using google currency calculator). 
Twitter 
A twitter account for the study was launched in March 2013 using the name 
‘@MOSAIC_study’, the purpose of this account was to provide information about the study to 
users of the social network (Figure 22d). At the study close date (31/07/2014) the account had 
a total of 222 ‘followers’. The account was used as a mechanism to distribute short informative 
text to potential study participants and provide a link to the MOSAIC website. The 
administrator of a widely used twitter account (4,607 followers) providing information to 
parents and academics about eczema, the Nottingham Eczema support group 
(@eczemasupport), was contacted to ask if they would inform their followers of the MOSAIC 
study. The Nottingham Eczema group informed their followers on 14 separate occasions about 
the MOSAIC study.  
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The number of participants who clicked on the website following notification of the study from 
twitter is unknown, and therefore measuring the success of this is difficult. 
7.6.2.4 Google advertisement  
Google is the largest search engine in the UK, accounting for 90% of all searches made from a 
desktop computer (160). Adverts can be placed on the search engine using google ‘Adwords’. 
Google adverts are related to the search terms entered by a user and given a prominent 
position at the top or side of the page distinguishing them from the main search results. An 
advert was created when UK users of google entered specific search terms about MC. The text 
within the advert was limited to 25 characters for the title, and 70 characters within the main 
text. The final advert text was “Molluscum Contagiosum: Take part in Cardiff University 
research about MC in children” (Figure 22c). 
The advert was shown once a user provided specific search terms (Table 35), google users 
could click anywhere on the advert and this would open a new web browser containing the 
MOSAIC study website. Each time the advert was clicked a cost was incurred, the cost of each 
click was based upon google analytics modelling which factored whether it was at peak or off-
peak times. Overall the advert made 167,181 impressions following a search, and was clicked 
492 times. The total cost incurred for these clicks was £328.55. 
Table 35. Search terms for Google ‘Adwords’ 
Molluscum Molluscum Contagiosum child 
Molluscum Contagiosum Molluscum Contagiosum treatment in 
children 
Molluscum Contagiosum Children Get rid of molluscum 
Molluscum in Children Molluscum in kids 
Children Molluscum Molluscum Contagiosum treatment children 
7.6.3 Schools 
Local schools in Cardiff and Swansea were emailed information about the MOSAIC study; the 
email contained a letter containing information about the study. If schools wished to 
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participate in the study by sending letters to parents they were asked to contact myself for the 
documentation to send. Parents of children who attended participating primary schools were 
then sent letters home either by hand or via an email to parents. The letters informed them of 
the study, what it involves and what to do if they would like to receive more information. 
Those who wished to receive more information about the study were either directed to the 
MOSAIC study website or were provided with my Cardiff University email address to contact 
me directly.  
One school responded to confirm they had forwarded this email to their parent distribution 
list; however other schools forwarded the email without notifying myself. I was notified of 
emails being sent from schools when parents emailed me directly to ask for information about 
the study. Primary schools in Cardiff (n=95) and Swansea (n=62) were emailed on 21/05/2013 
and 24/06/2013 respectively. The success rate of informing parents of the study through 
schools cannot be determined, as the denominator of how many parents were contacted is 
unknown. 
7.6.4 Recruitment timetable 
Table 36. Recruitment timetable by different methods 
Recruitment 
2013 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct 
Diagnosis confirmed by clinician 
GP surgeries recruiting 
from MCDTP validation 
                    
Dermatologist referrals 
in Welsh outpatient 
department 
IRAS 
amend 
R&D 
Approval 
                
Diagnosis confirmed using MCDTP 
Media recruitment 
(Western Mail article) 
                    
Online health forum / 
discussion board 
advertisement 
                    
Social Media 
(twitter/facebook) 
                    
Google Ad words           
Schools                     
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Recruitment of participants who had an MC diagnosis confirmed by a GP commenced in 
January 2013 at GP practices taking part in the validation of the MCDTP (Table 36). Within the 
original ethical approval dermatology clinics were not included as sites for recruitment; 
however an amendment was submitted to the ethics board, subsequently approved and 
dermatology clinics began recruitment in March 2013. Referral to the study using the MCDTP 
commenced in April 2013 once the MCDTP had provided sufficient accuracy in parental 
diagnosis. Recruitment ended in October 2013 allowing follow up of participants to August 
2014 (study end date). 
 Procedure 7.7
Participants completed a structured questionnaire about the presentation, burden of disease, 
advice, and the CDLQI at recruitment to the study. To describe the time to resolution of 
symptoms and transmission to other family members’ participants were followed up via text 
message or email until lesions had cleared, or the study period had ended. 
7.7.1 MC Questionnaire 
The MC Questionnaire was purposefully designed for this study to collect information from the 
participants that would fulfil the outcomes of the study. Information was collected to provide 
data of the following key areas; 
 Demographics: Age and gender. 
 History: Duration, number and site of lesions, previous skin conditions. 
 Treatment: All prescribed and non-prescribed treatments for MC that had been used. 
 Risk factors and transmission: Participation in sports activities, other children within 
household and whether they have had MC. 
 Diagnosis and advice: Whether diagnosis was confirmed by a doctor, whether they had 
received advice and information from the doctor and whether they had received 
information from other sources.  
A copy of the questionnaire can be found in Appendix 4.1. 
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7.7.2 Time to resolution and follow-up 
A primary outcome of this study was to describe the time to resolution of symptoms. Data 
describing the time to resolution of the condition was captured prospectively by the follow-up 
of participants, this also collected data on whether there had been further instances of 
transmission between other children within the family since completion of the original 
questionnaire. 
Participant Follow-up Procedure 
An excel spreadsheet was developed containing follow-up information about the study 
participants. Contact details were obtained from the final page of the MC questionnaire where 
participants provided an email address and/or telephone number. Emails were sent from the 
following Cardiff University email account – olsenjr@cardiff.ac.uk. A study mobile telephone 
was purchased for the specific purpose of sending follow-up text messages; this phone, when 
not in use, was located within a locked draw of a secure building at Cardiff University. This 
phone was not used for any other purposes other than this study to ensure confidentiality of 
participant personal data. 
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Figure 23. Text message and email follow-up procedure 
 
Each participant was sent an email and/or text monthly with the text “Please could you answer 
the following monthly follow-up questions? 1) Are your child's skin lesions still present? 2) 
Have any siblings developed Molluscum Contagiosum? Please reply to this email/text” 
(including one reminder) (Figure 23), if on two consecutive months there was no reply, the 
participants were not contacted again and marked in the database as ‘non respondent’.  
7.7.3 CDLQI 
The CDLQI is the most widely used dermatology specific QoL measure for children with 
dermatological conditions (67, 69). The questionnaire consists of 10 questions to establish 
impact upon quality of life around the following areas: 
 Symptoms and feelings 
 Leisure 
 School or holidays 
 Personal relationships 
 Sleep 
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 Treatment 
A copy of the CDLQI can be found in Appendix 4.2. 
 Data management 7.8
In order to facilitate ease of use by as many different participants as possible a hybrid system 
using both postal and online data collection was used for collecting study data. Combining 
these methods provided more opportunities for participants to take part in the study and by 
including an electronic survey it had the ability to improve response rates (161). 
7.8.1 GP/Dermatology referrals 
Questionnaires were posted to participants who were referred from the study following a 
positive MC diagnosis by a GP/dermatologist as well as being able to complete the survey 
online. Participants were provided with a stamped addressed envelope to return the 
completed forms. Returned questionnaires were uploaded using a purposely designed form 
into IBM SPSS Data Collection Interviewer v6.0.1. The data was exported as a ‘.sav’ file, and 
converted into a ‘.dta’ file for analysis in STATA v12. 
7.8.2 Web referrals using MCDTP 
Participants referred to the study via media advertisement were able to complete 
questionnaires online via www.mosaic-study.co.uk. As the data collected included patient 
sensitive and identifiable information a secure website was required. The website was 
designed and managed by the web development team (healthy ageing research group), 
Institute of Primary Care and Public Health, Cardiff University. The website followed the same 
questions and format as the paper questionnaire. Data was exported into a secure excel file 
and sent to myself when requested. 
7.8.3 Merging databases 
A password protected master file was created which contained merged data from the web 
recruitment tool and the data from the paper forms. Each field was individually checked to 
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ensure that the coding was the same for each response before exporting into a STATA data 
file. Each participant was assigned a unique study ID, a separate spreadsheet containing only 
follow-up details was created for use in the monthly follow-up text messages and emails. 
 Outcomes  7.9
7.9.1 Sample size calculation 
The main outcomes of the study were to provide descriptive statistics of differences between 
groups and proportions following the completion of the two study questionnaires (MC 
questionnaire and CDLQI).  
 
 
 
 
The sample size calculation (formula above) was based upon ensuring a representative sample 
of MC cases were recruited which described a range of children with varying presentations of 
the condition. No recent studies have described the prevalence of MC in the community for 
children in the UK or Northern America and therefore estimating the true prevalence of MC for 
the sample size calculation required assumptions.  
The meta-analysis presented in chapter two provided a combined overall estimated 
prevalence of MC in children as between 5.1% to 11.5%. Using an expected prevalence of MC 
in the community as 5.1% resulted in a sample size of 292 participants (as the prevalence 
estimate was less than 0.1 the precision used in calculation was half of the expected 
prevalence (d=0.025), as recommended (162)). Assuming a prevalence of MC as 11.5% 
resulted in a sample of 162 using a 95% confidence interval and a precision of 0.05. To ensure 
n =
𝑍2𝑃(1 − 𝑃)
𝑑2
  =
1.962 0.05(1 − 0.05)
0.0252
 
Formula: 
 
 
Where:  
n = sample size 
Z = Z statistic for level of confidence 
P = expected prevalence or proportion 
d = precision 
Sample size calculation based on Naing et al (2006) (162) 
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an adequate sample of children were recruited to provide accurate precision of 0.025 in a 
proportion of one, with a level of confidence of 95% and estimating a cautious lower estimate 
of MC in the community of 5.1%, a minimum sample of 292 children was required. 
7.9.2 Analysis 
7.9.2.1 MC Questionnaire 
Descriptive statistics were calculated for all outcomes. Distributions were described using the 
mean and / or median and the standard deviation (SD) and / or the first and third quartiles (Q1 
and Q3) and / or the range, depending on the distribution. Time to resolution is measured by 
the number of months in total that the lesions were present; the event start date was the date 
lesions were initially present and resolution measured as the point lesions were no longer 
visible. Survival estimates were calculated using Kaplan-Meier statistics. Hazard ratios show 
whether gender, having an effected family member, treatment (prescribed / non-prescribed) 
or a greater number of lesions impact on the time to resolution. Data from participants lost to 
follow-up were censored at the first incomplete follow-up time point; data for those who had 
not recovered by the end of the study were censored at the study end date. Transmission 
analysis (as a proportion) between family members was limited to only those living with family 
members aged under 14 years. Statistical analyses were performed within STATA v12. 
7.9.2.2 CDLQI 
Each response was given a score based on standard guidelines for the CDLQI (shown below) 
(67, 71) where each question is scored, these individual scores are then counted to provide an 
overall CDLQI score. A histogram of CDLQI scores was plotted to describe the distribution of 
data, the data from the CDLQI scores are positively skewed and no transformation was 
adequately able to improve the fit of normality, so a non-parametric Krustal-Wallis test was 
conducted to compare the medians for the predictor variables with two or more levels. The 
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overall mean, standard deviations and medians (Q1 and Q3) of CDLQI scores were calculated 
based upon individual question responses. The scoring for each question is; 
- Very much = 3 
- Quite a lot = 2 
- Only a little = 1 
- Not at all = 0 
- Blank = 0 
- Q7 – Prevented school = 3 
 Results 7.10
A total of 306 parents completed the study questionnaire between January and October 2013 
(Figure 24). Recruitment numbers were highest during May, June and July where health forum 
information was placed, letters had been sent to schools and google advertisement was active. 
90.5% of participants were recruited by self-diagnosis using the MCDTP via the study website, 
9.2% were referred to the study following a diagnosis from primary care, and one participant 
was referred from a dermatology outpatient clinic. Figure 25 shows the recruitment of 
participants through each campaign.  
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Figure 24. Monthly recruitment of study participants 
 
Figure 25. Source of recruitment for study participants 
 
7.10.1 Participant Characteristics 
The age of children ranged from four to 15 years, and the median age was positively skewed 
with a median (Q1, Q3) of 12 (5, 8). There was an even distribution between the genders (45.4% 
male). Participant characteristics are described within Table 37. In most cases children had 
more than one lesion, and 56.8% had more than 10. In a quarter of cases there were over 21 
lesions present (Figure 26). The most common anatomical location of lesions was legs (51.3%), 
torso (49.7%), and arms (49%). 69.6% of children had lesions in more than one site (Figure 27), 
the most common pair of locations were torso and arms (32.4%). Figure 28 provides an 
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illustration of the most common anatomical locations of lesions using data for all children 
included in the sample.  
Table 37. Participant characteristics 
i) Participant characteristics (n=306) 
a) Age (years) 
 
Mean (SD) 6.7 (2.4) 
Median (Q1 to Q3) 6 (5 to 8)  
Range Min=4, Max=15 
b) Gender 
  
  Number of participants % 
Male 139 45.4 
Female 167 54.6 
ii) Presentation 
a) No. of MC lesion/s present 
  
  Number of participants % 
1 21 6.7 
2-5 55 18.0 
6-10 56 18.3 
11-15 48 15.7 
16-20 50 16.3 
21+ 76 24.8 
b) Location of lesion/s (multiple responses available) 
  
  Number of participants % 
Legs 157 51.3 
Torso 152 49.7 
Arms 150 49.0 
Armpits 69 22.5 
Back 62 20.3 
Genitals 53 17.3 
Buttocks 51 16.7 
Face 49 16.0 
Neck 47 15.4 
Hands 13 4.2 
Feet 12 3.9 
c) Most frequent pairs of locations 
 
  Number of participants % 
Torso and arms 99 32.4 
Torso and legs 86 28.1 
Arms and legs 75 24.5 
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Figure 26. Number of lesions present by participant at point of survey completion 
 
Figure 27. Number of anatomical sites MC lesions present 
 
Figure 28. Distribution of lesions by anatomical site and frequency of presentation in study 
participants 
 
6.7 
18 18.3 
15.7 16.3 
24.8 
0
5
10
15
20
25
30
1 2-5 6-10 11-15 16-20 21+
P
er
ce
n
ta
ge
 
number of lesions 
30.4 
25.5 
18.3 
10.1 
7.2 6.2 
2.0 
0.3 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
1 2 3 4 5 6 7 8
P
er
ce
n
ta
ge
 
anatomical sites 
Page | 135 
 
7.10.2 Treatment and Advice 
81.1% (n=248) parents indicated that they had visited their doctor for advice about their 
child’s MC (Table 38). Figure 29 highlights the information parents recall being given during 
their child’s MC consultation. In 92.7% of cases a clear description of the disease was provided, 
and in most cases this was provided verbally (83.9%), in 15.7% of cases the parents were 
provided with printed information sheet about MC.  
Table 38. Treatment & Advice 
a) Has your doctor confirmed a diagnosis of MC 
  
  Number of participants % 
Yes 248 81.1 
No 58 18.9 
b) Did your child receive any treatment from the doctor? 
  
  Number of participants % 
Yes 58 23.4 
No 190 76.6 
If yes, what treatment? 
  
Treatment Number of participants % 
Antibiotic 18 31.0 
Topical ointment 31 53.4 
Steroid cream 3 5.2 
Antihistamine 2 3.4 
Curettage 1 1.7 
Molludab 1 1.7 
c) Did you use alternative treatments not prescribed by the doctor? 
  
   Number of participants % 
Yes 121 39.5 
No 185 60.5 
If yes, what treatment? (1 blank response) 
  
Moisturising lotion 21 17.4 
Cutting or squeezing 16 13.2 
Use in one or less cases 83 68.6 
d) Did seek advice from anywhere else? 
  
  Number of participants % 
Yes 167 54.6 
No 139 45.4 
If yes, where did you seek advice? 
  
Internet 144 86.2 
Healthcare practitioner 16 9.6 
Friends 7 4.2 
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The time to resolution of lesions was described to parents in 88.7% (n=220) of cases when they 
saw the doctor. Parents were told lesions would resolve by up to 12 months (28.2%), up to 18 
months (31.4%), up to 24 months (20.5%), and over 24 months (3.6%). 28 parents (12.7%) 
were provided information about the time to resolution but did not state what information 
they were given. 
Parents were told in 57.3% that the lesions were contagious, 24.9% were told that their 
children should take measures to avoid transmission; however 7% of parents reported being 
told that MC was not contagious. 
In 20.2% of consultations parents noted that physical contact was discussed. In most cases 
(38%) parents reported being told that their child should continue all activities as normal. 26% 
reported being told to avoid skin to skin contact and 22% were told not to share towels. In 4% 
of consultations parents were told that their child should discontinue with school swimming 
activities. 
Figure 29. Advice received from GP (when participant saw doctor) 
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7.10.3 Associations with other skin conditions 
A third of participants (34.6%) reported that their child had another skin condition present in 
the months prior to developing MC (Table 39). In almost a quarter of children there was a prior 
diagnosis of AE.  Other skin conditions were noted but these were present in less than 1% of 
cases. 
Table 39. Association with other conditions 
a) Other skin conditions present in the months prior to developing MC 
  
  
Number of 
participants 
% 
Yes 106 34.6 
No 200 65.4 
b) if yes, skin conditions named 
  
Area 
Number of 
participants 
% 
Atopic eczema 86 28.1 
Warts 3 0.9 
Chicken pox 3 0.9 
Vitiligo 2 0.9 
Impetigo 1 0.3 
Measles 1 0.3 
Other 10 3.3 
7.10.4 Activities 
A quarter of children (24.8%) with MC participated in sporting activities (Table 40). 
Table 40. Sporting activities 
Table 4: Sporting activities 
a) Participation in sporting activities 
  
  Number of participants % 
Yes 76 24.8 
No 230 75.2 
7.10.5 Transmission 
Of the total number of participants, 81.7% (n=250) of participants reported that there were 
more than one child aged 14 and under living in the same household. Of those with multiple 
children living in the same household 41% (n=102) indicated that there had been multiple 
cases of MC within the household. Transmission included occurrences both prior to 
(documented on MC questionnaire) and during follow-up. 
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7.10.6 Time to resolution 
Complete follow-up data were available for 269 (87.9%) children, with 21 (7.8%) of these 
patients not recovering by study end (August 2014). The remaining 16 (5.2%) were lost to 
follow-up (no response to follow-up email/text in two consecutive months). Data where 
participants exited the follow-up or lesions had not cleared by the end of the follow-up period 
were censored for the purposes of data analysis. For those with complete follow-up data, the 
time to resolution was a median (Q1, Q3) of 12 (8, 18), mean (SD) of 13.3 (8.2) months, and a 
range of 1 to 62 months (Table 41). 58.0% of children having recovered by 12 months, 29.7% 
still with lesions at 18 months, and 13.4% with lesions persisting at 24 months. 
Table 41. Time to resolution of MC lesions 
Statistic Months 
Mean (SD) 13.3 (8.2) 
Median (Q1 to Q3) 12 (8 to 18) 
Range Min=1, Max=62 
 
A Kaplan-Meier plot of time to resolution, including censored data, showed no difference by 
gender (Hazard ratio: 1.06: 95% CI 0.84 to 1.35, p=0.617) (Figure 30). There were no 
associations between the time to resolution and self-reported receipt of prescription 
medication, self-medication, having an effected family member or a greater number of lesions 
at recruitment (‘21+’) (Table 42, Kaplan-Meier survival estimates for these groups are 
presented in Appendix 4.5). However, there was a difference in the time to resolution between 
those who self-referred (mean 8.9: 95% CI 6.4 to 11.4 months) and those that were referred by 
a clinician (mean 13·3: 95% CI 12.3 to 14.2 months) (Hazard ratio: 0.58: 95% CI 0.34 to 0.98, 
p=0.40). 
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Figure 30. Kaplan-Meier survival estimates of lesions (in months) by gender 
 
Table 42. Association between total duration of symptoms and gender, prescribed and non-
prescribed medications, and number of lesions (Hazard Ratio) 
  Hazard Ratio 95% CI p 
  
Gender 1.06 0.84 to 1.35 0.617 
Prescribed medications (reported) 1.29 0.94 to 1.77 0.112 
Self-treatment (reported) 1.13 0.88 to 1.44  0.344 
Affected family member 1.22 0.93 to 1.60 0.141 
Number of lesions (‘21+’ at baseline) 0.95 0.58 to 1.56 0.843 
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 Quality of Life 7.11
Five participants returned incomplete CDLQI forms (containing no data in any fields) and 
therefore 301 were included within the final analysis. The distribution of CDLQI scores was 
positively skewed with a median (Q1, Q3) of 4 (2, 7) (Figure 31), and mean (SD) of 5.1 (4.8).  
Figure 31. Distribution of CDLQI scores 
 
There was no association between QoL and duration of symptoms (measured when 
completing CDLQI) or presence of AE. However, female gender, greater duration of lesions at 
baseline, and number of lesions were all positively associated with higher CDLQI scores 
(greater QoL impairment) at baseline (Table 43). 
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Table 43. CDLQI scores at recruitment 
CDLQI Scores 
Mean (SD) 5.1 (4.8) 
Median (Q1 to Q3)  4 (2 to 7) 
Max=0, 
Min=27 
By gender  N Median  Q1 to Q3 
Male 137  3 1 to 6 
Female 164  4 2 to 9 
H=12.8, p< 0.005  
Referral method  N Median  Q1 to Q3 
Clinical referral 29 4 2 to 8 
Web referral using MCDTP 272 4 1.2 to 7 
H=0.34, p=0.560 
By presence of eczema (at baseline) N Median  Q1 to Q3 
Eczema present 84 4 2 to 8.5 
No previous eczema diagnosis 217 4 2 to 7 
H=0.76, p=0.378 
By number of lesions (at baseline) N Median  Q1 to Q3 
1 20 2.5 0 to 5 
2 to 5 55 2 1 to 5 
6 to 10 56 2 1 to 5 
11 to 15 46 4 2 to 7 
16 to 20 49 3 2 to 7 
21+ 75 7 4 to 13 
H=55.8, p< 0.005 
By duration lesions present (at baseline) N Median  Q1 to Q3 
<1 month 47 2 2 to 5 
1-2 months - 
3-4 months 48 4 2 to 7 
5-6 months 41 4 1 to 8 
6-12 month 74 4 2 to 8 
>12 months 91 4 1 to 9 
H=4.65, p 0.326 
MANOA: F(57.0, 243) = 2.14, p < 0.005 
Note: ‘-‘ no children in this group 
 
 
Table 44. Interpretation of CDLQI score by severity banding (70) 
Score QOL Effect 
0 to 1 No effect 
2 to 6 Small effect 
7 to 12 Moderate effect 
13 to 18 Very large effect 
19 to 30 Extremely large effect 
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Using severity bands presented in Table 44 it indicates a small impact on QoL for most patients 
(70). However, 85 (28.2%) participants reported at least a moderate effect on QoL (CDLQI 
score >7) and 33 (10.3%) participants reported experiencing a large impact on QoL (CDLQI 
score >13) from their MC (Figure 32). 
Figure 32. Participants completing CDLQI by severity score band 
 
Where CDLQI scores are described by individual domains of the questionnaire the area with 
the highest effect on QoL is upon ‘symptoms and feelings’ where the impact ratio is almost 
double that of the other domains (Table 45).  
Table 45. CDLQI score by domain 
Domain Mean (SD) Median Q1 to Q3 Possible total 
Impact 
ratio 
Symptoms and Feelings 2.16 (1.61) 2 1 to 3 6 0.36 
Leisure 1.23 (1.86) 0 0 to 2 9 0.14 
School or holidays 0.36 (0.63) 0 0 to 1 3 0.12 
Personal relationships 0.49 (1.04) 0 0 to 1 6 0.08 
Sleep 0.38 (0.66) 0 0 to 1 3 0.13 
Treatment 0.51 (0.81) 0 0 to 1 3 0.17 
 
The CDLQI results calculated within this chapter have been added to the CDLQI meta-analysis 
produced in the earlier systematic review (chapter three) in Figure 33.  There is a very small 
change in the overall CDLQI effect from MC (mean CDLQI 4.32 from 4.15), and there is also a 
very small change overall in the effect of QoL from common skin conditions.  
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Figure 33. CDLQI meta-analysis including results from this study 
 
 Discussion 7.12
This study of 306 UK children is the largest cohort of children with MC recruited in the UK, and 
also the only study to prospectively follow-up children for the duration of symptoms. Children 
were recruited through two main routes, a clinical referral in primary or secondary care (9.5%), 
or self-referral by completing the MCDTP (90.5%) to confirm a MC diagnosis. Parents became 
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aware of the study through media advertisements, the most successful means of advertising 
the study were through online health forms (60%), and search engine advertisements (22.4%). 
Of those recruited, 269 (87.9%) completed the follow-up within the study period, 16 (5.2%) did 
not respond to follow-up in two consecutive months, and 21 (6.9%) were still reporting 
symptoms at the study end. Children who did not complete follow-up were included within the 
analysis and censored at their end of study date. The time to resolution of MC in children 
ranged between one to 62 months, and children experienced an overall median duration of 12 
months. Survival estimates show that 58% of children were clear of lesions by 12 months, 70% 
by 18 months and 87% by 24 months.  
Transmission of MC between family members was reported in 41% of cases where parents 
noted that there were further cases of MC in siblings; this analysis was limited to only those 
living with other children aged 14 and under. 
MC most commonly presented on legs, torso and arms, in 69.9% of cases lesions were present 
in more than one site. Over half of children had 10 or more lesions, and in a quarter of cases 
there were 21 or more. Less than a quarter of children had recently participated in sports 
(24.8%). Most children (81.1%) had their diagnosis of MC confirmed by a GP regardless of 
method of recruitment to the study. 60% of parents were reportedly told that the lesions 
would last between 12 to 18 months by GPs; this may have led to concern in 30% of cases 
where lesions lasted longer than this period. 
To describe the impact of MC on QoL participants completed the CDLQI; 301 children returned 
completed questionnaires. In most cases of MC there was a small (48%) or no (29%) effect on 
QoL. In 10% of cases there was a very large effect on QoL, and an extremely large effect was 
seen in 1%. A longer duration of lesions and larger number of lesions at baseline were both 
associated with greater impairment in QoL, which increased when there were more than 21 
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lesions present. Within the six domains of the CDLQI, MC has a greatest effect upon symptoms 
and feelings, the mean score of this domain was double that of all other domains. 
The following chapter will provide a comparison of the results presented in this chapter to 
other studies in the published literature (chapter eight). 
 Limitations 7.13
7.13.1 Potential limitations from the source of recruitment 
This prospective cohort study of MC cases recruited participants through a number of different 
methods such as health forums and online search engines, as well as clinical referrals from 
primary and secondary care centres. Although recruiting through various novel methods such 
as health forums and online search engines generated a relatively large number of 
participants, there are both strengths and potential limitations to these methods that will be 
described here.  
Limitations were that only a small proportion of participants (9.6%) were referred to the study 
following a clinical diagnosis by a GP or Dermatologist. Although the MCDTP provides good 
accuracy in parental diagnosis of MC, with high sensitivity and specificity, there is the 
possibility that children without MC might have completed the study questionnaires. In order 
to explore any effect of referral method the analyses were stratified by self or clinical referral. 
There were differences in the time to resolution of lesions between those who were self-
referred to the study (8.9 months) and those referred by a clinician (13.3 months), suggesting 
that the sample referred by clinicians may represent more severe cases. However there was 
little difference in CDLQI scores between those recruited by the two approaches.  
Recruiting through online health forums may also have introduced a bias as parents of children 
who are experiencing a more severe episodes of MC may be more likely to be actively 
searching for information about their child’s condition (163). However, if anything, children 
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recruited by these methods seem to have less severe disease than those recruited by a 
clinician. In contrast by recruiting actively from the community the study limits the effect of 
healthcare access bias which may have occurred if only children originating from the health 
care setting were recruited, which may have limited the generalisability of the findings to a 
healthcare seeking population. By recruiting from both the community setting and 
primary/secondary care centres the results are more representative of cases of MC in the UK 
population. Both of these approaches suffer the criticism that less severe cases of MC are less 
likely to be detected and suggest that the prevalence estimates reported here are conservative 
but perhaps the impact on QoL might be an over-estimate if only the more severe cases joined 
the study.  
It is important to recognise the benefits of using such an approach for recruitment. By allowing 
parents to self-refer and make the diagnosis using the MCDTP it enabled recruitment of 
children from over a large geographical area, and with a wide range in severity of MC. 
Although it might have been more secure to confirm the diagnosis by a GP or dermatologist, 
requiring this would invariably have led to some parents opting to not to take part and 
therefore resulted in selection bias. Therefore it is likely that this approach resulted in results 
which are more representative of the general population of children with MC. 
The majority of cases were recruited by self-diagnosis, and if the study was not limited through 
recruitment time and had a larger number of primary care centres recruiting children, a more 
even split between clinical and self-referral may have allowed further exploration of the 
differences between groups and potential bias.   
7.13.2 Potential limitations of study participants 
Parents who completed study questionnaires on behalf of their children were volunteers 
whose participation following being informed of the study through various awareness 
campaigns. Participant characteristic in terms of disease presentation and socio-demographics 
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may differ to the population who did not participate in the research; this is a common problem 
in research (164). There are methods of capturing the data for all of those presenting with a 
disease that won’t be affected by non-participation such as conducting retrospective reviews 
of case notes or examining routinely collected data from primary care, both study designs 
were considered earlier for this study. Both of these methods are also limited by the data 
collected in the systems, and additional questions or follow-up information cannot be 
collected easily. This method of data collection is also subject to healthcare access bias which 
limits participants to only those in the healthcare setting. It is difficult to measure the effect of 
selection bias, however in the discussion chapter of this thesis (chapter eight) I will discuss 
these results in context to those that have used inclusive data collection methods such as a 
case note reviews. 
7.13.3 Potential limitations in data collection 
Parents were asked to retrospectively ascertain when their child’s symptoms had developed, 
advice received if MC was diagnosed by a GP, treatments that were self-prescribed or 
prescribed by doctors, and the presence of other skin conditions in the 12 months prior to MC 
development. Parents providing this information may be subject to both recall and differential 
recall bias when being asked to describe events that occurred in the past. Accuracy in recall 
can be affected by the degree of detail in questions, the significance of the events being 
described, significance to respondents and the time period between event and recall (165). To 
minimise the impact of recall bias, minimal detail was focused upon retrospective data 
collection and the MC questionnaires were largely based on collecting current and follow-up 
data, the CDLQI questionnaire captured data of the child’s current symptoms. 
The CDLQI provides instructions that it should be completed by a child with the help of parents 
if necessary. Therefore, responses may have been influenced by parental perception in 
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younger children. However, although all measures of QoL in younger children are likely to be 
imperfect, the CDLQI is a well used instrument. 
7.13.3.1 Potential limitations in measuring QoL 
The CDLQI is designed to measure dermatology specific QoL regardless of other non-skin 
conditions that may impact on QoL. It allows for comparisons between patients with a wide 
range of skin conditions (67). However, it is unlikely to be as sensitive, responsive and relevant 
to individual patients as disease specific instruments (112). To address this, the analysis 
provided QoL data according to severity of their condition, age, and natural history. These 
factors help to place in context the QoL effect from MC and therefore provide a detailed 
description, which is more sensitive to individual patients with varying severity of MC.  
Participants could complete the CDLQI both on both paper and electronically via the study 
website. The CDLQI has not been assessed to show the extent to which it is valid for use 
online; however there were no significant difference in the CDLQI scores between the two 
data capturing methods, suggesting that the method of collection did not influence the overall 
results. 
 Conclusions 7.14
These data provide the most reliable estimates of the expected time to resolution to date, and 
can be used to help set realistic expectations. For most children, MC has a small effect on QoL, 
however, 1 in 10 children experience a very severe effect on QoL. MC appears to be highly 
contagious, with nearly half of the households that included additional children experiencing 
transmission to one or more children. These findings can be used to help inform parents and 
other interested stakeholders and will be discussed in the context of other published literature 
in the subsequent chapter. 
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Chapter eight: Discussion 
8. Overview 
This chapter will describe the main findings from the body of work presented in this thesis, 
consider potential limitations of these, place the findings in the context of other work in this 
field, consider the implications of the findings, and make recommendations for future 
research. 
 Main findings 8.1
The work presented in this thesis includes the first cohort study of UK children with MC that 
prospectively followed up participants for the duration of their symptoms. I developed a 
parental MC diagnostic tool which is the first, that I am are aware of, that has been assessed to 
describe the extent to which it is valid in diagnosing MC in primary care and used for 
recruitment in epidemiological research. Finally, an update of primary care consultation rates 
for MC has been provided and a matched case-cohort study of children diagnosed with AE to 
test the hypothesis that a history of AE increases the likelihood of consulting for MC in 
childhood. The main findings of this work are; 
 In a UK cohort of 306 children with MC aged four to 15 years, the median time to 
resolution of lesions was 12 months. There was variation in the time to resolution 
where 30% and almost 15% of children still had lesions present at 18 and 24 months 
respectively. 
 For the majority of patients, MC has a small effect on QoL when measured using the 
CDLQI. Strikingly however, 10.9% of affected children within the cohort experienced a 
very severe effect on QoL from their MC. Female gender, greater duration of lesions at 
baseline, and number of lesions were all positively associated with higher CDLQI scores 
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(greater QoL impairment) at baseline. There was no association between QoL and 
presence of AE. 
 Transmission of MC was common in children living in the same household. In children 
who lived within a household with others aged 14 years, transmission occurred in 41% 
of cases. 
 I developed a tool which allowed parents, when aided with pictures and text, to assess 
whether their child’s skin lesions was MC or not. The validity of the tool (MCDTP) was 
assessed in general practices in South Wales and provided good accuracy in parental 
diagnosis of MC when compared to GP’s (sensitivity 91.5%, specificity 88.2%). 
 We found that children aged aged two to seven years (12.3 to 17.8 per 1,000) 
consulted more than other age groups during the 10 year period 2004 to 2013. The 
rate of consultations declined during this period by 50.0% for both males and females. 
 We found children were more likely to have a future MC consultation if they had 
previously consulted to their GP with AE (OR 1.13 (95% CI 1.10 to 1.16) P<0.005). This 
was found in a matched case-cohort study of children who were diagnosed with AE by 
their GP compared to a control group of children with no history of an AE diagnoses. 
  Strengths and weaknesses of key findings 8.2
The limitations of each of the individual studies presented in this thesis were discussed at the 
end of the subsequent chapter. In the following section I will aim to bring together the key 
biases, limitations and strengths of the individual studies to discuss the importance of them 
being considered when interpreting the main findings of this thesis. 
8.2.1 Prospective cohort study of children with MC 
In chapter seven I conducted a prospective cohort study of children with MC to describe the 
presentation of symptoms, management (both clinical and non-clinical), time to resolution of 
symptoms, transmission and impact on QoL. Children could join the study by clinical or self-
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referral and by recruiting through these two arms it allowed a large number of children with 
MC to be recruited into the study. The most successful approach for recruitment was through 
self-referral using the MCDTP (91% of total recruitment). Recruiting the sample by self-referral 
meant that children living in the community were included in the study and the results were 
more representative of cases of MC in the UK, it also reduced the potential bias of these 
findings being limited to a healthcare seeking population. However there are limitations to this 
approach, as only 9% of participants joined the study following a clinical diagnosis by a GP or 
dermatologists there is the potential that children without MC may have completed the study 
questionnaires. The number of false positives should be limited by the thorough development 
process of the MCDTP, and it is important to note that no diagnostic tool is perfect (even 
expert clinical diagnosis (166)) and the MCDTP has sufficiently good characteristics to warrant 
use in this study. Furthermore, by using the MCDTP it allowed us to recruit children from the 
general population, and therefore limit selection bias. When the main study outcomes were 
analysed between the two recruitment arms there were differences in the overall time to 
resolution of lesions but there were no differences in QoL (CDLQI score). 
The majority of children in the study were those whose parents were seeking healthcare 
information about MC either through online searchers, on health forums or during a clinical 
consultation, and there is the potential that the results represent more severe cases of MC. 
Therefore slight caution should be given when generalising the findings to all cases of MC in 
the UK. However, as the results of this study will be provided to parents of children who are 
presenting with the condition in primary or secondary care by clinicians, or those seeking 
healthcare information from other sources such as online health websites, then these findings 
will be most appropriate to this population. 
A strength of this study was that for the main outcomes, time to resolution of lesions and 
transmission of MC between children living in the same household as an index case, this data 
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was collected prospectively which provides greater accuracy of the data collected. Other data 
such as presenting symptoms and QoL were collected upon completion of the main study 
questionnaire which collected information of current symptoms. However, the duration of 
symptoms (when completing questionnaire) and management were collected retrospectively. 
Retrospective data collection is subject to recall bias and by limiting the amount of data 
collected retrospectively in this study it should limit the impact of this in the main study 
findings.  
The MCDTP was used as a recruitment tool for those who self-referred to the prospective 
cohort study described here, and the next section will discuss the main strengths and 
weaknesses of the development and assessment of the extent to which the tool is valid. 
8.2.2 MCDTP  
The MCDTP was developed using a framework that was based upon forming a good disease 
definition for an epidemiological study that was recommended by epidemiologists (described 
in chapter five). The MCDTP was then assessed to measure the extent to which the instrument 
was valid in GP practices where a parental diagnosis was compared to that of a GP (chapter 
six). Although a transparent development and validation process was used for the MCDTP 
there are some key limitations in these methods that will be discussed here. 
The gold standard MC diagnosis was provided by GPs and although they will diagnose the 
majority of MC cases in the UK, with only a small proportion of children being referred to 
dermatologists, it may suffer the criticism that dermatologists are the true gold standard for 
diagnosing skin conditions in the UK. To measure agreement between the gold standard 
diagnosis used in this study with three clinical experts (two consultant dermatologists and a 
second GP with expertise in dermatology) the diagnosis provided high levels of agreement 
suggesting that the GP diagnosis is likely to be reliable.  
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The images used in the MCDTP were of lesions on white skin colour and although the clinical 
description of MC remains the same, this may limit the acceptability of the MCDTP to a more 
diverse population. Where the characteristics of the practice populations which participated in 
measuring the extent to which the MCDTP is valid are examined they provide similar data to 
that of England and Wales, suggesting that the MCDTP is acceptable for use in this population. 
No data of ethnicity was collected from participants completing the MCDTP and this is a 
limitation, if this data were collected we would have been able to describe the test 
characteristics between populations based on ethnicity.  
The development of this tool involved a comprehensive process that involved multiple key 
stakeholders. In particular, we sought to ensure that the language used in the tool was 
understandable to a lay audience, as even the most commonly used medical terminology 
should be carefully explained to parents to avoid confusion (129). 
Chapter four described consultation rates for MC in a retrospective longitudinal study of MC 
cases and a case-cohort study of AE, the next section will discuss the main strengths and 
weaknesses of this study. 
8.2.3 Primary care consultation for MC  
Within chapter four data was extracted from the CPRD database to describe the incidence of 
primary care consultations for MC in the UK and associations with AE. The CPRD database is 
the largest database of primary care consultation data in the UK and represents almost five 
million patients. Extracting routinely collected data of primary care consultations from large 
retrospective databases is useful for identifying the burden of a specific condition within the 
primary care setting and trends of consulting during a specified time period but this study 
design is subject to limitations which will be discussed here. 
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The data held within CPRD are not inclusive of all UK general practices, however, data are 
validated and found to be generalizable to the UK population, and the statistical analysis used 
in the study provides the range in which we believe the true estimates of MC consultations in 
the UK will lie. The analysis performed in this study is limited by the assumption that the data 
extracted is correct, therefore the numerator within the analysis will not under or over report 
incidence of MC. By the data being extracted by an experienced research analyst this should 
limit errors in the extraction process. 
As MC is a self-limiting condition and the most common management by GPs in the UK is for 
the condition to be left to resolve naturally, in these instances where clinicians are providing 
only verbal advice without treatments a Read-code for MC may not be recorded in the system 
or the diagnosis could be described as ‘free text’. This is a limitation of routinely collected 
datasets and our findings where no ‘free text’ data were extracted or analysed in this study, 
therefore the consultation rates provided may under-report the true number of MC diagnoses 
in primary care. When describing the relationship between AE and MC it must be noted that 
this is a conservative calculation of risk as it includes only those with a confirmed diagnosis of 
either MC or AE entered as a Read-code, the true prevalence of both conditions in the 
community may indeed be higher. 
For the retrospective longitudinal analysis, we were unable to assess the different ways MC is 
managed by GPs, although data of the management of MC in primary care was collected and 
discussed in chapter seven. There are also limitations in the assumption of correct recording of 
data held within CPRD; the database relies upon accurate recording of consultations by the GP, 
however by only including “up to standard” data the impact of this source of error will likely be 
reduced.  
The next section will describe the findings presented in this thesis and interpret them in the 
context of other published work. 
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 Interpretation of findings and comparison with other published work 8.3
8.3.1 Time to resolution 
Results of the systematic review in chapter two highlighted that the time to resolution of 
lesions is poorly described in the literature. The best available data was based upon two small 
studies in the 1960’s (Alaska:n=13, Fiji:n=14) which described the time to resolution as 
between two weeks and 24 months (13), and a mean duration of eight months (47). The data 
presented in this thesis, of a much larger prospective cohort of children, suggests an average 
time to resolution as 13 months. Variation in time to resolution is large, with approximately 
60% of children having all lesions resolve by 12 months, 70% by 18 months, and 90% by 24 
months. Combing this data with our finding that 60% of parents are being told that the lesions 
will last between 12 and 18 months suggests that many parents are not being given accurate 
information about the true prognosis of the condition.  
8.3.2 Transmission of MC within households 
A high proportion of children described further cases of MC in siblings aged 14 and under living 
within the same household (41%). Data can be compared to data collected in Alaska where 10 
children were followed up for the duration of their condition and two new cases of MC were 
reported in family members (13), this figure is lower from the data within this thesis however 
in Alaska it was not reported whether all 10 children did indeed cohabit with other children 
and this study included only a very small sample of data collected during the 1960’s. 
8.3.3 Quality of Life 
A key finding of this research was that around 10% of children experience a large or very large 
impact on QoL. Tests of association showed a higher CDLQI score in those presenting with a 
higher number of lesions which typically would be a contributing factor in QoL impairment. 
Although other studies have used the CDLQI in children with MC, I am not aware of any that 
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have provided a detailed distribution of CDLQI scores and associations with the presentation of 
the condition.  
The mean CDLQI score was slightly higher than those previously reported (3.1 (73), 4.9 (67)) 
but were within the same severity banding. Both previous studies and the findings within this 
thesis provide a mean CDLQI score that describes the condition as having a small effect on 
QoL. Where CDLQI results are combined within a meta-analyses of common skin conditions 
there are marginal differences in the overall effect from MC once the results of this thesis are 
included, suggesting these results are within the range of other published data. A study which 
examined QoL of MC using a short un-validated questionnaire showed that parents were 
significantly more concerned about MC than their child, with 82% of parents (n=23) stating ‘it 
concerned them moderately or greatly’, compared to 43% of children (23). This suggests that 
our data may have underestimated the effect on QoL for younger children where 30% 
reported at least a moderate effect on QoL. Although our study did not examine QoL upon 
family members, instruments designed specifically for the purposes of describing the impacts 
upon family members highlight that family members may experience psychological distress as 
much as, or in some cases more than, the patient (167). 
8.3.4 Primary care consultations for MC 
Two studies were identified in the initial systematic review (chapter two) which described 
primary care consultations in the UK for MC (5, 26). Both studies showed that the greatest 
consultation rate was in children aged one to four years (15.0 to 17.2 per 1,000), neither of 
these studies presented data separately for children aged zero to 14 years in individual age 
bands, instead presenting these as a five to 14 age group. By un-grouping children aged one to 
14 years our data highlights that MC consultations are greatest in those aged two to seven 
years (12.3 to 17.8 per 1,000). The behaviours of these groups, which may reduce the 
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opportunities for skin to skin transmission, could explain why there are differences in 
incidence rates. 
Modelling the consultation rates of MC calculated in this thesis with the most recent general 
practice population published for England and Wales by ONS for 2011 (108), and assuming a 
similar practice structure by age band for a hypothetical practice population of 6,000, provides 
an estimate that an average practice would experience 11 recorded consultations for MC per 
year in children aged one to 14 years. This figure is less than that previously published in 2005 
that estimated a practice with a population of 10,000 would expect to see 24 new cases of MC 
per year: 90% of those being children (n=21.6) (5). However this figure included adults, and 
when adults are removed and this figure is crudely calculated for a practice size of 6,000 it 
estimates 13 cases of MC per practice which is consistent with our data. 
8.3.4.1 Seasonality 
Data collected from Dutch general practices in 1987-88 described the seasonality of MC 
consultations and showed peaks during the months January to March and April to June (43). 
These findings are similar to the data presented in within this thesis where the rates were 
highest in the same two quarters and peaked during the months April to June. Without an 
understanding of the route and opportunities for transmission, little explanation for this 
seasonality in incidence rates can be given. Some possible reasons could be more outdoor 
activity during this period, increased skin trauma (from physical activities), children wearing 
less clothing, more insect bites and that early in the calendar year is when primary schools 
provide swimming lessons; and as swimming is shown to increase the risk of transmission this 
could cause an increase in consultations. Skin and soft tissue cell infections have a higher rate 
of consultations during the summer months (168) and the peak of MC consultations during 
June in our results suggest a similar pattern. 
Page | 158 
 
8.3.4.2 Trends in consulting for MC 
Annual trends of MC consultations to primary care in the UK were previously reported for the 
period 1994 to 2003 (5), where the incidence rate rose by 38.5% (8 to 13 per 1,000) from 1994 
to 1998. The rates remained constant until 2002 until there was a decrease in the rate during 
2003. Our analysis of data extracted from CPRD since 2004 continued this decline continuously 
for the full 10 year period of study data. The decrease in primary care consultations for MC 
may be caused by the increased availability of health care information online (169) which has 
seen a reduction in parents presenting to primary care where adequate information is 
available on health websites for parents to manage a condition at home (170). Caution must 
be given when obtaining healthcare information online as this is generally not monitored.  
A second consideration for the decreasing trends in consultations for MC may be due to the 
decreasing trends in some infectious diseases within Western populations, such as the UK. 
Reasons for reductions in some infectious diseases during the past century may be due to 
improved sanitary conditions, less extreme poverty and a decrease in large numbers of 
children living within one household. For MC, limited close contact to other children with the 
condition and improved sanitary conditions could significantly reduce the opportunity for 
transmission between children and the overall prevalence of the condition within the 
population. 
8.3.5 Relationship between MC and AE 
AE has been shown to be associated with abnormalities in immune regulation, and patients 
with AE are known to be more susceptible to a range of cutaneous infections (8). The results of 
the prospective cohort of children with MC highlighted that 34.6% of parents completing the 
survey described a second dermatological condition in the months prior to MC. The most 
common condition was AE (28%), a wide range in the prevalence of AE in children presenting 
with MC has previously been described as 18.2% (48), 24% (3), 30% (45) and 43% (52). These 
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studies did have a different study design to our prospective community cohort, where all three 
retrospectively reviewed the case notes of children who had been diagnosed with MC at 
dermatology secondary care centres. None of the children were recruited in the UK but in 
Greece, North America, and France. We can assume that there is a high prevalence of AE in 
children who are diagnosed with MC and estimate that between 18% to 40% of children will 
develop AE. Comparing this figure to the general population, in Greece a national survey 
described the prevalence of AE in children as 5% (48), although in the UK a national survey 
described a lifetime prevalence of AE in children aged 12 to 14 as 22.5% (171), and the 
presence of AE in the previous year as 12% in children aged two to 11 years (172). The lifetime 
prevalence of AE reported in the general population is slightly lower than that in children with 
MC, and an AE diagnosis within the previous 12 months is less than half that of children with 
MC suggesting that the prevalence of AE is higher for children with a current MC diagnosis 
compared to those without.  
A prospective observational study in a paediatric outpatient clinic in Brazil found no 
relationship between MC and the presence of AE (56), this was comparing children who 
presented with MC, AE, and both MC and AE, and included no comparison to a control group. 
North American children diagnosed with MC aged five years and under were more likely to 
have a current AE diagnosis (OR 2.51 (95% CI 1.10 to 6.01) p=0.029) or to have either a current 
or previous AE diagnosis (OR 3.58 (95% CI 1.77 to 7.55) p< 0.05) than controls when examining 
routinely collected data extracted from the Indian Health Service. The matched cohort study of 
AE cases in this thesis tested the hypothesis that children who have a history of AE are more 
likely to have a future MC consultation during childhood and is the first, that I am aware of, 
that retrospectively examined both a group of AE cases and control group. The results showed 
children were more likely to have a future MC consultation during childhood if they had 
previously consulted with AE than controls (OR 1.13 (95% CI 1.10 to 1.16) P<0.005).  
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In summary, the presence of MC is often accompanied by AE, and the prevalence of AE in 
children with MC is higher than that in the general population. Where a cohort of children with 
AE were compared to age sex matched controls it shows that children who have a history of AE 
are more likely to have a future MC consultation during childhood than controls. The risks 
associated with the development of MC, and factors increasing the opportunities for 
transmission of MC in children remain unclear and further research is required into this area.  
 Lay representation 8.4
There is little reflection of the overall experience of involving lay representatives in the 
research process and of the nature and level of involvement within the published literature 
(173). Here I aim to provide some insight of the experiences of lay representation for this 
research.  
SW joined the research team as a lay representative and contributed significantly to the design 
phase of the development and assessing the extent to which the MCDTP is valid by proof 
reading patient information leaflets and by providing overall feedback and direction in the 
processes and procedures involved in recruiting participants in GP surgeries. The feedback SW 
provided in ensuring that clear understandable language was used in the MCDTP and the 
suggestion of a study envelope in the validation of the MCDTP, which avoided receptionists 
asking potentially sensitive questions, proved effective in the recruitment of parents across 
most practices. 
Overall SW attended three meetings at Cardiff University, and discussed patient information 
documents or procedures via email on several occasions. During the end of 2013 
communication reduced significantly and after two months I received an email explaining that 
due to family circumstances (bereavement) and a new job she would be unable to continue to 
support the project. Having a lay representative involved in the project was rewarding and 
useful to the final study design but as a volunteer there must be limited expectations of 
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commitment which can be provided. There is the potential for other life commitments to 
contribute to a lay representative’s ongoing involvement in the study which was experience 
here. Evidence has suggested that lay representative can also provide insight to the data 
analysis and interpretation phases of research (33), and in the case of this research, insight did 
not extend this far. In summary, the involvement of SW enhanced the study design and 
procedures of the research positively; potential difficulties that may have arisen during 
recruitment in GP surgeries were avoided by the input of a lay representative. From this 
experience I would advocate the importance of having a lay representative involved in 
research projects but also provide caution to the expectations of their on-going involvement. 
 Implications and further research 8.5
8.5.1 Advice for parents and clinicians 
Key information a parent may wish to know about their child’s condition are; the causes of 
illness, implications of the condition, and future prevention (174). This information can be 
gained from epidemiological research such as the data collected from this study. By providing 
this information it can improve the experience during a consultation for both parents and 
clinicians. Our findings suggests that potentially GPs have been providing incorrect advice 
when describing the prognosis of MC to parents and this is mainly due to a lack of 
epidemiological data regarding MC, which was highlighted in chapter two. 60% of parents 
were told by GPs that their child’s lesions would last between 12 to 18 months and this may 
lead to concern in 30% of cases where the time to resolution of lesions may be longer than this 
period. This finding alone highlights the importance of distributing the findings from this thesis 
to ensure advice clinicians are providing uses the most recent evidence that this thesis can 
provide. The findings from this thesis suggest that the advice GPs should be giving to parents 
following an MC diagnosis in their child is; 
 MC is a common condition in children, most common for those aged one to nine years.  
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 The average time to resolution of lesions is 13 months; however for 30% of children 
they will still be present at 18 months and 10% at 24 months.  
 Transmission between siblings is high and can occur in 40% of children who have other 
children living within the same household.  
 Although the time to resolution of lesions can be significant, generally it should have 
no or a small effect on QoL.  
 There is little evidence of the causes of transmission or behaviours that will reduce the 
risks of transmission between family members. 
8.5.2 Dissemination of findings 
The two main methods used to disseminate the findings from the studies in this thesis were in 
scientific peer-reviewed journals and via a study specific website. The website was made freely 
available to both parents and clinicians (website address: www.molluscum-info.com). It is also 
important that these findings are provided elsewhere in sources such as information leaflets or 
health information websites online as by providing information about conditions in these 
sources it can have the potential to reduce consultations for minor conditions if parents have 
access to this information at home (175). This approach could be adopted for MC where 
parents could both diagnose and manage the condition at home without requiring a clinical 
consultation to confirm a diagnosis. The website hosting the MCDTP and URL went live in 
March 2014 and in the subsequent eight months it had 984 visits from 868 unique users and 
2,568 page views. A link to the website was included in a news article about MC published in 
the Daily Mail Online on the 7th October 2014 (176), in this article readers wishing to read 
more information about MC or view the MCDTP were directed to the study website. The 
website can also be promoted in primary care where GP practices can include a link from their 
practice website. 
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8.5.3 Challenging clinical perception of MC 
MC is often thought as being a trivial self-limiting condition by clinicians (2). However, most 
children will have lesions lasting more than a year, and one in 10 children will experience a 
very large effect on QoL. A higher effect on QoL is more apparent in children who have a 
greater number of lesions, and the greatest impact is on symptoms and feelings. Therefore, 
the notion that MC is always a benign, trivial illness needs to be challenged, and active 
treatment should be considered for some children, especially those with larger numbers of 
lesions and those with higher CDLQI scores.  
8.5.4 Alternative management of MC in severe cases 
Treatments of MC for severe cases should be considered by clinicians. The findings of this 
thesis would suggest that children with severe MC, having more than 21 lesions, and those 
with CDLQI scores greater than 12 (very or extremely large effect on QoL) should be 
considered for therapy. The current UK guidelines of treatment algorithms for psoriasis by the 
National Institute for Health and Clinical Excellence (NICE) suggest drug regimens based upon 
both a PASI (177) and DLQI (178) score (179). MC guideline developers should consider 
recommending that the CDLQI score and / or the number of lesions present should be taken 
into account when making management decisions, similar to NICE guidelines for psoriasis. 
8.5.5 Future uses and developments of the MCDTP  
The MCDTP was developed and provided good accuracy for use in children in the UK to allow 
parents to diagnose their child’s skin lesion as MC. The sample population used when assessing 
the extent to which the instrument is valid suggest that it is acceptable and generalisable for 
use in the UK or for populations with a similar demographic. The MCDTP is available online and 
recent publications have encouraged healthcare practitioners and organisations to promote 
use of the site and provide a link on their websites (180). The site could also be used for 
education and training purposes, and the website and/or paper tool could be used to identify 
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suitable patients for inclusion in other studies on MC. Factors such as parent confidence in 
their diagnosis can be incorporated into future epidemiological studies or primary care 
screening tools if a higher accuracy was required. 
The MCDTP could potentially be used in other more diverse populations but it would require 
further development of the language if translated and images used, potentially using children 
of varying skin colours. If a different version of the MCDTP was created I would suggested that 
a similar development and validation process to that used in this thesis. 
8.5.6 Recommendations for future work 
8.5.6.1 Improving knowledge of basic science of MC 
Epidemiological studies of MC have highlighted risks that are associated with a higher 
prevalence of MC in children, however currently there is little evidence describing the causes 
and routes of transmission in the development of MC in children. There is a clear gap in the 
basic scientific knowledge of MC to provide an understanding of the mechanisms of 
transmission and the causes of spontaneous clearing of the condition for healthy children; this 
gap in knowledge has been highlighted previously by clinical virologists (4) and this research 
has only further highlighted the importance of this knowledge for MC.  
8.5.6.2 Treatments Trials 
Recent reviews of treatments for MC have recommended the natural resolution of MC in 
children, and for most children this will be the most appropriate management. However for 
those who have a more severe episode of the condition and experiencing a significant effect 
on QoL (approximately one in 10 children) treatment should be considered. Parents and 
children may become frustrated with the significant time to resolution of lesions and may turn 
to alternative treatments for MC which are advertised widely on internet search engines when 
seeking information about MC. One treatment which has had much publicity for treating MC is 
MolluDab (5% potassium hydroxide) which is available both with and without prescription. A 
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treatment trial of potassium hydroxide showed that it did lead to a greater resolution of 
lesions compared to controls, however these differences were not statistically significant 
(181). Without the availability of a recommended treatment of MC further treatment trials are 
required to assess the effectiveness of therapeutic approaches in children with more severe 
MC. Any future treatment trials should be based upon the recommendations of the 2010 
Cochrane review of treatments for cutaneous MC (17). 
8.5.6.3 Cost analysis of MC treatments 
A cost-benefit analysis should be conducted to assess the feasibility of changing current clinical 
guidelines regarding the treatment of MC in children. The cost-analysis of treatments to the 
NHS and clinical commissioning groups should be conducted alongside any future treatment 
trials. Data collected within this thesis could be used to model potential treatment algorithms 
based upon CDLQI scores, MC severity and the number of children that consult to primary care 
or are referred to secondary care with MC. 
8.5.6.4 Describing the prevalence of MC 
Further research could aim to establish the prevalence of MC in the community; this is one 
element of the epidemiology of MC that still remains not very well described in the scientific 
literature. However, the justification of a prevalence study would need to be clearly defined as 
this type of study design can be expensive and burdensome to researchers. It would also be 
important to consider that those who do not present to a clinician with MC may be 
successfully managing the condition at home and that their lesions may be generally 
asymptomatic. Therefore I would suggest there is little benefit of a prevalence study and 
would question whether describing the prevalence of MC would indeed benefit the research 
field or change current clinical management. 
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 Conclusions 8.6
This thesis identified gaps in the current epidemiology of childhood MC and aimed to address 
this gap in evidence by conducting a longitudinal study of children presenting with MC in 
primary care and a prospective cohort study of children with MC in the UK. The research 
within this thesis has described the presentation of symptoms, management, time to 
resolution, transmission between family members, QoL, and associations between AE and MC. 
These findings have been made available to parents and GPs through an information website 
for MC, and also through publications in the scientific literature. 
Consultations in primary care are greatest in children aged two to seven years, and the rate of 
consultations have reduced significantly by 50% since 2004 to 2013. The presence of MC is 
often accompanied by AE and children who have a history of AE are more likely to have a 
future MC consultation during childhood than controls. The risks associated with of 
development of MC are not clear, and further research is required into this area, as with 
describing why there is a large variation in the time to resolution of lesions between children.  
MC is often perceived by some clinicians as being a trivial self-limiting condition (2), but data 
suggest that for a significant minority of children this is not the case. The time to resolution of 
lesions on average is 13.3 months but parents should be aware that for 10% of children lesions 
may not have resolved by 24 months. For almost half of children parents described that there 
were further MC cases within the household. Children with a greater number of lesions (21 or 
more) are more likely to experience a greater impact on QoL. Therefore, the notion that MC is 
always a benign, trivial illness needs to be challenged, and active treatment should be 
considered for some children, especially those with larger numbers of lesions and those with 
higher CDLQI scores. Further studies are required to assess the effect of therapeutic 
approaches in children with more severe MC. 
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Appendix 2 – Appendices relating to systematic review (chapter two) 
2.1 Systematic review MESH headings 
Search Strategy 
Database search: Ovid Medline, Embase, and Cochrane Databases 
Main Search 
Epidemiology of Molluscum Contagiosum 
[ *”Molluscum Contagiosum”/ ep [Epidemiology] ]  
OR  
[ Molluscum Contagiosum, OR 
Molluscum Contagiosum Virus 
 AND 
Cross-sectional studies, OR 
Prospective studies, OR 
Incidence, OR 
Prevalence, OR 
Retrospective studies, OR 
Population surveillance, OR 
Questionnaires, OR 
Case-control, OR 
Risk Factors, OR 
Health Surveys, OR 
Disease outbreaks] 
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Appendix 3 – Appendices relating to MCDTP development and validation (chapters 
five and six) 
3.1 Dermatologist questionnaire
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3.2 Topic Guide 
Key conversational topics for discussion with school and dermatology nurse, and patient 
representative 
1) How would you describe a lesions/wart? 
 
2) If you had a screening question to ensure of parents of children with lesions 
responded, what would you call the lesions? 
 
3) Looking at the key wording below, how would you state this in a format non-clinicians 
could understand but still ensuring the key diagnostic criteria remain? 
Firm, umbilicated pearly papules with a waxy surface 
Firm papule lesions 1-5mm, umbilicated, folds,  
Spots on the skin, flesh colours, domed shaped papules with central depression 
 
4) Looking at the attached version of the parental diagnostic tool, is the instruction page 
and answer page clear? 
 
5) In your opinion, what wording for a self-diagnostic tool would be best: 
‘McTool’ 
‘Child Molluscum Contagiosum Diagnostic Tool (CMCDT)’ 
‘Molluscum Contagiosum Self Diagnostic Tool (MCSDT)’ 
‘Molluscum Contagiosum Diagnosing Aid (MCDA)’ 
‘Identifying Aid for Molluscum Contagiosum in Children (IAMCC)’ 
Or other…. 
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3.3 MCDTP pilot questionnaire for parent group 
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3.4 Molluscum contagiosum info sheet for GPs (Double-sided A4 document)
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3.5 Letter of invitation to join MOSAIC study sent to practice managers
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3.6 MCDTP Validation - participant study pack 
a) Study envelope 
b) Participant information sheet 
c) Consent form 
d) MCDTP 
 
a) Study envelope (printed size: A5) 
 
  
Page | 214 
 
b) Participant information sheet (A4 double-sided)
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c) Consent form (A4)
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d) MCDTP (four page colour booklet, size: A5)
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3.7 Medical photography protocol
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Appendix 4 – Appendices relating to prospective cohort (chapter seven) 
4.1 Molluscum contagiosum cohort questionnaire 
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4.2 Children’s dermatology life quality index (CDLQI)
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4.2 GP practice MOSAIC study information cards 
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4.4 Western Mail printed article about molluscum contagiosum and MOSAIC study
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Western Mail printed article ‘text’ 
Spots, lumps or bumps on your child’s 
skin….could it be Molluscum Contagiosum? 
 
Skin conditions are more common than you might think with up to 24% of the population visiting their GP 
for a skin condition. Skin conditions can be are irritating; physically affecting sleep and day to day 
activities, also impacting upon quality of life. For children they can sometimes lead to name calling, 
teasing and bullying from other children. 
 
Molluscum Contagiosum, known generally as Molluscum, is a common skin condition that affects people 
of all ages but is seen mostly in children aged 1 to 14, especially in those under  10. The name 
Molluscum Contagiosum may sound like a spell from Harry Potter, but it refers to small skin coloured 
spots suddenly appearing on the skin. These viral spots are distinctive in appearance, having a small 
crater like dip in the centre and appearing in a small localised crop, usually on the arms, back, tummy, or 
legs which can last months or years. In some instances they can become troublesome, especially when 
accompanied by eczema where the spots can be inflamed, itchy and sometimes get infected. 
 
Sam, a parent of a young child with Molluscum Contagiosum, described the impact on her child, how she 
searched the internet to find out what her child's spots were, and what information she could find about 
Molluscum Contagiosum: 
"The size of the spots caused skin irritation on his tummy; he was constantly scratching them 
through clothes and often made his skin raw........ 
.......although it was easy enough to diagnose without the help of a doctor, finding out what to do 
was much more difficult. No website seemed to contain comprehensive information. My 
GP confirmed the diagnosis over the telephone but even then, the advice about what to do was 
limited.” 
 
In the UK around 1% of children will get Molluscum. There is a lot still unknown about Molluscum. This 
means when a doctor diagnoses Molluscum there is little information he or she can share with parents, 
such as how long the spots will last, will siblings develop spots, and does taking part in certain activities 
help or hinder the spots clearing-up . At Cardiff University, we want to find out more about Molluscum and 
so we are recruiting as many children as we can to find out how the condition affects them and how long 
it lasts – this is what we aim to do. 
 
We have developed an online tool which helps parents identify Molluscum in their child. The Molluscum 
Contagiosum Diagnostic Tool for Parents (MCDTP) was designed with dermatologists at University 
Hospital of Wales, piloted with local parents, and tested in GP practices across Cardiff and Vale to 
ensure it is works accurately. We have used the most effective images and text to support parents in 
making a diagnosis of Molluscum. 
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We are inviting parents whose child either has been diagnosed with Molluscum by a doctor, or they have 
spots, lumps or bumps on their skin, to take part in our study. When a parent signs up to the study they 
will be asked to completed two short online questionnaires, and then a monthly follow-up text or email 
until their child's spots have cleared. The text simply asks whether Molluscum is still present.  
By logging onto www.mosaic-study.co.uk, parents are able to view the MCDTP, and using it, be able to 
identify whether their child has Molluscum. 
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4.5 Kaplan-Meier survival estimates of MC lesions 
a) Kaplan-Meier survival estimates of lesions (in months) by prescribed medications (reported). 
b) Kaplan-Meier survival estimates of lesions (in months) by self-treatment (reported). 
c) Kaplan-Meier survival estimates of lesions (in months) by affected family member. 
d) Kaplan-Meier survival estimates of lesions (in months) by number of lesions (at baseline). 
 
a) Kaplan-Meier survival estimates of lesions (in months) by prescribed medications 
(reported) 
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b) Kaplan-Meier survival estimates of lesions (in months) by self-treatment (reported) 
 
c) Kaplan-Meier survival estimates of lesions (in months) by affected family member 
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d) Kaplan-Meier survival estimates of lesions (in months) by number of lesions (at baseline) 
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Appendix 5 – Ethical and research governance approval documentation 
5.1 Research ethics committee (REC) approval 
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5.2 Research governance approval (Cardiff and Vale UHB) 
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5.3 Research study sponsorship 
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5.4 Independent scientific approval committee (ISAC)
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5.5 CDLQI permission 
 
  
Page | 246 
 
5.6 WSPCR funding decision
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5.7 Letter of access for research (Cardiff and Vale UHB)  
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